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Abstract
There is strong evidence that a functional Nef protein of human and simian 
immunodeficiency viruses is a critical factor in contributing to viral pathogenesis. A 
variety of properties have been ascribed to Nef that may contribute towards these 
effects. However, the exact mechanisms by which Nef functions remain unclear.
A number of clones of SIV nef have been described which were generated after 
spontaneous evolution both in vivo and in vitro based upon changes relative to the 
wild type SIVmacJ5 virus (Rud et ah, 1994, Arnold et al, 1999, N. Almond, personal 
communication). Furthermore, additional clones exist which were based upon the 
repair mutants reported by Whatmore et a l  (1995) after infection of macaques with 
the attenuated SlVmacCS virus (Rud et al, 1994).
The aims of this study were two-fold. First, to utilise a panel of SIV Nef specific 
monoclonal antibodies (Arnold et al, 1999) to elucidate structural differences 
between wild type and attenuated SIV Nef clones and further information on the 
epitope recognised by the conformational dependant monoclonal antibody, KX70 
(Arnold et al, 1999). Second, by utilising yeast-2-hybrid technology to investigate 
interactions of the SIV Nef clones with selected cellular components and relate these 
findings to the manner in which the virus behaves in vivo.
The results indicate that the alpha helical region around which the attenuation in 
SrVmacCS lies is a key component of the epitope recognised by KK70 as well as 
being a key region for interaction of cellular components with SIV Nef. The repair 
mutants reported by Whatmore et a l (1995) did not regain the epitope recognised by 
KK70 as the amino acids evolved to a near wild type sequence. This indicates that it 
may be an overall structural effect that these mutations are having which is affecting
XVI
antigenicity. Interestingly, one of the repair mutants (J5(EIYL)) did regain the ability 
to interact with the cellular components. This was lost when this repair was presented 
in conjunction with the R191E mutation (J5(EIYL+R>E)). Interestingly, the R191E 
mutation alone (J5(R>E)) caused non-specific trans-activation of the GAL4-AD. 
Furthermore, GX2, which harbours a 66 nucleotide deletion at the 5’ end of Nef 
(disrupting the binding of KK75, a monoclonal antibody that recognises a linear 
epitope) also caused non-specific trans-activation of the GAL4-AD. These results 
suggest that the mutations in GX2 and J5(R>E) may have a significant effect on the 
overall structure of SIV Nef.
This study describes the use of a novel technique for the fine mapping of novel 
antigenic epitopes using monoclonal antibodies. The structural and yeast-2-hybrid 
data together highlight important observations of SIV Nef which can be related to 
structure and function in vivo, as well as being used as a basis for future in vivo 
studies.
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1. Introduction
1. Introduction
1.1. History of Retroviruses
‘It was a radical proposal that ran counter to the generally accepted central dogma o f 
molecular biology; that there is a unidirectional flow o f genetic information from  
DNA to RNA to protein. In this setting, Temins ’ hypothesis that RSV replicates by 
transfer o f information from RNA to DNA not only failed to win acceptance from the 
scientific community but was met with general derision
Geoffrey M. Cooper
The DNA Pro virus: Howard Temins’ Scientific legacy
Retroviruses were discovered in 1908, when two scientists Vilhelm Ellermann and 
Oluf Bang demonstrated that chicken leukosis, a form of leukemia and of lymphoma, 
was caused by a virus (Ellermann & Bang, 1908). Shortly afterwards, in 1911, cell 
firee transmission of a sarcoma to chickens was reported by Peyton Rous (1911). The 
viruses causing these chicken leukoses have been classified as avian leukosis viruses 
(ALV), whilst the virus observed by Peyton Rous is now known as Rous sarcoma 
virus (RSV). These viruses make up the avian sarcoma/leukosis virus genus (ASLV) 
within the retrovirus family.
The discovery of the mode of replication characteristic of retroviruses dramatically 
altered the general concept of the widely accepted ‘Central Dogma’; that is, the 
unidirectional flow of genetic information from DNA to RNA to protein, as described 
in the passage above. The retrovirus life cycle involves the copying of RNA into 
DNA and is mediated by a virus encoded polymerase enzyme. This process, which
results in a reversal of the normal flow of genetic information, is termed reverse 
transcription, hence the term ‘retrovirus’.
Retroviruses consist of a large and highly diverse family of enveloped RNA viruses. 
Retroviral virions are 80-100 nm in diameter, with an outer lipid envelope 
incorporating the viral glycoprotein. The viral genome consists of 7-12 kb, linear, 
single stranded, nonsegmented RNA, of a positive polarity and diploid in nature. 
Retroviruses are divided into two categories, simple and complex, which are 
distinguished by the organisation of their genomes. Simple retroviral genomes consist 
of three or four major coding domains, gag, pol, env and pro, which code only for the 
viral structural proteins (Figure 1.1). Complex retroviral genomes code for a variety 
of accessory (non-structural proteins) in addition to the structural viral proteins. The 
details of the genes encoding for non-structural proteins will be discussed later.
1.2. Genomic Organisation & Virion Structure
1.2.1. gfljg
The gag gene was named because it was recognised that the proteins it encodes acted 
as group specific antigens (the Gag proteins). Proteolytic cleavage of the Gag 
polyprotein produces the matrix (MA), capsid (CA) and nucleocapsid (NC) viral 
proteins. The minimum Gag protein unit reads MA-CA-NC (Figure 1.2), although 
additional segments can exist between these proteins which can be cleaved into 
smaller proteins or peptides, the precise functions of which remain unknown (for 
review see Wills & Craven, 1991).
The amino terminal of Gag consists of the membrane-associated, or matrix protein 
(MA). The presence of a 14-carbon fatty acid myristoyl group at the amino terminus 
of Gag suggests that Gag may localise to the plasma membrane. Mutation studies
5’ CAPI 1AAA 3’
R U5
gag pro env
US R
pol
Figure 1.1. A simple retroviral genome. The genetic map of ALV contains four major 
coding regions gag, pro, pol and env. Different reading frames are indicated by 
vertical displacement of the coding region. The pro gene is encoded in the gag reading 
frame. The terminal noncoding sequences include two direct repeats (R), a U5 (5' 
unique) andaU3 (3'unique) sequence.
Adapted from: Retroviruses, Cold Spring Harbor Laboratory Press, 1997.
Myr
MA CA NC
Figure 1.2. The organisation of a ‘minimum’ Gag protein unit. The vertical solid lines 
and the cleavage sites for viral protease. The sequences representing the mature 
proteins MA, CA and NC are shown. A myritylation motif (Myr) at the amino 
terminus is shown.
Adapted from; Retroviruses, Cold Spring Harbor Laboratory Press, 1997
have indicated that myristoylation is essential for retroviral assembly and may allow 
proteins to associate with plasma membrane. (Rein et al, 1986). However, the Gag 
proteins of some retroviruses, including ASLV, are not myristoylated. Therefore the 
presence of a myristoyl group may not be the only mechanism for membrane 
association. ASLV Gag is acetylated at the amino terminus, and although the exact 
consequence of this modification is unknown it may contribute to membrane 
association (Palmiter et al, 1978).
The capsid protein (CA) forms a protective shell (capsid) surrounding the 
ribonucleoprotein-genomic RNA containing complex. It is possible that other Gag 
proteins (MA and NC) may also be contained in the capsid. The capsid, together with 
the components it encloses, is known as the ‘core’.
The Mucleocapsid protein (NC) is a small basic protein which contains sequences 
required for assembly or budding of the virion. It is associated with the genomic RNA 
(Davis & Rueckert 1972, Fleissner & Tress 1973).
1.2.2. pro & pol
Infectious retroviruses carry three enzymes; reverse transcriptase (RT), integrase (IN) 
and protease (PR). The pro (pratease) gene encodes PR, which is responsible for the 
cleavage of the gag and pol polyproteins and sometimes part of env as well. The pol 
(po/ymerase) gene encodes IN and RT proteins, which are essential for the integration 
of the virus genome into the host cell DNA early during infection and for the process 
of reverse transcription, which will be discussed later (section 1.3) (Figure 1.3).

Figure 1.3. The organisation of the Pro and Pol proteins of HIV-1. Shown are the 
mature Pro and Pol proteins and their precursors, Sequences for the mature proteins 
PR, RT and IN are shown. The solid vertical lines show major cleavage sites and the 
thick horizontal bars show mature proteins. YMDD and DTG indicate conserved 
active site residues in PR and RT. The location of the RNase H domain of RT is 
indicated.
Adapted from: Retroviruses, Cold Spring Harbor Laboratory Press, 1997.
Gag
DTG
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1.2.3. env
The viral membrane of retroviral virions is studded with glycoproteins, encoded by 
the env gene, (envelope or Env proteins). These are involved are involved in 
attachment and subsequent entry of virus into host cells. All enveloped viruses have 
glycoproteins protruding from the viral membrane which bind to specific receptors. 
Retroviruses express two envelope glycoproteins, derived from a common precursor 
polypeptide. These are the ^wrface (SU) protein, responsible for recognition of 
specific cell-surface receptors and the ftransmembrane (TM) protein which anchors the 
SU-TM complex to the virion envelope and contains domains responsible for fusion 
of viral and cellular membranes.
Env polyproteins are synthesised from a spliced version of the genomic RNA from 
which gag-, pro- and pol-coàing sequences have been removed. The Env polypeptide 
becomes associated with the endoplasmic reticulum (ER) by binding to a signal 
recognition particle via its amino terminal leader segment (Figure 1.4). Further 
translation results in the polypeptide extruding into the lumen of the ER, with the 
carboxy-terminal tail of Env remaining in the cytoplasmic compartment. The leader 
sequence is cleaved off and Env is transported through the Golgi apparatus to the 
plasma membrane by vesicular traffic. In the Golgi, Env is cleaved further to yield the 
mature TM and SU proteins that are present in virions. Cleavage activates the fusion 
potential of the SU-TM complex, required for viral entry into the host cell. The SU- 
TM proteins remain attached to each other by noncovalent interactions or in some 
cases by disulphide bonds. Both SU and TM proteins are incorporated into the 
budding viral particle. The Env protein determines the type of cell a retrovirus can 
infect as it is responsible for recognition of specific cell surface proteins (the viral 
receptors) (Coffin et al, 1997).
-4 I
:y,
/ v t
i
4: %
Figure 1.4. The organisation of the Env protein of HIV-1. Shown are the sequences 
representing the mature proteins SU and TM. Vertical lines, separating the leader 
peptide (L) and SU and separating SU and TM, mark cleavage sites for cellular 
proteases. The hydrophobic fusion domain of TM is highlighted in yellow and the 
membrane anchor is coloured orange. The triangles indicate sites of predicted N- 
linked glycosylation addition.
Adapted from: Retroviruses, Cold Spring Harbor Laboratory Press, 1997.
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The basic retrovirus virion structure and location of the proteins is shown in Figure 
1.5. Complex retroviruses encode additional regulatory nonvirion proteins derived 
from multiply spliced messenger RNA, which will be described later with reference to 
Lenti viruses.
1.3. Viral Replication Cycle
The retroviral life cycle is unique and distinguishes this family of viruses from others. 
The unique stages are the transcription of the virion RNA into linear double-stranded 
DNA and the subsequent integration of this DNA into the genome of the cell. 
Retroviral DNA synthesis is dependent upon the two distinct enzymatic activities of 
the reverse transcriptase (RT) enzyme (a DNA polymerase that can use RNA or DNA 
as a template) and of ribonuclease H (RNase H), a nuclease that is specific for the 
RNA strand of RNA: DNA duplexes.
Initial attachment of the virus occurs to the target cell through the interaction of the 
SU protein of Env with a specific cell-surface receptor protein (Figure 1.6a).
Upon binding of the SU protein to its receptor, the virus envelope and host cell 
membrane fuse together allowing the virion core to be internalised into the cytoplasm 
of the cell. Reverse transcription of the RNA genome into double stranded DNA 
occurs in the cytoplasm (Figure 1.6b). Sequences essential for the reverse 
transcription process are present at the ends of the retroviral genomic RNA. These 
include direct repeats (R) which lie at the 5’ and 3’ ends of the RNA, and the U5 and 
U3 sequences (which lie at the 5’ and 3’ ends respectively) and which are internal to 
the R sequences (Figure 1.7). The process of reverse transcription involves 
duplication of the U5 and U3 region, therefore generating a DNA product that is
11
Figure 1.5. A schematic cross section through a retroviral particle. The viral envelope 
is formed by a cell derived lipid bilayer into which proteins encoded by the env region 
of the viral genome are inserted. These consist of the transmembrane (TM) and the 
surface (SU) components linked together by disulphide bonds. Internal 
nonglycosylated structural proteins are encoded by the gag region of the viral 
genome. They are, matrix protein (MA), capsid protein (CA) and nucleocapsid protein 
(NC). The major products of the po/-coding region are reverse transcriptase (RT) and 
integrase (IN). The protease (PR) is derived from the pro gene between gag and pol. 
Graphics: Andrew Davies, NIBSC
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Figure 1.6. A schematic representation of the retroviral life cycle. In brief, the virion 
attaches to a specific cell surface receptor (a) and the virion core penetrates into the cell 
after fusion of the viral and cell plasma membranes. Reverse transcription within the core 
structure occurs within the cytoplasm, copying the genome RNA into DNA (b). The viral 
DNA locates to the nucleus, where it integrates into the cellular DNA to form the provirus 
(c). The viral RNA is synthesised by cellular RNA polymerase II using the integrated 
provirus as a template (d). The transcripts are processed into genomic and mRNAs and 
virion proteins are synthesised from the mRNAs in he cytoplasm. Virions are assembled 
and bud (e) at the plasma membrane and the capsid proteins are cleaved (f).
Adapted from: Virology, Volume 2,3"" edition. Fields, Knipe & Howley, 1996.
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Figure 1.7. Reverse transcription of the viral RNA genome, generating a linear 
DNA duplex. Reverse transcription generates duplications of the U5 and U3 
regions, resulting in a DNA product that is longer than the RNA at both ends, which 
is the origin of the two long terminal repeats (LTRs), each consisting of the U3/R/U5 
regions.
Adapted from: Retroviruses, Cold Spring Harbor Laboratory Press, 1997.
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longer than the RNA at both ends. This is the origin of the two long terminal repeats
(LTRs) which are characteristic of the DNA form of the viral genome. The stages of
reverse transcription can be summarised as follows (Figure 1.8).
1. Minus strand synthesis is initiated using the 3’ end of a specific host derived 
transfer RNA which anneals to the primer binding site (PBS) in genomic RNA, as 
a primer. Synthesis of the minus strand DNA continues until the 5’ end of the 
genomic RNA is reached, generating a DNA intermediate known as minus-strand 
strong-stop DNA (-sssDNA). This -sssDNA is between 100-150 bp long.
2. RNase-H then degrades the RNA strand of the RNA:-sssDNA duplex.
3. The first strand transfer then occurs, resulting in the -sssDNA annealing to the 3’ 
end of a viral genomic RNA. This process is mediated by the R sequences present 
at the 5’ and 3’ ends of the RNA genome. The 3’ end of the -sssDNA was copied 
from the R sequences at the 5’ end of the viral genome and hence contains 
sequences complementary to R. After removal of the RNA template the -sssDNA 
can anneal to the R sequences at the 3’ end of the RNA genome.
4. Minus strand DNA synthesis resumes, accompanied by Rnase H digestion of the 
template strand.
5. The RNA genome contains a short polypurine tract (PPT) which is relatively 
resistant to RNase H degradation.
6. An RNA segment derived from the PPT primes plus-strand DNA synthesis. Plus 
strand synthesis stops after a portion of the primer tRNA is reverse transcribed, 
yielding a DNA known as plus-strand strong-stop DNA (+sssDNA).
7. RNase H removes the primer tRNA, exposing sequences in +sssDNA that are 
complementary to sequences at or near the 3 ’ end of plus strand DNA.
16
Figure 1.8. The process of reverse transcription. For details, see text. 
Adapted from: Retroviruses, Cold Spring Harbor Laboratory Press, 1997.
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8. The complementary PBS segments in the +sssDNA and minus-strand DNA 
anneal and result in the second strand transfer.
9. Plus- and minus-strand synthesis are completed, with plus and minus strands 
of DNA serving as a template for the other strand (Figure 1.8).
The double stranded DNA is transported into the nucleus and integrates into 
chromosomal DNA (Figure 1.6c). The integrated virus is now referred to as a 
provirus. The provirus is stable and all further replication occurs via the transcription 
of the provirus into RNA by cellular RNA Polymerase II (Figure 1.6d). This RNA is 
the source of both new genomes and the mRNA species. In all retroviruses, full length 
transcripts are packaged as new viral genomes or used as mRNA-coding for the gag, 
pro and pol genes. Upon transport to the cytoplasm, the spliced RNAs serve as 
mRNA for env and for regulatory genes. The translation products are assembled at the 
cell periphery into viral particles that are released from the cell by budding of the 
plasma membrane (Figure 1.6e). Following budding, the virion polyproteins are 
subjected to proteolytic cleavage by the viral protease and cellular proteases (Figure 
1.6f).
1.4. Nature and Classification of Retroviruses
The retroviral genomes may be exogenous or endogenous and many retroviruses are 
involved in cancer induction. These features and taxonomic classification are 
described below.
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Exogenous & Endogenous retroviruses
Exogenous retroviruses integrate into the genome of a host cell, forming a provirus, 
resulting in a permanent association between the cell and retrovirus. These are 
transmitted through infection.
The integration of a retrovirus into the chromosome of a germ cell allows the 
retrovirus to exist as a stable pro viruses for multiple generations. Viral genomes that 
are transmitted by proviral DNA in eggs and sperm are known as endogenous 
retroviruses. Once a germline infection is established, it can found a multicopy family 
of proviruses by further gene duplication within the germline compartment. 
Endogenous retroviruses have been found in all vertebrates.
Oncogenic retroviruses
Cancer inducing retroviruses (oncogenic retroviruses) are prevalent in nature. They 
can be categorised into non-acute transforming retroviruses, acute transforming 
retroviruses and trans-acting transforming viruses.
The non-acute retroviruses are abundant in nature and have been isolated from many 
species, including humans. They cause a variety of cancers, of which leukaemias and 
lymphomas are the most common, and contain a full set of viral replicative and 
structural genes. Cancer induction occurs by insertional mutagenesis, whereby the 
viral DNA integrates at or near to host proto-oncogenes or close to genes involved in 
growth control. This results in the host proto-oncogenes becoming transcriptionally 
activated or deregulated. The structure of the proto-oncogene product could also be 
altered as a result of viral DNA insertion. Alternatively, a tumour suppressor gene can 
be deactivated. All of these features contribute to genetic alterations that can affect 
growth control and result in oncogenesis.
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Acute retroviruses cause polyclonal tumour growth within days. They transform 
normal cells in vitro and induce rapidly growing tumours in vivo, a property which is 
associated with the viral oncogenes present in their genomes. Such viral oncogenes 
are derived from host proto-oncogenes through recombination. During the 
recombination process many of the viral oncogenes acquire mutations and deletions 
that enhance the oncogenicity of the proto-oncogene.
Trans-acting retroviruses, such as HTLV and BLV, induce cancers by a different 
mechanism to that of the acute and nonacute retroviruses. HTLV encodes additional 
genes to those in the genome of acute and non-acute retroviruses. In addition to gag, 
pol and env, it has a unique pX region, which encodes for 6 polypeptides, of which 
Tax and Rex are the most understood. It is the Tax protein that is involved in the 
immortalisation or transformation of T cells. This protein is a transactivator that 
enhances the transcription of the viral LTR and other cellular genes. Tax augments the 
expression of a variety of genes, including protooncogenes c-yww, c-fos, c-myc, c-sis 
and c-rel. Thus HTLV can produce a viral product that can activate proto-oncogenesis 
in trans.
Taxonomic Classification
Retroviruses are divided into seven genera defined by nucleotide sequence 
relationship and genome structure. These are the avian leukosis-sarcoma virus genus, 
the mammalian C-type virus genus, the B-type virus genus, the D-type virus genus, 
the HTLV-BLV genus, spumaviruses and lentiviruses. These are described in more 
detail below.
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The Avian Leukosis-Sarcoma Virus (ALSV) Genus
The avian leukosis-sarcoma virus group consists of exogenous and closely related 
endogenous viruses of birds (Payne 1992). This group has C-type virions and simple 
genomes that encode only gag, pol, env and pro genes. Many isolates of exogenous 
viruses have acquired oncogenes, such as src in Rous Sarcoma Virus. They are 
divided into ten subgroups according to their receptor usage, denoted A through to J. 
Subgroups A-D are characteristic of exogenous viruses from chickens, subgroup E 
belongs to endogenous viruses of chickens and subgroups F and G are from 
endogenous viruses of pheasants. The virus from Hungarian partridge belongs to 
subgroup H (Hanafusa et al, 1976), whilst subgroup I consists of Gambel’s quail 
(Troesch & Vogt 1985). Subgroup J is the most recently discovered and has been 
isolated from chickens (Payne & Howes 1991a, Payne et al, 1991b).
The Mammalian C-Tvpe Virus Genus
This genus incorporates a large number of endogenous and exogenous viruses from a 
diverse group of mammals including rodents (Kozak & Ruscetti 1992), carnivores 
(Hardy 1993), primates, reptiles and some exogenous viruses of birds. No replicating 
human viruses of this group have been isolated.
The B-Tvpe Virus Genus
The only infectious agent within this group is the mouse mammary tumour virus 
(MMTV) which has been isolated as both endogenous and exogenous viruses. These 
viruses contain gag, pol and env genes, as well as an additional coding region, sag, 
which encodes a superantigen activity. No oncogenic variants within this group have 
been described (Coffin «/., 1997).
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The D-Tvpe Virus Genus
The D-type viruses group comprises both endogenous and exogenous isolates from 
primates, and includes the Mason-Pfizer virus. Recent isolates include a virus 
associated with an immunodeficiency syndrome in some captive monkey colonies 
(sAIDS) (Fine & Schochetman 1978, review). There is no evidence that this group 
can exhibit any oncogenic capacity.
The HTLV-BLV Genus
The human T-cell lymphotropic virus-bovine leukemia virus group (HTLV-BLV) 
includes exogenous viruses associated with B-cell lymphoma in cattle and T-cell 
lymphoma as well as some neurological diseases in humans (Clapham et al., 1983, 
Ghysdael et al, 1985). Viruses from this group have a complex genome structure and 
contain at least two additional genes, tax and rex, which encode non-structural 
proteins important for gene expression.
Spumavirus Genus
Spumaviruses were discovered contaminating cells cultured from healthy monkeys in 
1954 (Enders & Peebles 1954, Rustigan et a l, 1955). They induce a characteristic 
foamy appearance {spuma, meaning foam in Latin) in the cytoplasm of cells cultured 
from a number of mammalian species, including monkeys, cattle, cats and humans 
(Flugel 1991, Loh 1993).
Lentivirus Genus
The discovery of lentiviruses can be dated back to 1904 (Valle & Carre 1904), with 
the description of equine infectious anaemia, although the actual classification of this
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virus as a retrovirus within the lentivirus family occurred much later. In 1957, Visna, 
a neurological disease in sheep caused by a virus was described. This gave rise to the 
concept of slow viral infections: hence the current terminology lentiVims, which was 
derived from lentus, the latin for slow. Lentiviruses have subsequently been isolated 
from sheep, goats, horses, cattle, cats, monkeys and humans. The nonprimate 
lentiviral group consists of the original slow virus, visna/maedi virus (VMV), caprine 
arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV), feline 
immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV). The 
Lentiviruses morphology is characterised by a cone-shaped or cylindrical nucleoid in 
the mature virion.
1.5. Human Immunodeficiency Retroviruses. HIV-1 and HIV-2
Human immunodeficiency virus-1 (HIV-1) and Human immunodeficiency virus-2 
(HrV-2) are members of the Lentivirus genus. They constitute important human 
pathogens that cause immunodeficiency in their hosts. HIV-1 and HIV-2 cause a 
lifelong infection, exhibiting complex interactions within the host and inducing a 
slowly progressing and chronically degenerative disease. Infection with HIV can 
remain asymptomatic for years or can be characterised by an initial dramatic weight 
loss and ‘flu-like symptoms or persistent diarrhoea. Progression of the viral infection 
(over years or decades) is characterised by an increase in susceptibility to 
opportunistic infections, a condition known as acquired immunodeficiency syndrome 
(AIDS). Globally it is estimated that approximately 34.3 million adults and children 
are infected with HIV (UNAIDS, 2000). The primary receptor for these viruses is the 
CD4 receptor, an integral component of the T cell receptor (TCR) complex on MHC-
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class II restricted T-cells, and one of the characteristics of AIDS is a decrease in the 
number of T cells carrying this receptor.
HIV-1 has spread throughout the world, whilst HIV-2 is concentrated in West African 
countries, such as Guinea Bissau, Ivory Coast and Senegal, with cases identified in 
America and Europe. Isolates of each type exhibit a high level of variance in their env 
gene, in specific hypervariable sites. Based on env sequences HIV-1 can be classified 
into two main groups, group M (‘main’) which represents the majority of infections 
worldwide and group O (‘outgroup’) which is rare and has only been isolated in 
Cameroon, Gabon and France. Group M can be further divided into nine subtypes or 
clades, denoted A-I. HIV-2 can be divided into five subtypes (A to E).
The first case of human AIDS was recognised in 1981. Evidence from 
epidemiological studies implicated an infectious agent. In 1983, Barre-Sinoussi and 
colleagues (Barre-Sinousi et al, 1983) described the isolation of a previously 
unknown human retrovirus, described as lymphadenopathy-associated virus (LAV), 
from an AIDS patient. This was supported by subsequent reports by Gallo {et a l,
1984) and Levy {et al, 1984), of a virus isolated from AIDS patients, called human T- 
cell lymphotropic virus type III (HTLV-III) and AIDS-associated virus (ARV) 
respectively. These viruses were subsequently classified as members of the Lentivirus 
genus, further defined as the causative agents of AIDS and renamed human 
immunodeficiency virus (HIV). The transmission of HIV by direct sexual contact 
(homosexual or heterosexual), by blood or blood products and from an infected 
mother to infant, either intrapartum, perinatally, or through breast milk (Fauci & Lane
1991) has now been demonstrated by extensive epidemiological studies.
The first case of a simian immunodeficiency virus (SIV, initially described as simian 
T-cell lymphotropic virus type III (STLV-III)), (Daniel et al, 1985, Letvin et al.
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1985) was observed in 1962. An outbreak of lymphomas, now associated with simian 
AIDS (sAIDS) was observed in captive rhesus macaques (Macaca mulatto) at the 
California Regional Primate Research Centre (CRPRC) in Davis, California 
(Mansfield et al, 1995). SIV was subsequently observed to induce symptoms in all 
other Asian macaque species (cynomolgus and nemestrina macaques) similar to those 
of AIDS in humans. Within their natural hosts however, the various isolates of SIV 
(SrVagm (affican green monkey), SIVsm (sooty mangabey), SlVmnd (mandrill), 
SIVsyk (sykes) and SIVcpz (chimpanzees)) do not cause disease. The viruses isolated 
from some of these captive animals (SIVmac (macaque), SIVcyn (cynomolgus) and 
SIVmne (nemestrina)) appear to be closely related to SIVsm, implicating a common 
origin for all (Mansfield et al, 1995). The likelihood of cross transmission from the 
naturally infected sooty mangabeys to macaques is therefore high.
1.6. Receptor usage
Receptor usage varies amongst enveloped viruses. The HIV Env protein recognises 
and binds to CD4 present on the surface of macrophages and helper T lymphocytes 
(Dalgleish et a l, 1984). More recent studies have indicated that an additional 
coreceptor is required to mediate efficient entry into cells (Berger 1997). These 
'fusion cofactors' are present on CD4+ target cells and determine the specificity of 
Env-mediated fiision. HIV exhibits a high mutation rate resulting in a high degree of 
variability in the env gene. One of the consequences of such mutations is that 
individual HIV-1 isolates, tested in vitro, have distinct cytotropisms for infection of 
different CD4+ human cell types. Some isolates replicate in continuous T cell lines, 
but only poorly in macrophages. Others infect macrophages more efficiently than T 
cell lines. This difference in tropism has led to isolates being designated T-cell tropic
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(TCL-tropic) or macrophage tropic (M-tropic). Further analysis investigated the 
determinants responsible for cytotropism and it was concluded that the env gene 
(specifically a region of gpl20 including the V3 loop) determined whether a virus 
would exhibit a TCL- or M-tropic phenotype. To explain why Env mediates fusion 
with only a limited number of CD4+ target cells, it was suggested that the target cell 
contained an essential cofactor required for Env-dependant fusion. A cofactor which 
fused to Env from the IIIB isolate was identified as a seven-transmembrane segment 
G-protein coupled receptor and named 'fusin', later renamed CXCR4 (Feng et al.,
1996). This was established to be an essential cofactor for TCL-tropic HIV-1 isolates. 
The identification of fusin lead to a focus on the G-protein coupled receptor 
superfamily in the search for a cofactor for the M-tropic isolates. Finally, CCR5 was 
identified as a fusion cofactor for M-tropic HIV-1 strains (Berger et al., 1997.)
1.7. Genomic Organisation of Immunodeficiency Viruses
The Lentivirus genus has a complex genomic structure. The genomes of HIV and SIV 
consist of three major open reading frames, gag, pol and env, which encode the core 
proteins (p24, p i7, p9 and p7), the viral replication enzymes (reverse transcriptase, 
RNase H, protease and integrase) and the envelope glycoproteins (Env) respectively 
(see section 1.2). HIV and SIV also have two regulatory genes, tat and rev. HIV and 
SIV differ in their additional accessory genes. HIV-1 encodes vif, vpr, vpu and nef, 
whilst HIV-2 and SIV encode vif, vpx, vpr and nef (Figure 1.9). These genes are 
sometimes referred to as non-essential, as they are not required for viral replication in 
tissue culture. Proteins produced from the vif vpr and nef genes are assembled into 
virions.
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Figure 1.9. The genomes of HIV-1, HIV-2 and SIV. The start of the gene is indicated 
by the small number from the upper left hand comer of each rectangle and is the 
position of the a  in the a t g  start codon for that gene. The number in the lower right is 
the last position of the stop codon.
Shaded boxes denote tat and rev spliced exons.
Red boxes denote 5’LTR and 3’LTR.
Blue boxes denote standard retroviral genes, gag, pol and env.
Orange boxes denote accessory genes, vif, vpx, vpr/vpu.
Yellow box denotes the nef gene.
In the HIV-1 HXB2 genome, the *5625 and *5772 mark the positions of the 
frameshifts in the vpr gene; 16062 indicates a defective a c g  start codon in vpu\ f8424 
and f9168 mark premature stop codons in tat and nef.
Adapted from: Human Retrovimses and AIDS (1999). Ed; Kuiken C, Foley B, Hahn 
B, Marx P, McCutchan F, Mellors J, Mullins J, Wolinsky S, Korber B.
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1.7.1. Regulatory Genes
a. tat
The tat gene (/ransactivator of transcription) is located between the vpr and env genes. 
Tat is expressed early in the viral life cycle and is essential for viral gene expression, 
replication and pathogenesis (Dayton et al., 1986, Fisher et al, 1986). Tat is 
translated from multiply spliced viral transcripts that do not require Rev for export 
from the nucleus to the cytoplasm (Jones & Peterlin, 1994).
An arginine rich motif (ARM) within Tat binds to the 5’ bulge region of the trans­
activation response element (TAR), which is located within the LTR and is 
transcribed within the 5’ end of all viral transcripts. Tat regulates the process of 
elongation (Jones & Peterlin 1994, Kao et a l, 1987), therefore, in its absence, 
transcription complexes assemble on the viral promoter (LTR), but RNA polymerase 
II synthesises only short transcripts (Kao et a l, 1987). When Tat binds to TAR the 
RNA polymerase II is then competent for elongation (Kao et a l, 1987, Laspia et a l, 
1989, Feinberg et a l, 1991). The highly specific interaction between Tat and TAR is 
mediated by the cyclin subunit of the positive elongation factor b (P-TEFb). By 
interacting with the human cyclin T1 (hTl), Tat recruits the cyclin dependant kinase 9 
(CDK9), which phosphorylates the C-terminal domain (CTD) of RNA polymerase II. 
The conversion of RNA polymerase II from unphosphorylated to phosphorylated 
form is the point of transition from initiation to elongation (Jones, 1997).
b. rev
In order to encode nine different genes in an approximately 9 kb genome, HIV and 
SIV utilise alternative reading frames and complex patterns of RNA splicing (Gallo et 
al, 1988, Schwartz et a l  1990). The Rev protein (regulator of expression of virion
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proteins), expressed early in the viral replication cycle, is involved in the regulation of 
viral gene expression during the replication cycle (Kim et ah, 1989, Pomerantz et al., 
1990). Rev is responsible for the efficient export of unspliced and singly spliced viral 
mRNAs (Feinberg et al. 1986). In an infected cell. Rev binds to the Rev Responsive 
Rlement (RRE) in viral transcripts and shifts the balance from multiply spliced 
transcripts (encoding tat, rev and nef early in the viral replication cycle) to both singly 
spliced and unspliced transcripts (encoding viral structural proteins Gag, Pol, Env and 
the accessory proteins Vif, Vpu, Vpr and Vpx expressed in the late stages of 
replication). Hence, the genes expressed by HIV and SIV can be divided into two 
groups. The Rev independent genes are expressed from RNAs that are completely 
spliced and are exported to the cytoplasm by the normal mRNA export pathway. The 
Rev dependent genes are the intron containing messages that are retained in the 
nucleus and are expressed only when the Rev protein is present. The Rev protein itself 
is expressed from a completely spliced message, therefore expression of Rev 
dependent messages is delayed until a threshold level of Rev is attained (Felber et al., 
1990). Hence, the intron containing messages are known as the late genes, whilst the 
Rev independent messages are the early genes.
Rev interacts with a specific loop in the RRE via an arginine rich RNA binding motif 
(ARM) which also serves as the Rev nuclear localisation signal (NLS) (Zapp & 
Green, 1989, Malim et al., 1990). A leucine rich domain between amino acids 75 and 
84 in Rev acts as a nuclear export signal (NES) which can induce the efficient nuclear 
export of linked substrate proteins (Fischer et al., 1995, Wen et al., 1995).
Overall, Rev is responsible for mediating temporal regulation of viral gene expression 
and influencing transport of mRNA from the site of synthesis in the nucleus to the 
cytoplasm.
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1.7.2. Viral Accessory Genes
Although the term ‘accessory’ implies that these genes are dispensable for viral 
pathogenesis, it is in fact the opposite which is true. It has been shown, on many 
occasions, that deletion or attenuation of any of these genes has a dramatic effect on 
the viruses’ ability to replicate in vivo, revealing an altogether more critical 
requirement for these genes in vivo.
a. vif
The vif gene (viral mfectivity/actor) is located downstream of the pol gene. Early 
studies on the requirement of the HIV-1 and HIV-2 vif gene for viral replication 
revealed that the infectivity of vif deleted virus is reduced up to 1,000 fold relative to 
wild type HIV in certain CD4+ T-cell lines (H9) (Fisher et al, 1987, Strebel et al, 
1987). More recently, the HIV-1 vif gene has been demonstrated to be required for 
replication in T-cell lines such as CEM, H9 and peripheral blood lymphocytes, but not 
in others, such as SupTl, C8166 and Jurkat (Fan & Peden 1992, Gabuzda et al,
1992). Vif has been implicated in playing a role in virion maturation, as well as in 
uncoating and/or internalisation of virus in restrictive cells, thereby enabling the 
reverse transcription process to produce linear viral DNA molecules (Coffin et al,
1997). Furthermore, Desrosiers et a l  (1998) revealed that attempts to recover virus 
from PBMCs of rhesus macaques infected with SIVmac239Av/ (SIVmac239 virus 
with a deleted v if gene) proved unsuccessful, as were attempts to detect SIV DNA by 
PGR from these animals. The relative virulence of the virus, due to the deletion in vif, 
was reduced to 10'  ^ in comparison with wild type SIVmac239 virus. More recently, 
the cellular protein CEM 15 was identified as the critical homologue for Vif (Sheehy 
et a l, 2002).
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Small amounts of Vif have been demonstrated in virus particles. Initially, Vif 
packaging appeared to be non-specific, however, it has now been shown that Vif is 
specifically packaged into virions as a component of the viral nucleoprotein complex, 
a process which is dependent upon the packaging of viral genomic RNA in permissive 
and restrictive HIV-1 target cells. Mutations in the zinc finger domains which 
abrogated packaging of viral genomic RNA also abolished packaging of Vif (Khan et 
al, 2001).
b. vpr & VPX
Hral j^rotein r (vpr) is present in HIV-1, SIVcpz, S IV syk , SIV agm  and SIVmnd- By 
contrast, HIV-2 and several other strains of SIV, such as SIV m ac and SIVsmm, contain 
both vpr and vpx (Myers et al, 1994). These genes are homologous, suggesting that 
vpx may be a duplication of vpr. The presence of vpr and vpx in the viral particle 
suggests that they may function during the early stages of viral replication.
Mutagenic studies of HIV-1, HIV-2 and SIVmac have revealed that a virus containing 
mutations within vpr can still replicate to wild type levels in CD4+ T-cell lines and 
cultured primary lymphocytes (Dedera et al, 1989). However, at low multiplicities of 
infection HIV-1 vpr mutants replicate poorly in T-cell lines in comparison to wild- 
type viruses.
Studies have implicated a role for vpr in nuclear localisation of the pre-integration 
complex (Heinzinger et a l, 1994). This gene has also been implicated in the 
regulation of viral and cellular gene expression (Levy et a l, 1993). Using in vitro 
transient expression assays, a plasmid expressing the HIV-1 vpr gene was shown to 
activate its homologous LTR, as well as promoters of several heterologous viruses. 
Other studies based on analysis of stable transfectants of a human muscle tumour cell
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line harbouring the HIV-1 vpr gene, have implicated a nuclear role for vpr, as vpr was 
observed to block cell proliferation and induce expression of muscle cell markers. 
This suggests that vpr could influence viral gene expression by altering host cell 
regulatory mechanisms which subsequently enhance viral replication.
The levels of Vpr incorporated into virions, by comparison to Vif and Nef are 
significantly high. For the packaging of Vpr, a leucine rich element in the p6 region of 
p55 Gag polyprotein and a region of Vpr that overlaps a predicted a-helical domain 
(amino acids 16-33) have been described to be critical (Di Marzio et al., 1995, Kondo 
et al., 1996, Lu et al., 1995, Mahalingham et al., 1997). It has been described that 
HIV-1 Vpr is primarily cytoplasmic, which could facilitate the packaging of Vpr into 
virions (Jenkins et ah, 2001).
It has been demonstrated that the carboxyl terminus of Gag is required for the 
incorporation of Vpx into virions (Wu et al, 1994). An interaction of Vpx with p27 
CA in the virion has been described (Horton et al, 1994). Furthermore, for the uptake 
of SIVmac Vpx and SIVmac Vpr into virus like particles a dileucine containing motif 
in the N-terminal half of p6®^  ^has been shown to be required (Accola et a l, 1999).
c. vpu
The viral j^rotein u gene is present in HIV-1 and SIVcpz, located 3’ to tat and rev. 
HIV-2 and other lentiviruses lack this gene.
Virus strains deficient in vpu can replicate in CD4+ T-cell lines and in both primary 
T-lymphocytes and macrophages. However, these viruses are several fold less 
efficient at releasing virions into the extracellular medium compared with wild type 
viruses (Klimkait et al, 1990, Terwilliger et al, 1989). These studies demonstrated 
that functional Vpu was necessary to release particles fi*om the plasma membrane of
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infected cells. Vpu has been demonstrated to cause the rapid degradation of the CD4 
receptor in the endoplasmic reticulum (Willey et ah, 1992, Vincent et al., 1993) when 
cells were expressing all three proteins. This activity is sequence specific, requiring 
the anchor and cytoplasmic domain of CD4. It is also specific to the ER. However, the 
mechanism of Vpu dependent CD4 degradation remains unclear.
d. nef
The nef gene (previously described as V o rf  or orfB) is unique to primate lentiviruses 
and is located at the 3’ end of the viral genome, where it overlaps part of the 3’ long 
terminal repeat (Figure 1.9). This gene is expressed early in the viral replication cycle, 
with reports of Nef specific mRNA constituting approximately 80% of the viral 
mRNA present in infected cells at early time points after infection (Robert-Guroff et 
al., 1990). The nef gene encodes a protein product ranging from 206 amino acids in 
HIV-1 to 265 amino acids in HIV-2 and SIV, with a molecular mass between 27-35 
kDa (Harris, 1996). The high degree of conservation of this gene in HIV and SIV 
suggests an critical role in the viral life cycle. However, contrary to the current 
opinion for an essential role of nef in the viral life cycle, it was initially described to 
have a negative influence on viral replication, hence the term negative /actor.
The Nef protein is cotranslationally modified at the N terminus by the addition of a 14 
carbon saturated fatty acid; myristate; Met-Gly-X-X-X-Ser/Thr (Allan et al., 1985). 
Studies have shown that the addition of this group is required for the membrane 
association of some viral and cellular proteins, such as the MARCKS protein (Li & 
Aderrem, 1992) and the Src family of protein tyrosine kinases (Resh, 1994). The 
myristate is covalently linked to the N terminal glycine in a reaction catalysed by N- 
myristyl transferase. Myristoylation is required for localisation of Nef on the
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cytoplasmic face of the plasma membrane in infected cells (Yu & Felsted 1992). It 
has been described to be essential for the interaction of Nef with a subset of cellular 
membrane-associated proteins designated p280, p32 and p28 according to molecular 
weight. It was suggested that one or more of these proteins could represent a 
membrane target for Nef. However p97, a protein present in soluble and membrane- 
associated cell fractions was found to bind nef independently of myristoylation 
suggesting that for Nef the particular interaction with the N terminus of Nef is not 
required (Harris & Coates 1993). Myristoylation has also been described to be 
essential for the interaction of HIV-1 Nef with actin, forming a high-molecular-mass 
complex (Fackler et al, 1997).
In order to investigate if myristoylation is important for interactions between Nef and 
cellular processes, Harris (1995) generated Nef as an N-terminal fusion with GST and 
expressed this protein in the baculovirus system. These myristoylated Nef fusion 
proteins interacted with Lck, a member of the Src family of tyrosine kinases (section 
1.9.le) and P-COP, a component of non-clathrin coated vesicles. These interactions 
were demonstrated to be dependent on the presence of the myristate moiety as a non- 
myristoylated Nef fusion protein did not bind to p-COP. This suggests that as well as 
a mechanism for targeting Nef to membrane structures, myristoylation is also 
important in mediating interactions between Nef and other cellular proteins, therefore 
contributing to the ability of Nef to perturb signal transduction pathways.
Nef has been reported to be detected in HIV-1 virions which lack an active viral 
protease (PR), whilst smaller amounts of intact Nef were present in wild-type virion 
preparations. In these instances, a smaller Nef with an apparent molecular mass of 18 
kDa was observed.
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Myristoylation was observed to be crucial for the association of Nef with virions. A 
truncated Nef, containing only the N-terminal 86 amino acids including the myristate 
moiety was found to be incorporated as effectively into virions as full length Nef, 
suggesting that cell membrane association of Nef through myristoylation may be 
sufficient for the incorporation of Nef into the virion particles. (Bukovsky et a l, 
1997). Welker and colleagues (1998) defined the signal at the N terminus required for 
virion incorporation as a bipartite membrane targeting signal, consisting of a 
covalently attached myristic acid and a cluster of positive charges in the N terminus of 
the protein. This signal was found to be reminiscent of a Src homology region 4 
(SH4), which mediates plasma membrane targeting of protein tyrosine kinases of the 
Src family (Resh, 1994). The ability of Nef and N-terminally altered Nef proteins to 
bind to the membrane correlated with their incorporation into virus particles and was 
independent of other viral proteins.
1.8. Structural and Biochemical Features of Nef
The Nef protein of HIV-1 is 206 amino acids, whilst that of SIV and HIV-2 is 
approximately 250 amino acids in length. As previously mentioned, it is a 
myristoylated protein which is important for association with cellular membranes.
The three dimensional structure of HIV-1 Nef, coupled with the SH3 domain of Fyn 
or Hck tyrosine kinases has been resolved (section 1.12e) (Arold et al., 1997, Lee et 
al., 1996). Furthermore, the structure of Nef alone and bound to a peptide from the 
CD4 cytoplasmic tail has been determined by nuclear magnetic resonance (NMR) 
(Grzesiek et al., 1996a, Grzesiek et ah, 1996b). These studies showed that the HIV-1 
Nef core consists of a type II polyproline helix (amino acids 70-77), which is the main 
binding site for the Src family kinases. Also present are two alpha helices (aa 81-120),
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a four stranded anti-parallel beta-sheet (aa 121-186) and two additional alpha helices 
(aa 187-203). Residues 60-71 and 149-180 form flexible solvent-exposed loops. The 
three proximal helices of the Nef core domain (aa 70-120) form a cavity which is 
potentially accessible to drugs. Binding to this crevice could disrupt interactions 
between Nef and Src family kinases (Grzesiek et al., 1996a, Grzesiek et al., 1996b). 
The NMR structure of a peptide corresponding to the n-terminal domain of Nef has 
also been resolved. This region was found to form a well-ordered alpha-helix from 
residues 6-22, with the N and C terminal regions having a less ordered structure 
(Bamham et al., 1997).
1.9. Early Studies of nef
The nef gene was initially described as exhibiting homology with the nucleotide 
binding sites of GTP binding proteins (Guy et al, 1987). Data indicated that E. coli 
derived Nef could bind GTP and autophosphorylate, suggesting that it had homology 
with regions in the Ras family of proteins involved in GTP-binding. This implicated a 
role for nef in interfering with pathways involved in control of cellular functions. 
Subsequent experimentation failed to reproduce these findings and it was suggested 
that the results may have been due to contamination with a bacterial GTP-binding 
activity (Harris et al, 1992).
In addition, early studies of nef described it to be dispensable for viral replication in 
vitro (Fisher et al, 1986). A series of mutants of the biologically active molecular 
clone HIV pHXB2D containing deletions of 55, 109, 85 and 100 base pairs in the nef 
gene, as well as deletions encompassing the last 14 bases of the envelope gene, the 
initiation codon for nef and the first 159 or 182 base pairs of nef, were transfected into 
the human T-lymphoid cell line H9. The ability of these mutants to produce virions
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indicated that the various deletions within the nef gene had no effect on the ability of 
HIV-1 (then known as HTLV-III) to replicate in vitro.
The pHXB2 plasmid was used in further studies where deletions were introduced into 
the nef gene (Terwilliger et al., 1986) removing 11 or 50 amino acids from the 3’ nef 
open reading frame. After transfection of these mutants into the Jurkat-ra^ III and the 
C8166-45 cell lines, cell number, cell-free reverse transcriptase activity, HTLV-III 
specific surface immunofluorescence and syncytium formation were investigated. 
Provirus containing deletions within the nef gene exhibited a cytopathic effect. 
Although it was concluded that nef was dispensable for replication and the cytopathic 
ability of the virus, the high degree of conservation of the nef gene indicated an 
important role in the life cycle of the virus. It was therefore suggested that this gene 
may be required for growth in cell lines other than those used in these experiments, or 
that the function of this gene may be one which was not measured in the assays 
described.
By contrast, Luciw et al. (1987) used molecularly cloned provirus of HIV San 
Francisco isolate 2 (HlVsrz) containing mutations in three regions of the nef gene 
(then known as 3’ orf), to transfect the human lymphoid T cell line HuT78. They 
demonstrated that the virus produced was cytopathic, with titres five fold greater in 
comparison to wild type virus. A greater level of viral protein was also detected in 
mutant virus infected cells, with increased levels of both proviral and unintegrated 
forms of DNA being produced in lymphoid cell cultures. It was suggested that these 
mutants were exhibiting increased replication ability, possibly through interaction 
with the LTR region.
Initial studies of the effect of Nef therefore suggested that mutation of «e/led to more 
efficient viral replication, implicating a nonessential role in the viral life cycle.
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although this was to be disputed and proved incorrect in subsequent investigations. 
(Fisher et al, 1987, Terwilliger et al, 1986, Luciw et al, 1987).
Two reports appeared simultaneously in 1989 that disputed data demonstrating that 
deletions within nef resulted in an increase in viral infectivity in vitro. Hammes et a l 
(1989) used two different nef expression vectors, as well as a control vector 
containing a ffameshift mutation in the nef coding sequence. This group showed an 
inability of Nef proteins to inhibit transcriptional activity of the LTR in a variety of 
cell types, including primary human T lymphocytes, Jurkat or YT-1 leukaemic T 
cells, U-937 promonocytic cells and nonlymphoid COS cells, over a broad dose 
range. No differences were exhibited by the proviral clones containing wild type or 
mutated nef genes, indicating the lack of a Nef-mediated negative effect on in vitro 
viral replication.
This result was supported by a parallel study using two isogenic HIV-1 (HIV-1-W13) 
strains, one of which lacked nef expression (Kim et al, 1989). Comparison of viral 
entry, measurement of unintegrated HIV DNA after infection of H9 or primary T cells 
and assays to measure reverse transcription, RNA expression and virus production in 
a number of different cell lines were performed. No obvious differences were 
observed between the wild type and the nef deficient virus strains. By contrast, it was 
observed that the presence of nef conferred a growth advantage to the virus, an effect 
that was most apparent in primary T cells. This data was therefore consistent with 
speculation that the high degree of conservation of the nef gene implicates an 
important role in the viral life cycle.
It is likely that early experiments performed which concluded that nef was dispensable 
for viral replication may have been due to the restricted number of cell lines used, or 
due to conditions during experimentation which did not allow the true effect of nef to
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be exerted. Indeed, Terwilliger et al. (1986) concluded that although within their 
experiments nef was proven to be dispensable for replication, that due to the high 
degree of conservation of this gene that it must have an important role in the viral life 
cycle.
1.10. Genetic & Molecular Analysis of Using the Macaque Model
The progress from infection to disease in cynomolgus and rhesus macaques infected 
with SIVmac is usually 1-4 years. However, infection with virus harbouring deletions 
within specific regions has been shown to result in low viral loads and animals 
remaining asymptomatic for longer periods of time. At the nucleotide level SIV , 
HIV-1 and HIV-2 exhibit an overall homology of approximately 40%, with SIV and 
HIV-2 having a homology of approximately 70% (Chakrabarti et al, 1987), 
suggestive of a common origin for these viruses. This could implicate cross species 
transmission of SIV into humans, similar to that of the sooty mangabeys to macaques. 
The macaque therefore represents a model in which viruses can be tested to determine 
which genetic modifications attenuate pathogenesis in vivo.
Studies were performed using the SIV model to determine if deletions within specific 
regions of the nef gene correlated with an attenuated phenotype in vivo. Deletions 
were introduced into key regions of the nef gene and the subsequent effect of these 
mutations studied in the pathogenic outcome of disease.
Kestler et a l (1991) used the infectious molecular clone SIVmac239 (Reiger & 
Desrosiers, 1990) to investigate the importance of the ne/’gene for virus replication in 
vivo. SIVmac239 contains a premature stop codon at the 93^  ^codon of nef. This codon 
was mutated by oligonucleotide-directed site specific mutagenesis to create 
SrVmac239/ne/-open. The same method was used to introduce a 182 bp deletion in
41
nef. These three forms of virus, SIVmac239/ne/stop, SIVmac239/ne/open and 
SrVmac239/ne/deletion were used to determine the requirements of the nef gene both 
in vivo and in vitro.
In vitro kinetics in CEMxl74 cells, in primary cultures of rhesus monkey peripheral 
blood lymphocytes (PBLs) and in primary rhesus monkey alveolar macrophage 
cultures revealed no differences between the three types of virus, consistent with 
previous reports for HIV-1 (Hammes et al, 1989, Kim et al, 1989).
Studies were extended to rhesus macaques. Five animals were infected with 
SIVmac239/ne/stop, seven with SIVmac239/nq/open and six with SIVmac239/nq/ 
deletion. Although all animals became infected, virus recovery from animals 
inoculated with the SIVmac239/«e/-deletion proved increasingly difficult with time. 
The nef gene from two animals infected with SIVmac239/nq/stop was amplified and 
cloned. These clones were obtained from one animal at the time of death and from 
others at various time points during the asymptomatic stage of persistent infection. All 
clones revealed that the stop signal at the 93^ codon had reverted to a coding codon. 
This would imply that there is a strong selective pressure for the virus to maintain an 
open, functional form of the nef gene, thereby suggesting that nef is performing a 
critical function for the virus life cycle in vivo.
The virus load in rhesus macaques that received the SIVmac239/ne/'-deleted virus was 
observed to be at least 100-fold lower than those in rhesus macaques that received the 
other two viruses. The p27 gag protein in the cell-free plasma was also found to be 
below the level of detection (approximately 0.05 ng/ml). Therefore, whilst the 
presence of the 182 bp deletion had no effect on the ability of the virus to replicate in 
vitro, in vivo the virus exhibited a much lower virus load. This indicates that the 
presence of a fully functional nef gene is an important factor for the progression to
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AIDS in rhesus macaques. This is in agreement with the effect of the reversion of the 
stop signal at the 93^  ^codon to a coding codon.
SrVmac251 is a swarm of SIV which can infect and cause an AIDS-like syndrome in 
rhesus and cynomolgus macaques. A stock of SIVmac251 virus was used to infect 
rhesus macaque number 32H (Cranage et al, 1990). A low passage pool, designated 
11/88 stock was subsequently prepared from virus re-isolated from this monkey. This 
swarm of virus, designated SIVmac32H, derived from the 11/88 stock has been 
selected as a virus challenge for EU co-ordinated projects for the development of an 
AIDS vaccine and has also been used following inactivation with formaldehyde as an 
immunogen in macaque vaccination trials. The attenuated clone SIVmac32H(C8) has 
also been selected for a subsequent European study. The wild-type clone 
SrVmac32H(J5) has also been used as a challenge virus in a number of UK studies. 
Rud and colleagues used SIVmac32H (Rud et al, 1994) to study the effects of 
specific deletions within the nef gene on the pathogenic outcome of infection. The 
molecular clone SIVmac32H(J5) (hereafter referred to as J5) has no premature stop 
codons within any of its genes and is derived from SIVmac32H. This clone encodes a 
full length Nef protein. The SIVmac32H(C8) (hereafter referred to as C8) clone 
contains a naturally occurring 12 base pair deletion within the nef gene which results 
in an in-frame deletion of four amino acids, DMYL, at positions 143-146. Clone C8 
has two additional amino acid changes, at amino acid 191, Arg>Lys (R191K), and 
amino acid 249, Thr>Ala (T249A). The location of these changes in a region of the 
nef gene that overlaps with the 5’ end of the U3 region of the 3’ LTR. There are 
further nucleotide changes within the 3’ LTR which are not known to be associated
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with any critical motifs. The position of these changes in the 3’ LTR, however, are not 
in any of the major transcriptional control elements of the 3’ LTR.
Electroporation of C8 and J5 clones into C8166 cells revealed no replicative 
advantage or disadvantage to be associated with the defect in the nef gene of clone C8 
(Rud et a l, 1994), an observation that is consistent with reports of Kim et a l (1989) 
and Hammes et a l (1989) for HIV-1.
However, data generated using in vivo models yielded significantly different results, 
which relate to the difference in the nef gene between the two viruses (Rud et al,
1994). Pairs of Chinese rhesus macaques were infected with equivalent titres of virus 
derived from J5 or C8 and blood samples taken at regular intervals. PBMCs were 
isolated and co-cultivated with freshly passaged C8166 cells. Virus load and the time 
to appearance of a cytopathic effect was measured. It was found that virus could be 
isolated from macaques infected with the C8 virus only during the first 20 weeks post 
infection, whilst firom the macaques infected with J5, virus could be isolated for at 
least 40 weeks. Virus was recovered from various tissues of both J5 infected 
macaques and from one of the two C8 infected macaques. To rule out the possibility 
that Chinese macaques may be more resistant to AIDS-related pathogenesis, the virus 
pool of J5 was titrated in Indian rhesus macaques. Seven of the eight macaques 
became infected, with one animal being sacrificed due to its rapidly deteriorating 
condition. Post mortem examination showed several pathological abnormalities 
within this animal consistent with SIV infection. This data highlights the difference in 
the pathogenic outcome of the wild type J5 and the attenuated C8 virus.
Cynomolgus macaques were also found to be susceptible to infection by J5 and C8, as 
determined by virus isolation and PCR analysis. However, whilst the condition of one 
of the J5 infected animals declined rapidly until it had to be sacrificed at nine months
44
post infection, the C8 infected cynomolgus macaques which had been infected for the 
same duration of time did not exhibit any signs of disease. As observed in the Chinese 
rhesus macaques, all of the cynomolgus macaques infected with C8 became 
intermittently positive for virus isolation after approximately 6 months of infection 
(Rud et al, 1994, Almond et a l, 1995). The observation that such a small deletion 
can significantly affect the virus’s ability to achieve its full pathogenic potential in 
vivo leads one to speculate on the potential functions of the region in the J5 nef gene, 
which is deleted in C8 in vivo. A comparison of the phenotypes that C8 and J5 virus 
exhibit in in vitro assays would enable a detailed study of the effect subtle differences 
in nef can have on some of the critical functions of the virus (section 1.10). 
Serendipitous observations by Whatmore et a l (1995), using the molecular clone 
SrVmacC8, has enabled the dissection of Nef function to be taken further. Seven 
Indian rhesus macaques were each infected with SIVmacC8 by intravenous 
inoculation. Whilst replication of the virus was consistent with C8 virus in six out of 
seven animals, one animal, 45R, was found be persistently positive for virus isolation. 
The proportion of virus infected-PBMC in 45R, as determined by serial dilution, was 
found to be at least 583-fold greater than the other animals, suggesting that a virus 
with a more virulent phenotype than that of the attenuated SIVmacC8 had developed 
in the animal coincident with higher levels of virus replication The anti-SIV p27 
antibody titre in this animal was initially higher than the mean titre for the rest of the 
group but fell after 17 weeks of infection to levels much lower than that of the other 
animals. At 12 weeks post infection a significant decline in CD4/CD8 ratio was 
observed in animal 45R and by 58 weeks had reached just 28% of the preinfection 
value. The clinical condition of this animal rapidly deteriorated, consistent with the 
development of an AIDS-like syndrome. At 63 weeks post infection lymphocyte
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depletion from lymph nodes and spleen was observed, as well as colitis, small 
intestinal cryptosporidiosis and Pneumocystis carinii pneumonia (Whatmore et al, 
1995).
Analysis of the complete nucleotide sequence of the neflV LTR region of PBMC 
associated provirus at regular intervals revealed that at 62 weeks after infection at post 
mortem, the 12 base pair region deleted in the SIVmacCS virus had been repaired 
with the amino acid sequence EKIL. This sequence motif continued to evolve, such 
that at 25 weeks the sequence was EIYL and by 45 weeks it had evolved to DIYL, 
identical to the equivalent motif in the pathogenic clone SIVmac239 and only one 
amino acid different from the original wild type sequence of DMYL. The remaining 
nucleotide changes within SIVmacCS remained stable. Interestingly, at week 45, 
when the gene sequence had evolved to DIYL, the SIVmacCS provirus used a 
different aspartic acid codon (GAT) than that used in SIVmacJ5 (GAC). This would 
suggest that there is a pressure for the virus to restore the amino acid sequence of Nef, 
rather than to restore the specific nucleotide sequence. This supports the idea that the 
attenuation of C8 is through the disruption of Nef rather than a U3 specific sequence. 
Therefore, the reversion to virulence of the virus was attributable only to the effect the 
mutations had on the nef gene and was not due to effects on the 3’ LTR. This is 
consistent with previous observations which concluded that the function of the n e f y  
LTR region is as a nef coding sequence, as mutation of the U3 region has limited 
effect on the ability of the virus to replicate or virulence in vivo (Ilyinskii et a l, 1994).
It therefore appeared that the repair of this ‘attenuating’ region within SIVmacC8 was 
directly responsible for the progression to disease in animal 45R, indicating that this 
region may be vital to the virus for achieving its full pathogenic potential in vivo. It is
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possible that the attenuation within C8 results in a Nef protein that is not as stable as 
wild type Nef and this could contribute to the observed decrease in pathogenicity. 
Certainly, the stability of C8 Nef has been demonstrated with by infecting cells with 
vaccinia derived C8 and J5 Nef virus proteins and pulse labelling with 35^ methionine 
over a specific period of time. It was observed that the rate of turnover of the C8 
proteins was greater than that of J5 protein, but only by a marginal difference (A. 
Gallimore, PhD thesis, personal communication).
The study by Whatmore et al. (1995) is consistent with the previous report (Kestler et 
al, 1991) which showed that progression of infection in rhesus macaques occurred 
when SIVmac239/«q/'-stop, a clone containing a stop signal at the 93^  ^ codon within 
nef, exhibited reversion of the stop signal to a coding codon. Whilst these 
observations are intriguing, these studies still demonstrate that C8 is remarkably 
stable in the remainder of infected animals.
1.11. Study of nefm  Viral Pathogenesis Using the Mouse Model
Mouse models provide an alternative in vivo model for the study of nef and AIDS 
pathogenesis. The SCID-hu mouse is an in vivo model which allows the measurement 
of HIV pathogenesis in the absence of a host immune response. As a result of this the 
pathogenicity of the virus can be observed without the interference of a normal 
immunological response. The SCID-hu mouse model is constructed by the surgical 
implantation of human fetal liver and thymus under the murine kidney capsule of 
severe combined immunodeficient (SCID) mice (McCune et a l,  1988, Namikawa et 
al, 1999). These tissues form a conjoint (Thy/Liv) organ, which histologically 
resembles a normal human thymus. Infection of this organ with HIV-1 induces a 
similar disease pathology as that observed in humans (Papiemik et a l, 1992,
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Rosenzweig et al., 1993). The depletion of CD4 cells observed in the SCID-hu mouse 
system correlates with a high viral load.
Jamieson and colleagues (1994) showed that HIV-1 strains with deletions or 
frameshift mutations in nef were attenuated in their replicative and pathogenic 
potential using the SCID-hu mouse model. This was confirmed by Aldrovandi & 
Zack (1995), who looked at the deletions of individual accessory genes on the 
pathogenicity of HIV-1nl4-3 in the SCID-hu mouse model. The ne/'-minus strains were 
observed to exhibit a significantly attenuated phenotype. This was observed as 
decreased levels of thymocyte depletion and proviral load in Thy/Liv implants 
infected with 100 lU of virus, decreased pathology in biopsies taken at 3 weeks post 
inoculation and decreased virus detected by flow cytometry and quantitative PCR. 
However, when a ten-fold increase in the levels of the nef-minus virus was introduced 
to the system, the virus replicated to high levels in vivo. This data suggests that in 
absence of a complete immune response, the deletion of nef in HIV-1nl4-3 results in a 
less virulent phenotype than that of wild type HIV-1nl4-3.
Studies utilising transgenic mice expressing the whole coding sequences of HIV-1 
under the regulatory sequences of the human CD4 (CD4C) gene, with viral expression 
occuring in the same subsets of cells normally found to be infected in HIV-1 have 
also been performed. These mice develop a severe AIDS-like disease similar to that 
observed in humans infected with HIV-1 (Hanna et al., 1998a & b). Simard and 
colleagues (2002) investigated disease progression of SIV using a similar transgenic 
mouse model. Transgenic mice were constructed expressing the SIVmac239 nef gene 
in the natural target cells of the virus, under the control of the human CD4 gene 
promoter (CD4C). These mice developed a severe AIDS-like disease, similar to that 
observed when HIV-1 nef was expressed in transgenic mice and exhibited a disease
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progression similar to that of simian AIDS. Whilst the mouse model represents an 
important in vivo system within which to study HIV-1, this system does present 
limitations for study, primarily from the point of view that within HIV-1 infected 
mice, every CD4+ cell expresses protein, compared to the macaque model, where 
only a proportion of the CD4+ cells express the viral protein. This should therefore be 
taken into consideration if choosing an animal model within which to study disease 
pathogenesis.
1.12. Clinical Evidence for the Importance of nef
Rapid Progressors (RPs) of HIV infection are defined as developing AIDS within 
three years of infection and are estimated to constitute 3% of HIV infected 
individuals. By contrast, approximately 5-15% of patients will remain asymptomatic 
for more than 12 years before any clinical signs of disease. These long term non 
progressors are distinct from the RPs in that their viral loads remain low, CD4 levels 
are normal and virus isolation proves difficult. The reasons for the differences in 
progression rates are unclear but could reflect the genotype of the virus or initial 
immune response to the presence of virus, which if sufficiently strong to suppress 
viral replication could result in viral loads remaining low. It is also possible that some 
other unknown factor(s) within the host can prevent viral replication.
The study of a variety of cohorts of long term non progressors has proved important 
for understanding HIV pathogenesis and the mechanisms underlying disease 
development, both from the perspective of the virus and the host (Learmont et al., 
1992, Deacon et al, 1995, Kirchhoff et al, 1995). In certain cohorts long term non 
progression has been associated with virus apparently attenuated by encoding a 
defective nef gene. Such clinical data obtained from long term non progressors
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represents an invaluable insight into the effect attenuations within the nef gene can 
have on the replication of the virus in vivo, in terms of the viral load, CD4 counts and 
the ability to reisolate virus from such individuals.
The Sydney Bloodbank Cohort consists of a group of 6 patients infected with HIV-1 
by a single donor over a period of 2 years (Learmont et al., 1992). It was found that, 
between approximately 6-10 years after infection, 5 of the 6 recipients and the donor 
remained clinically free of symptoms, with normal CD4 levels and no evidence of 
virus through detection of p24 antigen production. The sixth subject died soon after 
HIV-1 infection was diagnosed from unrelated causes. HIV-1 was only isolated from 
one recipient. This isolate was unable to induce syncytia in a co-culture assay using 
SupTl cells and exhibited a reduced host range in vitro. This group of patients was of 
a broad age range and an equal proportion of the sexes and there were no other 
obvious common host factors. The possibility of a host immune response being 
responsible for the delay to progression to AIDS was excluded and it was thought 
more likely to be due to the transmission of a non pathogenic strain of the virus.
A report in 1995 by Deacon et al. (1995) revealed the possible cause for the slow 
progression exhibited by this cohort. At this time the patients still exhibited normal 
levels of CD4 and had not developed any AIDS-defming symptoms or HIV-related 
symptoms, or received any form of anti-retroviral chemotherapy.
HIV was isolated from 3 of the recipient members of the cohort and the ability of the 
viruses to replicate was compared to that of reference isolates HIV-1nl43 and HIV- 
Iada- All three virus isolates were replication competent. However, two replicated 
very poorly in comparison to the third isolate, which in turn revealed a prolonged 
replication time in comparison to HIV-1nl43 and HIV-Iada- Subsequently, a region of 
the HIV-1 DNA, including the whole of the nef gene and the U3 region of the long
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terminal repeat (LTR) was amplified by double or triple-nested PCR (Deacon et al,
1995). The sizes of amplified DNA obtained from members of the cohort compared to 
the HIV-1nl43 control virus were found to be consistently between 160-430 bp smaller 
and the regions harbouring the deletions were found to be within the ne/7LTR region. 
The original donor yielded an amplified fragment of approximately 550 bp in length, 
which, with comparison to full length virus indicated a deletion of approximately 290 
bp. Subsequent sequence analysis of the amplified fragments from the nef gene-LTR 
region of the recipients revealed deletions of various lengths; some from the portion 
of the nef gene that does not overlap with the U3 LTR region, others from at least one 
part of the «q/LTR overlap region. It was therefore concluded that the nef or LTR 
defects were responsible for the attenuated course of infection observed in these 
patients.
Kirchhoff et a l (1995) described a group of haemophiliacs exposed to HIV-1 through 
transfusion of contaminated Factor VIII before 1983 and subsequently diagnosed as 
HIV positive. Analysis of DNA prepared from peripheral blood mononuclear cells 
(PBMCs) from a 44 year old male, known as patient 1, revealed a deletion of 118 base 
pairs in the nef gene. Recovery of HIV-1 from this patient proved difficult, with 
antigen capture assays for p24 proving negative, and serum and plasma samples taken 
in 1985 and 1994, respectively, proving negative by Western blotting for antibodies to 
Nef. This patient also exhibited a low viral DNA burden, approximately 1 viral DNA 
copy per 100,000 PBMC by HIV-1 gag PCR, which is approximately 10-3,500 times 
lower than levels observed in patients with parallel progressive or slowly progressing 
infection. However, five other patients from this group who also appeared to have non 
progressive HIV-1 infection revealed a prevalence of full length nef sequence, as well 
as the presence of Nef reactive antibodies.
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It was assumed that patient 1 was originally infected with a nef defective strain of 
HIV-1, although such information is not available as the patient was infected before 
the advent of blood screening in 1983. This report therefore supported the idea that an 
intact nef gene is required for the virus to achieve its full pathogenic potential in vivo. 
However, one must appreciate the role of additional host factors contributing to long 
term non progression, such as the maintenance of a strong initial immune response to 
the virus.
More recently Greenough & Desrosiers (1999) described that patient 1 had 
subsequently exhibited declining CD4 T-lymphocyte levels, observed initially in 
1997, although the plasma viral RNA levels have remained low and attempts to 
culture virus have remained unsuccessful. Therefore, it may be that this patient, 
having been through a long asymptomatic phase (which may have been due to 
defective nef gene), may now have progressed into the first stages of disease 
development.
A study by Huang et al. (1995a) revealed results that did not agree with those 
previously described. This group performed a study on 10 patients who lacked any 
clinical symptoms and exhibited normal stable CD4+ T-cell counts, despite being 
HIV positive for between 12-15 years. Sequences of nef were isolated and analysed 
by nested PCR and DNA sequencing. No obvious deletions were apparent within the 
nef gene, with the majority (91.1%) of sequences containing an intact nef open 
reading frame. There were no obvious differences between consensus nef sequences 
derived from patients with AIDS and those from this group of 10 long term non 
progressors. In this study the presence of strong HIV-1 neutralising antibodies and 
virus-suppressive CD8+ T-cell activity suggested that a vigorous immune response is 
involved in maintaining low levels of virus (Huang et al, 1995a).
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These observations were taken further by replacing the nef gene of an infectious 
molecular clone, HIV-1hxb2, with the nef gene derived from the above group of 10 
patients (Nef-HIV-lHXB2) (Huang et al, 1995a & b). A nef gene from a separate 
patient with AIDS was also replaced into the HXB2 clone as a control (Nef+HIV- 
1hxb2). The Nef+ HIV-1hxb2 replicated more efficiently than Nef- HIV-1hxb2 in 
resting PBMCs and mitogen pre-activated PBMC. A comparison of in vitro growth 
kinetics of these viruses carrying nef genes derived from long term non progressors 
with that of the virus containing nef derived from a patient with AIDS revealed no 
obvious differences.
Parallel studies reported by Michael et a l (1995a) showed no obvious correlation 
between the structure or function of the nef genes and the rates of disease progression 
amongst nine patients of the San Francisco Men’s Health Study. A subsequent study 
was carried out by the same group (Michael et al, 1995b) of a patient infected with 
HIV in 1981 by blood from an HIV+ blood donor, whereby the blood donor and two 
other recipients of the same blood transfusion had all died of AIDS, whilst this patient 
remained healthy. No gross deletions were observed in the nef gene of this patient. By 
contrast, there were obvious deletions in v if vpr, vpu and tat. It was concluded that 
this patient may have been infected with an attenuated component of a virus pool. The 
defects in a variety of accessory genes within this patient suggests that this was 
contributing to the lack of progression to AIDS. However, due to the absence of 
changes within nef, this gene cannot have contributed to the attenuated phenotype of 
virus in this patient.
Therefore, although in some cases infection with HIV defective in regions of the nef 
gene may account for increased length of the asymtopmatic phase prior to overt 
disease progression, one cannot rule out other important factors. These include the
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hosts’ initial immune response, vims which is defective in regions other than nef and 
the ability of the host to somehow suppress the ability of the vims to replicate in vivo. 
However, the nef gene remains of considerable interest due to the effect deletions 
within this regulatory gene can have on disease outcome. Further study of the nef 
gene could contribute to our understanding of the behaviour of the vims in vivo.
The combination of clinical data and results from infection studies should further our 
understanding of these vimses and help in the development of novel therapeutic or 
preventative strategies. However, in order to study the viral genetics of HIV one 
needs to be able to manipulate experimental conditions and this is not possible with 
patients. Experimental study requires an animal model where the vims can be 
manipulated to observe the outcome, with the hope of understanding the underlying 
mechanisms of the properties of vimses in long term non progressors. The SIV 
macaque model, as described in section 1.9 represents such a model.
1.13. Functions of nef
The effect of attenuations within specific regions of the immunodeficiency vimses are 
not restricted to the nef gene, as has been widely described within the literature. 
However, due to the difference in pathogenicity between the clones SIVmacCS and 
SIVmacJS, significant interest lies in studying how such subtle differences within this 
gene can have such an effect on the vimses’ ability to propagate itself in vivo. The 
Nef protein has been described to have wide and diverse functions in vitro and it is 
possible that the deleted region within SIVmacCS may contribute to one or more of 
these functions. Dismption of this region would prevent the vims from achieving its 
full pathogenic potential.
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Since there is little evidence that the Nef protein interacts directly with other viral 
proteins, components of the infected cell which interact with or are influenced by Nef 
have been described extensively. In order to fully understand the function of Nef, it 
will be important to identify and characterise potential target molecules in the infected 
cell with which it may interact. An understanding of the interactions of Nef may pave 
the way for new therapeutics against HIV. Described are some of the functions of Nef 
and the benefit each of these functions may provide to the virus in vivo.
a. Interaction with a Cellular Serine Kinase
Sawai et al. (1994) demonstrated that HIV-1 SF2 Nef expressed either in the form of 
a CD8-Nef fusion protein, or native Nef protein in T-cell lines, specifically interacted 
with a cellular serine kinase. Two proteins, of molecular mass 62 kDa and 72 kDa 
(subsequently named p62 and p72 respectively) were found to co-immunoprecipitate 
with Nef and to be phosphorylated in in vitro kinase assays. Inhibitors of protein 
kinase A and protein kinase C failed to inhibit this Nef-associated activity. A serine 
kinase was implicated as these proteins were phosphorylated solely on serine residues. 
The region of Nef between amino acids 45-127 was revealed to be important for this 
Nef associated kinase (NAK) interaction and truncations within this region resulted in 
decreased kinase activity. There are several amino acid motifs in this region which are 
conserved throughout HIV-1, HIV-2 and SIV Nef which in turn implicates them in 
this function. In particular, mutations of Arg>Lys at positions 109 and 110 of HIV- 
1SF2 Nef produced a stable protein which exhibited no kinase binding activity. 
Further investigation with a myristoylation defective mutant (a mutation of Gly>Ala 
at amino acid 2), again disrupted kinase binding activity. This indicates the
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importance of the targeting of Nef to intracellular membranes as a requirement for its 
association with a cellular kinase activity (Sawai et al, 1995).
Expression of Nef in the baculovirus system, as the N-terminal portion of a GST 
fusion molecule, has supported the notion that myristoylation is required for binding 
to cellular proteins. Proteins identified were both soluble and membrane associated in 
cytoplasmic extracts of the Jurkat human T cell line. Mutations which prevented 
myristoylation prevented these interactions (Harris & Coates 1993).
Antibodies directed against a p21 associated kinase (PAK) were found to 
immunoprecipitate the p62 and p72 proteins in an in vitro kinase assay. PAKs are 
highly conserved ubiquitous serine kinases important for the transduction of external 
signals to the nucleus. Nef from SIV or HIV-1 infected cells has been shown to 
associate with PAK in infected lymphoid cells (Sawai et al, 1996).
A proline rich region, PXXP (positions 104-107), previously identified to have 
homology to the consensus sequence required as a ligand for the SH3 domains in 
members of the Src family of non-receptor protein tyrosine kinases, is present in the 
Nef protein. In vitro kinase assays showed that alanine substitution of the prolines at 
positions 104 and 107 disrupted the ability of the Nef to associate with NAK. 
Positions 106, 108, 109 and 122 were also shown to be essential for Nef association 
with NAK (Khan et al, 1998) since mutations at these sites rendered the Nef 
defective for the activation of PAK.
Subsequent in vivo data using seven juvenile rhesus macaques infected with 
SIVmac239, where the proline residues at positions 104 and 107 had been substituted 
for alanines, revealed that five of these animals showed a reversion to the PXXP 
motif, as well as restoration of the NAK positive phenotype. These observations 
demonstrate a strong selection for a functional SH3 ligand in v/vo, which is associated
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with the ability of Nef to interact with NAK. This reversion was also associated with 
the progression of virus pathogenesis, with two of the animals developing fatal simian 
AIDS. However, findings by Lang et a l (1997) contradict this data. This group 
similarly used SIVmac239 (Reiger & Desrosiers 1990) to investigate the importance 
of the PXXP motif in vivo. Changes from PXXP to AXXA at positions 104 and 107 
abolished the ability of Nef to associate with the PAK-related serine/threonine kinase. 
Whilst single nucleotide changes in the nef gene have been shown to rapidly revert to 
wild-type within two weeks of infection (Kestler et al, 1991) there was only a slight 
selective pressure for the reversion of this double mutant. At the same time, mutation 
of this region did not seem to attenuate the virus, as the two rhesus macaques infected 
with the AXXA-Nef variant showed very weak humoral responses, rapid disease 
progression, high viral load and high p27 plasma antigenaemia. This data suggests 
association of SIV Nef with serine/threonine kinases is dispensable for high virus load 
and disease progression in macaques. However, the failure of infection with even 
wild-type SIV to induce a strong antibody response may be an indication that the two 
macaques used in the study by Lang et a l  (1997) were particularly susceptible to SIV 
infection. Therefore, these results may not be representative of the majority of animals 
challenged with this virus.
An association with a cellular serine kinase therefore appears to benefit the virus in 
some way, as observed by the strong selective pressure for the maintenance of the 
PXXP motif essential for an interaction with the NAK (Khan et al, 1998). Further 
investigation is required to be able to identify the exact mechanisms of viral 
replication or pathogenesis that this interaction is affecting.
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b. Downregulation of CD4
The CD4 receptor is the primary receptor for SIV, HIV-1 and HIV-2 and an integral 
component of the T cell receptor (TCR) complex on MHC-class II restricted T-cells. 
A decrease in the number of T cells carrying this marker is a clinical hallmark of the 
immune system dysfunction characteristic of ADDS.
HIV-1 and SIV Nef have been described to downregulate cell surface CD4 
expression, by inducing endocytosis of the CD4 receptor and its subsequent 
degradation in lysosomes. The TCR on CD4 positive cells recognises specific 
antigens carried by the major histocompatibility complex class II (MHC-II) molecules 
on antigen presenting cells and it is the extracellular domain of CD4 which binds to 
MHC-II (Doyle & Strominger 1987). This results in activation of an associated 
tyrosine kinase, p56^ ^^  (Rudd et al, 1988) and the internalisation of CD4 (Acres et al, 
1986). The p56^ ^^  phosphorylates the Ç chain of the TCR and may also recruit another 
kinase, ZAP-70 (Strauss & Weiss 1992). This activates the T cell cascade, the end 
product of which is interleukin-2 (IL-2) production and cell proliferation (Altman et 
al, 1990). Interference with T cell function would disrupt an important cellular 
cascade, promote survival of the virus in the host and benefit replication. The precise 
role and mechanism of CD4 downregulation, however, remains to be defined. 
Downregulation of CD4 by Nef is independent of species type (Garcia et al, 1993). 
This function of Nef was observed in murine NIH 3T3 cells transfected with retroviral 
vectors containing the HIV-1 nef gene, compared with control cells transfected with 
empty vector, using a variety of laboratory adapted strains of HIV-1. Thus HIV-1 Nef 
does not require human specific factors for this effect. Furthermore, human CD4+ 
cells with a truncated CD4 cytoplasmic domain were unaffected by Nef (Garcia et al., 
1993). The conservation of the amino acid sequence within the cytoplasmic domain of
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the CD4 receptor between different species (human and murine) suggests that this 
region may be important for downregulation. The specificity of CD4 downregulation 
by Nef was shown in a study (Aiken et al, 1994) whereby the surface levels of CD4 
in CEM T lymphoid cells infected with wild type HIV-1 strains revealed a more rapid 
degree of CD4 downregulation compared with cells infected with strains mutated in 
nef.
Myristoylation has been described to be a requirement for Nef induced CD4 
downregulation (Harris & Neil 1994), suggesting nef needs to be associated with cell 
membranes to exert this effect. This requirement has been assessed using the 
baculovirus system. Sf9 cells were co-infected with AcCD4 and other baculoviruses 
expressing Nef-GST, a non-myristoylated derivative (AcNef(m-)GST), myristoylated 
GST (AcmyrGST) or non-myristoylated GST. Fractions firom lysates of these cells 
were immunoblotted with antibodies against GST or CD4. It was found that CD4 
could be detected only when co-expressed with Nef-GST, revealing a requirement for 
both myristate and Nef amino acid sequences (Harris & Neil 1994).
The 20 amino acid long membrane proximal region of the cytoplasmic domain of 
CD4 has been described to be essential for downregulation (Aiken et al, 1994). 
Furthermore, it has been shown that the mutation of two consecutive leucines at 
positions 413 and 414 to alanines within the cytoplasmic domain, generating the 
molecule C D 4 l l 4 1 4 a a ,  resulted in the complete absence of Nef mediated 
downregulation. This observation was confirmed by mutation of the leucine at 
position 414 to an alanine alone. This dileucine motif is also present in the 
cytoplasmic regions of CD3 y and ô chains, where it has been described to function as 
an endocytic and lysosomal targeting signal (Letoumer & Klausner 1992), illustrating 
the importance of this motif in the endocytic pathway.
59
The downregulation of CD4 by Nef occurs via a mechanism distinct from that of 
phorbol ester induced downregulation. This was demonstrated by mutation of CD4 at 
the serines at positions 408 and 415 to alanine and leucine respectively, and the 
methionine at position 407 being replaced by a threonine. All of these changes were 
tolerated by Nef, suggesting that Nef downregulates CD4 by an alternative 
mechanism which remains to be defined.
Various mechanisms for Nef induced downregulation of CD4 have been postulated. 
The most feasible is that Nef is acting as a connector between CD4 and the cell 
sorting machinery. Using chimeric integral membrane proteins consisting of 
extracellular and transmembrane regions of CD4 or CD8 and the membrane 
associated domain of HIV-1 Nef, Mangasarian et al. (1997) showed that Nef was able 
to act in cis as a connector between CD4 and the cell sorting machinery. This was 
dependent upon the presence of the dileucine motif within CD4, as previously 
described (Aiken fl/., 1994).
c. Interactions with Adaptor Proteins
Further studies to identify key components of the endocytic pathway that interact with 
Nef to downregulate CD4 have been performed. Clathrin coated pits (CCPs) are 
plasma membrane invaginated domains with clathrin on their cytoplasmic side. They 
play a key role in the endocytosis of membrane associated receptors, through the 
recognition of specific motifs in the cytoplasmic tails of the receptors.
The implication that Nef induces CD4 downregulation through interaction with 
members of the endocytic pathway has led to studies observing interactions between 
Nef and CCPs. Evidence for CD4 internalisation by Nef, by increasing the association 
of CD4 with CCPs has been documented (Foti et al, 1997). It was observed that Nef
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triggered the formation of cell surface CCP, whilst at the same time inducing CD4 
endocytosis, by mediating the generation of CD4-enriched CCP. This was exhibited 
by tracing surface CD4 molecules with ^^^I-anti-CD4 and labelling transferrin 
receptors (Tf-R) with anti-Tf-R antibodies as controls. When Nef was present, the 
number of CCP per cell containing only CD4 was increased three fold, whilst the 
effect on the CCP incorporating the transferrin receptor was only increased by 
approximately 7%. Furthermore, mutation of the dileucine motif at positions 413 and 
414 in CD4 to alanines completely abolished the ability of Nef to induce CD4 
downregulation. Nef induced the formation of CCP only in the presence of wild type 
CD4. Therefore, to generate CCP with the ability to internalise CD4 an intact receptor 
cytoplasmic tail is required.
Adaptor proteins (APs) mediate protein sorting and are present in the cell. In order for 
CCPs to assemble at the plasma membrane and at the trans-golgi network (TON), an 
interaction is required between clathrin and these adaptor proteins (Pearse & 
Robinson 1990). Adaptor Protein-1 and Adaptor Protein-2 (AP-1 and AP-2 
respectively) act at the TGN and plasma membrane respectively. They are 
heterotetramers consisting of two large subunits of approximately 100 kDa (y and p ’ 
for TGN APs, a  and p for plasma membrane APs), a medium chain of approximately 
50 kDa (pi or AP47 for AP-1, p2 or AP50 for AP-2) and a small chain of 
approximately 20 kDa (a l and a2) (Figure 1.10). As well as mediating the formation 
of CCPs, they also recruit receptors that carry internalisation signals recognisable by 
the CCPs in their cytoplasmic tail.
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Figure 1.10. The Adaptor protein complexes. AP-1, the trans-golgi network (TGN) 
adaptor, AP-2, the plama membrane adaptor. They are involved in mediating protein 
sorting, by interacting with clathrin coated pits (CCPs) in order for the CCPs to 
assemble at the plasma membrane. They are heterotetramers consisting of two large 
subunits of approximately 100 kDa (y and (3 for the TGNs APs, a  and p for the plasma 
membrane APs), a medium chain of approximately 50 kDa (pi or AP47 for AP-1, p2 
or AP50 for AP-2) and a small chain of approximately 20 kDa (a l or AP 19 for AP-1, 
a2 or API 7 for AP-2).
Adapted from: Page LJ & Robinson MS (1995). Targeting signals and subunit 
interactions in coated vesicle adaptor complexes. J  Cell Biol. 131(3): 619-30.
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based motifs within the cytoplasmic domain of integral membrane proteins (Ohno et 
al, 1995). The signal is YXX([), whereby Y is a tyrosine, X is any residue and ^ is an 
amino acid with a bulky hydrophobic side chain and is present in a variety of 
membrane proteins (Trowbridge et al, 1993). The medium chains have been 
postulated to act as signal-binding components of the clathrin-dependent sorting 
pathway (Ohno et al, 1995).
Nef accelerates the endocytosis of CD4 by interaction with CCPs. The medium chain 
of adaptor complexes recognise the cytoplasmic tail of some receptors. Therefore the 
likelihood of a possible interaction between Nef and the medium chain of the adaptor 
proteins has been investigated.
Chimeric proteins consisting of the GAL 4 activation domain (see section 4.1) with 
either full length or truncated (amino acids 121-435) murine p2 adaptin, or full length 
adaptin (AP47), were constructed. These were used as targets for an interaction 
through the use of yeast-2-hybrid technology with fusion proteins of GAL 4 DNA 
binding domain comprising HIV-1r7, HIV-Ilau HIV-2rod or SIVmac239 Nef used as 
baits (Piguet et al, 1998). A strong and specific interaction was detected with full 
length and truncated p2 with HIV-2 and SIV Nef. A weaker interaction was detected 
with AP47, whilst HIV-1 exhibited no interaction with any of the target proteins.
The N-terminus of HIV-2rod and SIVmac239 Nef contains amino acid residues 
reminiscent of the endocytic signal, YXX(|), as previously described. Mutation of the 
tyrosines to glycines at positions 39 of HIV-2rod Nef and 28 and 39 of SIV Nef 
abolished the interaction between these Nef proteins and the p2 adaptins. These 
results were further confirmed with Nef proteins fused to GST (Piguet et al, 1998).
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However, it was also suggested that Nef may be downregulating the CD4 receptor by 
an additional unknown mechanism to that described, due to the low levels of CD4 
downregulation that were consistently observed.
Interactions of SIV Nef with the AP-2 complex have been further demonstrated to be 
dependent on the presence of sequences within the N-terminus of SIV Nef (Piguet et 
al, 1998), whilst HIV-1 Nef interacts with components of the AP-2 complex via 
sequences within its C-terminus (Bresnahan et al, 1998). These have been confirmed 
by studies using SIVmac239-Nef, where co-localisation of SIVmac239-Nef GFP was 
observed with the p and a  subunits of AP-2 (Greenberg et a/., 1997). This co­
localisation was mediated by an N-proximal targeting element on SIVmac239 Nef, 
between tyrosine Y29 and glycine G38, and an N-distal element between glutamine 
Q58 and aspartic acid D88, as determined by examining the effect of a range of 
mutations and substitutions on the cellular distribution of the SIVmac239-GFP fusion 
protein relative to AP-2. Disruption of residues 64-67 in the N-distal AP-2 interacting 
element of SIVmac239-Nef also affected CD4 downregulation, whilst disruption of 
the sequences within the N-proximal region had no effect, suggesting that these two 
regions have different functional roles (Greenberg et a l, 1997).
CD4+ cells are involved in co-ordinating an efficient immune response, therefore 
downregulating the receptor favours viral replication, resulting in survival and spread 
of the virus both in vivo and in vitro^ Removal of cell surface CD4 would impair the 
normal T cell activation pathway and could minimise the toxic effects of envelope 
and superinfection by a second virus (Weller et al, 1980).
Downregulation of the CD4 receptor is a complex process dependent upon many 
factors. Further investigation of the interaction between Nef and CD4, and members
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of the endocytic pathway may lead to a better understanding of this effect of Nef and 
identify possible targets for therapeutic intervention.
d. Downregulation of MHC Class I Molecules
Major histocompatibility complex (MHC) restricted cytotoxic T lymphocytes (CTL) 
contribute to the cellular immune response mounted against virus infections in 
humans. They are effector T cells which following recognition of viral protein 
antigens, displayed in context of MHC class I, can mediate the killing of virus 
infected cells. Viral antigens are processed within the infected cell into short peptide 
fragments, transported to the cell surface and presented in association with MHC 
molecules. HIV-1 specific CTLs have been detected in HIV-1 infected patients at 
different clinical stages of infection and isolated from different sites. HIV-1 infection 
may perturb MHC-class I molecule expression, affecting the ability of the host 
immune system to respond.
The Nef protein of HIV-1, HIV-2 and SIV downregulates the expression of MHC 
Class I molecules (Schwartz et al, 1996), preventing the recognition and lysis of 
infected cells by CTLs. Infection of human CD4+ peripheral blood lymphocyte (PEL) 
T cell lines, CEM, HT and U937 cell lines with HIV-1 revealed a decrease in the 
expression of MHC class I molecules on the cell surface. Further studies using 
promonocytic U937 cells chronically infected with HIV-1 showed a decrease in the 
expression of MHC class I heavy chain at the cell surface, compared with non­
infected cells (Schwartz et al, 1996). The cell surface expression of MHC class I 
molecules was unchanged in the presence of a nef HIV-1 mutant in U937 cells, 
indicating that Nef stimulates the degradation of MHC class I molecules, similar to 
CD4. The ability of ammonium chloride, an inhibitor of lysosomal degradation to
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restore the half life of the MHC class I molecules localised this effect to the lysosomal 
compartment.
Further attempts to identify the elements within the MHC class I molecules 
responsive to Nef by construction of mutants with deletions within the HLA-A2 
(human leukocyte antigen) gene of the MHC-I molecules also revealed the 
cytoplasmic domain to be important (Le Gall et al, 1998). The sequence YSQA 
(between residues 320 and 323) was observed, similar to that of the prototypic 
tyrosine based signal found in many membrane proteins that are endocytosed (section 
1.9.1c). Mutational analysis also revealed a requirement for Tyr-320 for Nef induced 
downregulation. Expression of HLA-B molecules was also modulated by Nef, an 
effect which was observed in HeLa cells and CEM cells, whilst HLA-C molecules 
were unaffected. The absence of a prototypic tyrosine based motif within the HLA-C 
molecule could account for this.
In the presence of Nef, MHC-I molecules were also found to co-localise with clathrin 
and AP complexes. HeLa cells were transfected with vectors containing HLA-B7, 
HLA-A2 WT and HLA-A2-Y320A (HLA-A2 gene with tyrosine 320 mutated to an 
alanine) in the presence and absence of Nef. Intense cell surface staining was 
observed for HLA-B7, HLA-A2 WT and A2-Y320A in the absence of Nef, which 
decreased when Nef was present, with the exception of HLA-A2-Y320A which 
remained unaffected.
Furthermore, HeLa cells transfected with HLA-B 7 in the presence of Nef showed that 
MHC-I colocalised with clathrin and y-adaptin, at the Golgi and plasma membrane, 
whilst in the absence of Nef the MHC-1 molecules were found at the cell surface. Nef 
appears to be mediating the recognition of tyrosine based motifs in the MHC-1 by 
adaptor complexes.
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By downregulating the cell surface expression of MHC-I, Nef can protect cells 
against lysis by CTLs (Collins et al, 1998). The modulation of MHC-I expression can 
result in target cells becoming increasingly sensitive to NK lysis (Brutkiewicz & 
Welsh 1995). HLA-C molecules are not affected by Nef and can protect against NK 
lysis. It has been speculated that in the presence of Nef, in vivo infected cells exhibit 
limited recognition by CTLs without increased lysis by NK cells. Nef-induced escape 
of CTLs and NK could contribute to the survival of HIV (Le Gall et al, 1998).
CTLs have been implicated as playing a critical role in the control of HIV replication. 
Most HIV positive individuals exhibit a strong CTL response against HIV, which is 
mediated by CD8+ MHC class I restricted lymphocytes. The appearance of HIV- 
specific CTLs is associated with the initial control of viraemia. However, during 
disease progression, the fall in CD4+ T cells is associated with a decrease in CD8+ T 
cell numbers and a reduction in virus specific CTL activity. A decrease in CD4+ and 
CD8+ cells is also associated with HIV-associated programmed cell death (apoptosis). 
This apoptotic event can be triggered by the binding of a variety of cell surface 
receptors to their ligands. Fas, a member of the TNF / nerve growth factor receptor 
superfamily and Fas ligand (FasL) appear to play an important role in the apoptotic 
process in HIV.
The mechanisms of protection induced by attenuated SIV (SIVmacC8) have been 
proposed to involve the induction of a viral-specific CTL response (Xu et al, 1997). 
Although CTL responses were elicited from SIVmacJ5 infected animals, at 3 months 
post infection there was a striking difference in the responses of the animals to 
challenge with C8 and 15. All C8 infected animals showed multiple virus specific 
CTL responses to nef, gag / pal, env, RT, rev and / or tat. By contrast, no detectable
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virus specific CTL activity was observed in PBMC of J5 infected animals. The degree 
of apoptosis in each set of infected animals was investigated. Spontaneous apoptosis 
was found to be higher in J5 infected macaques, therefore implying that CD8+ T cells 
from J5 infected animals are more vulnerable to apoptosis than those from C8 
infected animals. The J5 infected animals showed a higher level of Fas expression 
than C8 and a greater degree of FasL upregulation compared with C8.
The strong CTL activity observed in the C8 protected animals correlated with a lower 
frequency of apoptosis of CD4+ and CD8+ T cells. It was suggested that the failure of 
C8 infected CD4+ cells to upregulate FasL expression avoided apoptosis and could 
allow the generation of an efficient antiviral response. By contrast, the J5 infected 
CD4+ cells upregulated FasL expression, which induced apoptosis of SIV-specific 
lymphocytes, including CTLs expressing Fas. This resulted in an increase in virus 
pathogenicity and subsequent disease progression. Therefore, the upregulation of 
FasL represents a mechanism by which the virus can evade the immune response, by 
interfering with the development of an effective CTL response (Xu et al, 1997).
e. Interactions with Proteins containing SH3 Domains
Src Homology 3 (SH3) domains are present in a variety of proteins involved in 
intracellular signalling and cytoskeletal organisation. The Src family of protein 
tyrosine kinases includes 9 members; Src, Lck, Fyn, Yes, Blk, Fgr, Lyn, Hck and Yrc. 
A short proline rich motif acts as a ligand for SH3 domains and a minimal PXXP 
consensus sequence has been identified as a critical determinant for SH3 binding.
Nef possesses an SH3 binding motif between amino acids 69-78, a domain which is 
well conserved amongst nef isolates. These residues are repeated in every third
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position of the polypeptide, occurring in HIV-1 as a tetraproline motif, whilst HIV-2 
and SIV Nef have three such repeated prolines.
The interactions between Nef and members of the Src family kinases were 
investigated by generating a Nef peptide containing amino acids 6 5 -8 2  of H IV -1 nl4-3. 
This contains the tetraproline PXXP motif as a fusion with GST (Saksela et al, 1995). 
Specific binding to Hck and Lyn SH3 domains was observed, whilst there was no 
binding to the SH3 domains of Lck and Fyn. These observations confirmed that a 
minimal PXXP motif is required within Nef in order to interact with proteins 
containing SH3 domains. Furthermore, due to the selectivity observed, these 
interactions appear to be highly specific.
Mutational analysis of full length HIV Nef protein, expressed as GST fusions, 
revealed an absolute requirement for the two internal prolines at positions 72 and 75. 
Mutation to alanine abolished the binding of Hck SH3, confirming this interaction 
was indeed mediated by the PXXP motif. The binding of Lyn SH3 appeared to be 
dependant upon the arginine residue at position 71 and was significantly weaker than 
that observed for Hck. Further investigation revealed the presence of a single PXXP 
motif in the C terminus of Nef, disruption of which significantly affected the ability of 
Nef to interact with Hck, even in the presence of an intact N terminal PXXP motif. 
The binding to Lck was affected to a much less degree than that of Hck, suggesting 
that in this interaction the N terminal PXXP motif was the more critical factor. 
Mutation of the PXXP motif does not impair the ability of Nef to downregulate CD4. 
Furthermore, viruses containing intact nef genes grew significantly better than those 
containing mutations within the PXXP motif in PBMCs, revealing a requirement of 
intact PXXP for Nef-mediated enhancement of HIV replication (Saksela et al, 1995). 
The interaction with proteins containing SH3 domains is advantageous, as the virus
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has evolved to exploit SH3 mediated cellular processes to enhance its replication 
capacity, as well as perturbing signal transduction pathways and preventing normal 
cell function.
f. Interaction with the C Chain of the T Cell Receptor Complex
The T cell antigen receptor (TCR) is a complex multichain structure. It consists of an 
antigen-binding heterodimer (Ti a/p) and five invariant chains, (CDS y, ô, s, ^2 )- The 
CD3 chains can be divided further into y, 5, s and Ç chains. Expression of each of 
these chains is required for efficient surface expression of the TCR (Figure 1.11).
The Nef protein alters T cell receptor signalling in T cells. TCR signals resulting from 
antigen recognition events are involved in the regulation of all the major aspects of T 
lymphocyte function. The interaction of Nef with the TCR could have important 
implications for AIDS pathogenesis. Natural HIV-1 and SIV Nef proteins have been 
demonstrated to block a subset of signals emanating from the TCR in human CD4+ 
Jurkat T cell line, as was measured by a block to the induction of expression of the 
early activation marker CD69 by anti-CD3 monoclonal antibody (lafrate et al, 1997). 
Mutations in the core region of HIV-1 Nef significantly affected the ability of Nef to 
block CD3 signalling, particularly the mutation of P72 and P75 in the PXXP motif to 
alanine and D86 for alanine. These three amino acid residues form part of the SH3 
binding surface of Nef and are required for the interaction with the Src family SH3 
domains (Lee et al, 1996) (section 1.9.le).
Using a chimeric molecule, consisting of the extracellular and transmembrane 
domains of the Ç chain, it has been demonstrated that transducing signals can be 
elicited that are indistinguishable from those generated by the intact TCR (Irving &
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Figure 1.11. The oligomeric T cell receptor (TCR). The TCR consists of six genes, all 
of which are required for efficient plasma membrane expression. The a  and p chains 
form the ligand binding subunit involved in recognition of an antigenic peptide bound 
to a major histocompatibility (MHC) molecule. The CD3Ç chains are responsible for 
signal transduction. The antigenic recognition motif (ARAM), within these chains 
(depicted as rectangles) is responsible for the signal transduction capability of these 
chains.
Adapted from: Weiss A (1993). T cell antigen receptor signal transduction: a tale of 
tails and cytoplasmic protein-tyrosine kinases. Ce//73(2): 209-12
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Weiss 1991). This data implies that the Ç chain is an essential component of the TCR 
for signal transduction.
Specific binding of Nef to TCRÇ has been observed. Using deleted forms of 
SIVmac239 Nef protein and yeast-2-hybrid analysis Howe et a l (1998) showed the 
binding of full length Nef to TCRÇ for SIVmac, SIVsm and HIV-2. Through the use 
of a series of amino and carboxy terminal deletion mutants of SIVmac239, the central 
core region (aa 98 to 235) of Nef was identified to be responsible for this binding. A 
parallel study by Bell et a l  (1998) confirmed this interaction. Interactions of TCRÇ 
with J5 and C8 Nef were investigated using yeast-2-hybrid technology. J5 was found 
to interact with three clones which expressed the cytoplasmic chain of TCRÇ, as did 
SrVmac239. C8, however was incapable of binding to the Ç chain. This was 
confirmed by the observation that when TCRÇ was co-immunoprecipitated with J5 
and C8 Nef in the JJK T-cell line, J5 exhibited the highest efficiency of co- 
immunoprecipitation. Furthermore, J5 and SIVmac239 Nef proteins downmodulated 
the cell surface expression of the TCR-CD3 complex, whilst C8 had no effect.
The ability of these viruses to disrupt T cell function could provide a selective 
advantage for the virus by reducing the ability of the host to mount an efficient 
immune response. Furthermore, Nef could have an effect on a range of T cell 
responses, which could in turn have a direct effect on the viral life cycle in vivo, such 
as functional activation and programmed cell death.
1.14. Summary
The nef genes of SIV, HIV-1 and HIV-2 can exert multiple that have been widely 
documented both in vivo and in vitro. The ability of Nef to exploit a variety of host 
mechanisms in order to maintain efficient viral replication in vivo reveals the highly
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adaptable nature of the immunodeficiency viruses and makes the treatment and 
prevention of these viruses a difficult task. The nef gene is therefore an important part 
of the viral genome to study in order to further our understanding of the behaviour of 
the virus in vivo and develop a novel strategy against the virus.
1.15. Objectives
Numerous in vitro properties of Nef have been outlined, as well as the role it has in 
vivo through use of the SIV model of infection and the study of asymptomatic 
patients. However, it still remains unclear which of the numerous properties ascribed 
to Nef is responsible for the dramatic effect it has on viral replication in vivo.
By using the SIV model system the biological properties of Nef can be investigated. 
Through the study of different SIV clones which differ only in sequences within the 
nef gene it is possible, by using in vitro based assays, to relate in vivo and in vitro 
biological properties to the differences that exist between the clones.
The aim of this project is to examine the functional differences that exist between 
clones of SIV differing only in the nef gene and attempt to relate the results to the 
differences observed in the pathogenic outcome of these viruses in vivo.
This will be achieved using a range of molecular clones that differ only in their nef 
sequence (see section 3.1). The experiments will involve:
• Antigenic studies of SIV nef clones expressing wild type and attenuated 
phenotypes in macaques.
• The ability of SIV nef clones, expressing wild type and attenuated phenotypes in 
macaques to interact with members of the signal transduction pathway
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2. Materials & Methods
2.1. Methods used in antigenic studies
2.1.1. Polymerase chain reaction (PCR)
PCR reactions contained 1.2 mM magnesium chloride, 10 p-M dNTPs, 0.5 pM of each 
primer, 2.5 units Ampli Taq Gold™ polymerase (Perkin-Elmer, Roche, UK), template 
DNA and buffer supplied with the enzyme in a final volume of 100 pi. Primers had 
been designed to incorporate Baniill and EcdBl restriction sites to facilitate cloning. 
The reaction was incubated in a thermal cycler (Hybaid, UK) at 94°C for 10 minutes 
followed by 40 cycles of 94°C for 1 minute, 55°C for 2 minutes and 72°C for 3 
minutes. This was followed by a 10 minute incubation at 72°C and the reaction cooled 
to 4°C.
2.1.2. Analytical gel electrophoresis
Agarose gels were prepared in 1 x TAE buffer and electrophoresis performed using 
the Horizontal gel electrophoresis system, model H4, BRL, USA.
DNA samples (10 pi) were added to 3 pi 5x sample buffer and run on a gel against a 
0x174 and/or XHindHl molecular weight marker at 150V for approximately 1.5 
hours. Following electrophoresis, gels were stained using 1 pg/ml ethidium bromide 
(in water) for 10 minutes and destained in water for 15 minutes. DNA was visualised 
by transillumination and the result recorded photographically.
2.1.3. Southern blotting
To transfer nucleic acids from an agarose gel onto a membrane for detection by radio­
labelled probes, gels were immersed with gentle agitation in denaturing solution for
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20 minutes (to denature double stranded DNA) followed by neutralising solution for 1 
hour (to neutralise the DNA).
A sheet of stiff plastic was placed over a tray and a piece of blotting paper folded and 
laid on top, ensuring the blotting paper hung over the edges and into the tray. 
Approximately 500 ml of 6 x SSC was poured over the blotting paper and into the 
tray, ensuring the overhanging edges of the blotting paper were immersed in the 
buffer. The denatured gel was placed on top of the blotting paper, reverse side up (to 
ensure optimum transfer of DNA) and a piece of nylon membrane (cut to the size of 
the gel) placed on top of the gel. An additional three pieces of blotting paper were laid 
on top and wetted with 6 x SSC. A stack of absorbant paper towels was placed on top 
and weighed down with a flat sheet of plastic and heavy weights. This was left 
overnight at room temperature to allow adequate transfer of nucleic acids.
The following day the membrane was moistened with 6 x SSC and the nucleic acids 
were cross-linked onto the nylon membrane by irradiation with ultraviolet light (UV 
Stratalinker™ 2400, Stratagene, UK).
2.1.4. Labelling of probes
To detect a specific DNA sequence by hybridisation, oligonucleotides were end- 
labelled with ATP, as follows.
To a microfuge tube, 2.5 pi y^^P ATP (4000 Ci/mmol), 1 pi 5 pM oligonucleotide, 2.5 
pi 10 x One-Phor-All buffer (Pharmacia, UK) and 1 pi T4 polynucleotide kinase were 
added and the volume made up to 25 pi with water. The contents were mixed by 
briefly pulsing in a microfuge. Contents were incubated for 10 minutes at 37°C 
followed by 10 minutes at 65°C.
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2.1.5. Hybridisation of DNA
Membranes were incubated for approximately 45 minutes at 42°C with approximately 
20 ml hybridisation buffer. Hybridisation of a specific oligonucleotide to membrane 
bound DNA sequences was achieved by overnight incubation at 42°C (Hybridisation 
oven, Hybaid, UK) of a labelled oligonucleotide with the membrane in the 
presence of the hybridisation buffer.
Following hybridisation, the membrane was washed three times in 6 x SSC at room 
temperature and exposed to X-ray film with an intensifying screen at -70°C for an 
appropriate period of time.
2.1.6. Purification of PCR products
The volume of each PCR reaction was made up to 200 pi with filtered water. This 
was extracted twice with phenol and the DNA (aqueous layer) was transferred to a 
fi-esh microfuge tube. This was further extracted with chloroform and the aqueous 
layer transferred to a fresh microfuge tube.
Selective precipitation of DNA molecules was achieved by the addition of a half 
volume of propan-2-ol and a one tenth volume of 5 M sodium perchlorate followed by 
incubation on ice for 5 minutes. This was centrifuged at 10,000 x g  for 10 minutes, 
the supernatant was removed and the pellet allowed to dry for 5 minutes. The DNA 
pellet was resuspended in 96 pi filtered water. DNA (lOpl) was analysed by agarose 
gel electrophoresis (section 2.2.3) and the results recorded photographically.
2.1.7. Restriction endonuclease digestion of PCR and plasmid DNA
Endonuclease reactions were performed as follows (using GibcoBRL products). For 
PCR amplified DNA, 86 pi PCR DNA, 20 units BamYil, 20 units EcoRl and 10 pi
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REact^ 3 buffer (Gibco BRL, UK) were added to a microfuge tube and incubated at 
37°C for 2 hours. For plasmid DNA, 1 pg DNA, 5 units BamYH, 5 units EcoRl, 2 pi 
REact^ 3 buffer (Gibco BRL, UK) and 15 pi water were added to a microfuge tube 
and incubated at 37°C for 2 hours.
Endonuclease digested PCR DNA (5 pi) and plasmid DNA (1 pi) were analysed by 
agarose gel electrophoresis (section 2.2.3) to ensure complete digestion and the result 
recorded photographically.
2.1.8. Purification of restriction endonuclease digested DNA
Restricted DNA was purified as described previously (section 2.2.6) and resuspended 
in 50 pi water. The purified DNA was analysed by gel electrophoresis (section 2.2.3) 
to check for recovery and the result recorded photographically.
2.1.9. Ligation of PCR DNA into plasmid
Ligation reactions contained approximately 0.25 pi restricted plasmid DNA, 1 pi, 3 pi 
or 9 pi of restricted purified PCR DNA (as described above), reaction buffer and 1 
unit T4 DNA ligase (Gibco BRL, UK) in a final volume of 20 pi. Control reactions 
were also included, from which insert DNA, or insert DNA and DNA ligase were 
absent. The reactions were incubated at 16°C overnight.
2.1.10. Transformation of bacteria
A glycerol stock (stored at -70°C) of E. coli XL-1 Blue cells (Stratagene, UK) was 
used to inoculate 10 ml of LB broth and grown overnight at 37°C at 220 rpm in an 
orbital incubator (Gallenkamp). The overnight culture was centrifuged at 4°C/20,000 
X g  for 5 minutes, resuspended in half the original volume using cold 100 mM
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calcium chloride and incubated on ice for 30 minutes. Cells were re-centrifuged at 
4°C/20,000 X g  for 5 minutes and resuspended in one-tenth of the original volume 
using cold 100 mM calcium chloride.
Bacteria were transformed by adding 10 pi of ligation product to 200 pi competent 
bacterial cells, chilling on ice for 30 minutes, heat shocking at 42®C for 90 seconds 
and incubating at 37°C with 300pl of LB broth for 2 hours. Transformed bacteria 
were plated onto LB amp plates and grown overnight at 37°C to select for 
transformants.
2.1.11. Replica plating
A grid of squares measuring approximately 1 cm x 1 cm was drawn onto the base of 
LBamp plates. Single bacterial colonies which had grown on the selective media were 
picked using a sterile loop and streaked diagonally across each square. These were 
incubated at 37°C overnight.
Transfer of bacterial colonies onto charged nylon hybridisation membranes 
(Whatman, UK) was performed by placing the membrane on top of the bacterial 
colonies and incubating at room temperature for 5 minutes. The bacterial colonies that 
had been transferred to the membrane were denatured by incubating in denaturing 
solution for 3 minutes, neutralised by incubating in neutralising solution for 5 minutes 
and hybridised with a probe specific for the DNA as described (section 2.2.4 & 
2.2.5). Autoradiography was performed by exposing membranes to X-ray film at 
approximately -70°C for an appropriate period of time with an intensifying screen to 
confirm the presence of the appropriate DNA in each replica colony.
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2.1.12. Preparation of DNA from transfected E. coli
Replica colonies identified as being positive by hybridisation were used to inoculate 
3ml LBamp broth and incubated overnight at 37°C at 220 rpm in the orbital incubator. 
Approximately 1 ml of the overnight culture was added to 1 ml 50% glycerol in LB 
and stored at -70°C.
a. Small scale preparation of DNA
Small scale preparation of plasmid DNA from 2 mis of overnight culture was 
performed using a commercial mini-prep kit (Promega Wizard™ minipreps DNA 
purification system). This kit utilises a modified alkaline lysis method (Bimboim & 
Doly (1979), Ish-Horowicz & Burke (1981)) which is followed by the binding of the 
plasmid DNA to resin under low salt and pH conditions. All other impurities are 
removed by a medium salt wash. The plasmid DNA is eluted in a high salt buffer and 
concentrated and desalted by isopropanol precipitation.
DNA was resuspended in 50 pi TE buffer. The DNA was analysed for the presence of 
the appropriate DNA by restriction endonuclease analysis using BamKl and EcdBl 
followed by agarose gel electrophoresis.
b. Large scale preparation of DNA
A glycerol stock identified as positive for the appropriate insert DNA was used to 
inoculate 5 ml of LBamp broth which was grown at 220 rpm at 37°C for 
approximately 7 hours. This was diluted into 500 ml LBamp broth and grown 
overnight at 220 rpm at 37°C.
A large scale preparation was performed using a commercial maxi-prep kit (Promega 
Wizard™ maxipreps DNA purification system). This method utilises the same
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approach as the small scale preparation. Following isopropanol precipitation, DNA 
was eluted in 1.5 ml TE buffer. The concentration of DNA was determined using a 
spectrophotometer at 260 nm. Typically, a concentration of between 0.5-1.0 mg/ml 
was obtained, assuming 1.0 OD2 6 0  is equal to 50 pg/ml.
DNA was analysed for the presence of the appropriate insert DNA by restriction 
endonuclease analysis using BarnRl and EcdBl. The restricted DNA was 
electrophoresed and the result recorded photographically.
2.1.13. Production of recombinant fusion protein
a. Intitial procedure
Glycerol stocks of bacteria identified as containing the relevant DNA insert (encoding 
a GST-Nef fusion protein) by small and large scale preparations of DNA were used to 
inoculate 100 ml cultures of LBamp broth and grown at 37°C overnight at 220 rpm in 
an orbital incubator. This culture was then added to 900 ml LBamp broth and grown 
to an optical density of 0.3 at 595 nm. Recombinant protein production was induced 
by the addition of 1 ml 100 mM IPTG and cultures were grown for a further 4 hours. 
Cells were centrifuged at 4°C/20,000 x g  for 15 minutes and the pellet resuspended in 
3 ml PBS. Cells were sonicated at 5 microns for 4 minutes and centrifuged at 
4°C/20,000 X  g  for 15 minutes to obtain the final protein supernatant.
b. Modified procedure
Glycerol stocks of recombinant bacteria containing the relevant DNA inserts were 
used to inoculate 3 ml cultures of LBamp broth which were grown at 37°C overnight 
at 220 rpm in an orbital incubator. Approximately 30 pi of this culture was inoculated 
into 3 ml LBamp and grown to an optical density of 0.3 at 595 nm. Recombinant
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protein production was induced by the addition of 30 pi 100 mM IPTG and cultures 
were grown for a further 1 hour. Cells were centrifuged at 4°C/20,000 x g  for 15 
minutes and permeabilised by ffeeze-thawing using dry ice in two short bursts.
Cell pellets from each of the 3 ml cultures were resuspended in 3 ml ice cold PBS 
containing a predissolved commercially available protease inhibitor cocktail tablet 
(Roche, UK). Cells were sonicated on ice at 5 microns in 2 x 2 minute bursts and 
further permeabilised using 1% Triton X-100 with gentle agitation at 4°C for 1 hour. 
Cells were centrifuged at 4°C/20,000 x g for 15 minutes to obtain the final protein 
supernatant.
2.1.14. Preparation of samples for SDS-PAGE analysis
Samples were taken periodically during the course of protein production (1 hour after 
IPTG induction, after freeze thawing, after sonication and after permeabilisation using 
Triton X-100) for analysis by SDS-PAGE. Cells from 100 pi of culture were 
centrifiiged and resuspended in 100 pi filtered water; 100 pi of 2 x SDS-PAGE 
sample buffer was added and the samples boiled for 5 minutes.
2.1.15. SDS -PAGE
The electrophoresis apparatus was set up according to manufacturer’s specifications 
(BIO-RAD, Protean® II, xi cell, UK) (Table overleaf).
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Separating gel 12.5% Stacking gel 3.75%
Acrylamide 9.4 ml 1.5 ml
1 M Tris HCl pH 8.8 7.5 ml -
IM Tris-H ClpH 6.8 - 2.5 ml
Filtered water 12.74 ml 15.7 ml
10% SDS 300 pi 200 pi
Temed 30 pi 50 pi
10% ammonium 
persulphate
60 pi 100 pi
Table 2.1.1. Recipe for the preparation of SDS-PAGE gels
Acrylamide solutions were prepared according to Table 2.2.1. The separating gel was 
poured between the glass plates and allowed to set. The stacking gel was then poured, 
the combs for the wells inserted and the gels allowed to set. In the apparatus, two gels 
were run in parallel. When set, gels were transferred to the central segment of the 
SDS-PAGE tank. Running buffer (800 ml) was added to the base of the tank and 350 
ml added in between the two gels, to allow the flow of current. Approximately 25 pi 
of protein samples were loaded against a 20 pi protein ladder and the samples run at 
150V for 5 hours.
2.1.16. Semi-dry electrophoration transfer
To transfer proteins onto nitrocellulose membranes for detection by Western blot, 3 
pieces of blotting paper cut to the size of the SDS-PAGE gels were soaked in blotting 
buffer and placed on the semi-dry electrophorator base (Sartorius, UK). The gel was
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laid down and a piece of Hybond-C Extra nitrocellulose membrane (Amersham Life 
Science, UK) laid on top for transfer of the protein. An additional three pieces of 
blotting paper moistened in buffer were laid on top and the voltage set to 4 mA/cm^ of 
gel surface area. Transfer of protein from the gel to the nitrocellulose membrane was 
allowed to occur for 45 minutes.
Following transfer, membranes were blocked overnight at room temperature with 
gentle agitation in PBS containing 5% (w/v) milk powder/1 % (v/v) Tween-20.
2.1.17. Western blotting
Membranes were washed in PBS containing 1% (v/v) Tween-20 for 5 x 5 minutes 
with gentle agitation at room temperature prior to incubation with either the primary 
monoclonal or polyclonal antibody at the recommended dilution in PBS containing 
5% (w/v) milk powder/1% (v/v) Tween-20 for 1 hour at room temperature.
After antibody binding, membranes were washed further in PBS containing 1% (v/v) 
Tween-20 for 5 x 5 minutes with gentle agitation. Membranes were then incubated 
with the appropriate secondary antibody at the recommended dilution in PBS 
containing 5% (w/v) milk powder/1 % (v/v) Tween-20 for 1 hour at room temperature. 
Membranes were washed 5 x 5  minutes in PBS containing 1% (v/v) Tween-20 with 
gentle agitation at room temperature. Western blots were developed by incubating for 
1 minute at room temperature with equal volumes of Solutions I & II (ECL™ Western 
Blotting detection system, Amersham, UK), exposing to X-ray film for approximately 
1 minute (can be adjusted to improve exposure) and developing.
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2.1.18. Binding of recombinant protein to Glutathione Sepharose 4B (GS4B) 
beads
Approximately 2 ml samples of recombinant GST-Nef fusion protein (prepared as 
described in section 2.2.13) were added to 400 pi of Glutathione Sepharose 4B beads 
(GS4B, Pharmacia Biotech, UK) prepared according to manufacturer’s specifications. 
The GST-Nef fusion protein was allowed to adsorb to the GS4B beads via the GST 
tag for 30 minutes using gentle agitation at 4°C. The suspension was centrifuged and 
the supernatant removed. The pelleted sepharose was washed 3 times with 1 ml PBS. 
Approximately 200 pi of elution buffer was added to each sample and the suspension 
incubated at 4°C with gentle agitation for 30 mins. The suspension was centrifuged 
and the supernatant, containing the Nef protein, was collected.
Before elution, samples of GST-Nef protein bound to GS4B beads were prepared for 
SDS-PAGE analysis as previously described (section 2.2.14). Samples of purified Nef 
protein, after elution, were used to coat an ELISA plate (section 2.2.20).
2.1.19. ELISA using glutathione coated plates
A 3-fold dilution of GST and GST-Nef protein in PBS containing 5% (w/v) milk 
powder/1 % (v/v) Tween-20 was dispensed into the wells of Reacti-Bind™ 
Glutathione coated 96 well plates (Pierce & Warriner, UK) and incubated at room 
temperature for 1 hour. Plates were washed manually 5 times using PBS containing 
1% (v/v) Tween-20 and incubated with a 1:20 dilution of an appropriate anti-Nef Mab 
in PBS containing 5% (w/v) milk powder/1 % (v/v) Tween-20 for 1 hour at room 
temperature. Anti-GST antibody was also used, at a dilution of 1:2000.
Plates were washed extensively with PBS containing 1% (v/v) Tween-20 to ensure 
removal of the primary antibody. They were incubated with a 1:200 dilution of
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secondary anti-mouse HRP antibody (for anti-Nef) or anti-rabbit HRP antibody (for 
anti-GST antibody) for 1 hour at room temperature and finally washed with PBS 
containing 1% (v/v) Tween-20.
ELISA substrate was added and the reaction allowed to proceed for 15 minutes. The 
chromogenic reaction was stopped by the addition of 25 pi sulphuric acid. The 
absorbance was determined spectrophotometrically at 450nm on an ELISA plate 
reader (Coulter Microplate Reader). The absorbance readings were analysed 
graphically and statistically using Microsoft Excel 97. Absorbance readings were 
entered into a Lotus 123 package using an in-house procedure (NfBSC, UK). End­
point titres were calculated by extrapolating the linear portion of the absorbance 
(OD)-log dilution curve. The end-point was defined as the dilution at which the 
extrapolated linear portion is equal to the cut-off readings.
2.1.20. Coating of ELISA plates with recombinant GST-Nef protein
The concentration of the protein, obtained as described in section 2.2.13, was 
determined using a commercial protein assay kit according to manufacturer’s 
recommendations (BIO-RAD, UK).
The recombinant GST-Nef fusion protein was diluted in filtered water and 50 pi 
added to each well of a labelled ELISA plate. The recombinant protein was dried onto 
the plate overnight at 37°C. The plate was blocked by addition of 200 pi 5% (w/v) 
milk powder/1 % (v/v) Tween-20 for 30 minutes and washed 5 times with PBS 
containing 1% (v/v) Tween-20. The plate was incubated with antibodies according to 
the method described for the glutathione coated plates (section 2.2.19).
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2.2. Methods used in yeast studies
2.2.1. Large scale preparation of plasmid DNA
A glycerol stock of E. coli strain DH5a (Stratagene, UK) transformed with plasmid 
(pASI-CYHII/R5i’HILI) DNA was streaked onto an LBamp plate. This plate was 
incubated overnight at 37°C in an incubator (Gallenkamp).
A single colony was inoculated into 3ml LBamp broth and grown at 37°C at 220 rpm 
for 7 hours in a bench top incubator (New Brunswick Sciences). Approximately 200 
pi of this culture was used to inoculate 200 ml LBamp broth and grown at 37°C 
overnight at 220 rpm in the bench top incubator.
The overnight culture was used in a large scale preparation of plasmid DNA using a 
commercial maxi-prep kit (QIAGEN QIAfilter Plasmid Maxi Prep kit). This protocol 
is based on a modified alkaline lysis method (Bimboim & Doly (1979), Ish-Horowicz 
& Burke (1981)) followed by the binding of plasmid DNA to resin under low salt and 
pH conditions. All other RNA, proteins, dyes and low-molecular weight impurities 
are removed by a medium salt wash. The plasmid DNA is eluted in a high salt buffer 
and concentrated and desalted by isopropanol precipitation.
The DNA pellet obtained was dissolved in 1.5 ml TE (pH 8.0) and the concentration 
calculated using a spectrophotometer at 260 nm, assuming an OD2 6 0  of 1.0 is equal to 
50 pg/ml. Typically, a concentration of between 0.5-1.0 mg/ml was obtained.
2.2.2. Sequential restriction endonuclease digestion of plasmid DNA
Restriction endonuclease digestion was performed using 1 pg plasmid DNA, 2 units 
SaE, 10 X buffer B (Roche, UK) in a final 50 pi volume, incubated at 37°C for 1 hour.
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The plasmid DNA was then isolated using a commercial nucleotide removal kit 
(QIAgen QIAquick Nucleotide Removal kit). This kit utilises a silica membrane, to 
which the DNA adsorbs in the presence of high salt, whilst all other contaminants 
pass through the column provided. The final DNA was eluted in 45 pi water.
The plasmid DNA was subsequently digested using 2 units BamRl, 10 x buffer B 
(Boehringer Mannheim) in a total volume of 50 pi. This was incubated at 37°C for 1 
hour.
2.2.3. Déphosphorylation of plasmid DNA
The digested plasmid DNA (50 pi) was dephosphorylated by incubation with 1 pi calf 
intestinal phosphatase at 37°C for 1 hour.
2.2.4. Preparative gel electrophoresis
Agarose gels were prepared in 1 x TBE buffer (containing 5 pg/ml ethidium bromide) 
and electrophoresis performed using the Horizontal® 58 gel electrophoresis system 
(Gibco BRL). Sample (9 pi) was added to 1 pi 10 x DNA gel loading buffer and run 
on a gel against a 1 kb DNA ladder at 100 V for 1 hour. DNA was visualised by 
transillumination and the result recorded photographically.
2.2.5. Extraction of plasmid DNA from agarose gels
A slice of gel containing the plasmid DNA was excised carefully using a sterile 
scalpel and the DNA extracted from the gel using a commercial kit (QIAgen 
QIAquick Gel Extraction Kit). This kit utilises the same principle as the nucleotide 
removal kit. The DNA was eluted in 30 pi sterile water.
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2.2.6. Transfection of pGEX-4T3-fig/'DNA into E. coli DH5 a  cells
Approximately 1 ng.of pGEX-4T3-ne/maxi-prep DNA (section 2.2.12b) was used to 
transform competent E. coli DH5a cells. Competent E. coli DH5a cells were 
removed from storage at -80°C and thawed on ice for 10 minutes. Cells (40 pi) were 
added to 1 ng DNA. As a control, pUC19 plasmid DNA (1 ng) was added to 40 pi 
DH5a cells. Mixtures were chilled on ice for 30 minutes and heat shocked at 42°C for 
1 minute. Samples were further incubated on ice for 2 minutes prior to addition of 900 
pi LB broth and incubated for 1 hour at 37°C at 225 rpm in the bench top incubator. A 
sample of the cells (200 pi) was plated onto LBamp plates and incubated at 37°C 
overnight.
2.2.7. Preparation of pGEX-4T3-Mgf DNA
Six single colonies (transformants) from each different pGEX-4T3-«e/" clone were 
picked, inoculated into 6 ml LBamp broth and grown overnight at 37°C at 220 rpm in 
the bench top incubator.
a. Midi scale preparation of DNA
Four of the pGEX-4T3-«e/'overnight cultures were used in a midi scale preparation of 
DNA performed using a commercial kit (QIAgen Tip 20 kit). This is based on a 
modified alkaline lysis method (Bimboim & Doly (1979), Ish-Horowicz & Burke, 
(1981)) followed by the adsorption of DNA onto silica in the presence of high salt. 
The final DNA was eluted in 50 pi TE (pH 8.0).
b. Small scale preparation of DNA
Four of the pGEX-4T3-we/' cultures were used in a small scale preparation of DNA 
performed using a commercial kit (QIAGEN QIAprep Spin miniprep kit). This kit is 
based on the same principle as the QIAgen Tip 20 kit. The final DNA obtained was 
eluted in 50 pi TE (pH 8.0).
c. Restriction endonuclease digestion of DNA
The DNA obtained from midi and small scale preparations was restriction 
endonuclease digested sequentially using BamRl and SaE as described (section 2.2.2). 
The digested DNA was subjected to agarose gel electrophoresis and the DNA excised 
and extracted as described (section 2.2.5).
2.2.8. Ligation of »gfPNA into plasmid DNA
Ligations reactions contained 5 pi restricted plasmid vector DNA (section 2.2.2), 12 
pi restricted purified wq/'DNA (section 2.2.7c), reaction buffer and 1 unit DNA ligase 
(Sigma, UK) in a final volume of 20 pi. Control reactions were included, from which 
either insert DNA, insert DNA and DNA ligase, or plasmid DNA were absent. The 
reactions were incubated at 16°C overnight.
2.2.9. Transfection of //gfPNA into plasmid DNA
A 5 pi portion of the ligation mix was transfected as described (section 2.2.6) into 
competent E. coli DH5a cells. Cells were plated onto LB plates and incubated 
overnight at 37°C.
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2.2.10. Preparation of pASI-CYHII/^yyHII.I-wgfDNA
a. Small scale preparation
For each transformed clone, six single colonies of nef DNA  ligated into plasmid 
vector DNA (pASI/CYHII-R5 .sHILI-«q/) were inoculated into 3 ml cultures of LBamp 
broth and grown overnight at 37°C at 220 rpm, in the bench top incubator.
An overnight culture (1 ml) was added to 1 ml 50% glycerol and stored at -80°C. A 
small scale DNA preparation of the remainder of the culture was performed as 
described (section 2.2.7b). The DNA obtained was digested sequentially with 
restriction endonucleases SaE and BamRl (section 2.2.2), gel electrophoresed (section 
2.2.4) and visualised by transillumination to detect for the presence of the appropriate 
DNA insert.
b. Large scale preparation of DNA
A positive glycerol stock (for each pASI/CYHII-j8 ^'jHII.I-«q/" clone) identified by 
restriction endonuclease analysis of small scale preparations of DNA was used to 
streak LBamp plates and incubated overnight at 37°C to generate single colonies. A 
single colony was picked and inoculated into 5 ml LBamp broth and grown overnight 
at 37°C at 220 rpm for approximately 7 hours in a bench top incubator. 
Approximately 100 pi of this culture was inoculated into 100 ml LBamp broth and 
grown overnight at 37°C at 220 rpm in the bench top incubator. A large scale DNA 
preparation was performed using a maxi-prep commercial kit as described (section
2.2.1). The concentration of DNA was determined at 260 nm using a 
spectrophotometer.
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2.2.11. Restriction endonuclease analysis of large scale DNA preparations
Maxi prep DNA (1 pg) was sequentially digested using restriction endonucleases Sal\ 
and BamHl as described (section 2.2.2). The presence of the appropriate DNA insert 
was determined by analytical gel electrophoresis and transillumination and the result 
recorded photographically.
2.2.12. Sequencing of pASI-CYHII/^ysHII.I-Mgf constructs
Sequencing was performed using 1 pg of DNA, 15 pmol primer and 1.5 pi DMSO in 
a final 30 pi reaction volume and utilising BigDye terminator chemistry. Cycle 
sequencing protocol was performed according to manufacturer’s recommendations 
(Applied-Biosystems, CA, USA) for a 96-well block PGR machine. The cycle 
parameters were adapted for templates of approximately 9 kb and above. Neat 
BigDye terminator mix was used in each reaction. The cycle consisted of dénaturation 
at 95°C for 5 minutes and then 30 cycles of annealing at 55°C for 15 seconds, 
extension at 64°C for 4 minutes and dénaturation at 95°C for 30 seconds. Samples 
were stored at 15°C.
Equipment used were PE Biosystems ABI Prism 377 sequencers and ABI Prism 3700 
Capillary sequencers. Sequences were analysed using Lasergene 99 software.
2.2.13. Double transformation of Y190
A plate of YEPD agar (supplemented with adenine and glucose) was streaked with a 
glycerol stock of Y190, wrapped with parafilm (Parafilm ‘M ’ laboratory film, 
American Can™, Chicago) to prevent drying and incubated at 30°C for 3-4 days. A 
single colony was picked and inoculated into 10 ml YEPD media (supplemented with 
adenine and glucose) and grown overnight at 200 rpm at 30°C in the bench top
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incubator. Approximately 1 ml of overnight culture was added to 100 ml fresh, pre­
warmed YEPD media (supplemented with adenine and glucose) to an OD of 
approximately 0.2 at 600nm. This was then grown at 30°C at 200 rpm in the bench top 
incubator for approximately four hours. When the OD at 600nm was between 0.6 and 
1.0 the cells were transferred into 2 x 50 ml Falcon tubes and centrifuged at 800 x g at 
room temperature for 2 minutes. The pellet was washed twice by resuspension in 20 
ml water and centrifuged. The cells were resuspended in 20 ml LiAc/TE solution and 
centrifuged again. The pellet obtained was resuspended in 1 ml LiAc/TE solution, 
transferred to a microfuge tube and centrifuged at 7000 x g  for 2 minutes. For every 
100 ml of original culture the resulting pellet was resuspended in 1 ml LiAc/TE 
solution.
In sterile microfuge tubes, 1 pg of binding domain (BD) DNA and 1 pg of the 
appropriate activation domain (AD) DNA (section 4.1) were added to 5 pi of 10 
mg/ml salmon sperm carrier DNA. Approximately 50 pi of cell suspension and 300 pi 
of 40% PEG/LiAc/TE solution were then added. The samples were mixed by gentle 
tapping and incubated at 30°C for 30 minutes at 150 rpm in the bench top incubator. 
Tubes were transferred to 42°C for 20 minutes. Cells were pelleted at 7000 x g  for 2 
minutes, the final pellet resuspended in 1 0 0  pi filtered water and spread onto minimal 
media agar plates (supplemented with the appropriate nutrients, but lacking 
tryptophan and leucine). Plates were wrapped in parafilm and incubated at 30°C for 
approximately 4 days, with periodical inspection for signs of colony growth.
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2.2.14. Liquid assay (adapted from Harshman et al., 1988)
Single yeast colonies transformed with BD DNA and AD DNA were picked in 
quadruplicate from selection plates and inoculated into 5 ml minimal media 
(supplemented with the appropriate nutrients, but lacking leucine and tryptophan), and 
grown overnight at 30°C at 200 rpm in the bench top incubator. Overnight cultures 
were added to fresh minimal medium (supplemented with the appropriate nutrients 
but lacking tryptophan and leucine) to an OD of approximately 0.2 at 600 nm and 
grown for a further four hours until the OD was between 0.6-0.8 at 600 nm. One 
millilitre of the culture was centrifuged for 1 minute at 6000 x g  and the cells 
resuspended in 200 pi lysis buffer (see section 2.3). Cells were permeabilised by two 
rounds of plunging into liquid nitrogen and thawing at 37°C. Samples were placed on 
ice and 100 pi of the sample (V) was added to tubes containing 600 pi Z- 
buffer/ONPG/p-mercaptoethanol. These were vortexed and transferred to a 37°C 
water bath. The development of yellow colour was observed and reactions stopped by 
the addition of 250 pi IM sodium carbonate. Tubes were centrifuged for 1 minute and 
the absorbance of the supernatant read at A4 2 0 . In order to normalise these readings, 1 
ml water was added to a cuvette, 2 0  pi of the sample added and the absorbance read at 
Aôoo. The values obtained were substituted into the equation;
U = 1000 X A420 / [(A600/W)V(To-Ti)]
Where A420 = absorbance at 420 nm 
A600 = absorbance at 600 nm 
Ti = Time in 
To = Time out 
W = 20 pi
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V = 100 pi
Graphical representation and statistical analysis of values obtained were performed 
using a Microsoft Excel worksheet.
2.2.15. B-galactosidase assay
The remaining colonies were lifted onto filter discs and permeabilised by plunging 
into liquid nitrogen and thawing at room temperature twice. Discs were placed in a 
tray and 2 ml of 100 mg/ml X-gal/DMF/p-mercaptoethanol applied to the underside 
of each filter disc which were covered and incubated at room temperature in a ftime 
hood for approximately 4 hours to allow colour to develop. The filters were dried 
overnight.
For a kinetic assay, filter discs were incubated with X-gal/DMF/p-mercaptoethanol 
solution for 1 hour, 2 hours or 6 hours and then dried overnight before inspection.
2.2.16. Protein production
Vector DNA (pASI/CYHII-.g55HII.I) and plasmids containing the appropriate DNA 
insert (pASI/CYHII-Ri'^HII.I-nq/) were transfected into Y190 cells as described in 
section 2.2.13. One single colony was picked and inoculated into 10 ml of WHAUL 
media (supplemented with the appropriate nutrients but lacking tryptophan). This was 
grown overnight at 30°C at 220 rpm in the bench top incubator. The following day 
this was subcultured in fresh WHAUL media (containing the appropriate nutrients but 
lacking tryptophan) to an OD of 0.2 at 600 nm and grown for a further 4 hours until 
the OD was approximately 0.6 at 600 nm. The cultures were centrifuged at 4°C/2000 
X g and the pelleted cells resuspended in 20 ml filtered water. Cells were centrifuged 
at 4°C/2000 X  g  for 3 minutes and the pellet resuspended in 300 pi 10% TCA. Glass
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beads (Sigma, UK) were added to the level of the meniscus and the tubes vortexed for 
5 minutes to lyse the yeast. A Pasteur pippette was used to transfer the suspension to a 
fresh microfuge tube, avoiding the beads. This was then centrifuged at 10,000 x g for 
20 minutes and the supernatant discarded. The pellet was resuspended in 100 pi SDS- 
PAGE sample buffer containing p-mercaptoethanol and the sample heated at 100°C 
for 5 minutes. The pH was adjusted to neutral by adding 1 pi volumes of 5 M sodium 
hydroxide. The sample was centrifuged at 10,000 x g  for 5 minutes, the supernatant 
removed and the samples incubated at 100 °C for 10 minutes. Samples were ready for 
analysis by SDS-PAGE.
2.2.17. SDS-PAGE
A 4-20% Tris-Glycine precast gradient gel was used (Novex, UK) for sodium dodecyl 
sulphate polyacrylamide gel electrophoresis of protein samples. Gels were set into the 
tank (Novex, UK) and 100 ml of Tris-Glycine SDS running buffer (Novex, UK) 
added between the two plates and to the base of the tank. Approximately 15 pi of 
protein samples were loaded against 3 pi protein marker and the gels run at 120V for 
1.5 hours.
2.2.18. Semi-dry electroblotting
Before transfer, an Immobilon™-P membrane (Miilipore, MA) was soaked in 100% 
methanol for 1 minute and dipped briefly in SDS-PAGE running buffer. Semi-dry 
electroblotting (Ancos semi-dry electroblotter, model A, Denmark) was performed at 
100 mA per gel, as described (section 2.2.16). After transfer membranes were blocked 
overnight in 3% (w/v) non fat milk powder in PBS (pH 7.4).
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2.2.19. Western blotting
Western blotting was performed as previously described (section 2.2.17). The 
antibodies were added at the recommended dilutions in 3% (w/v) non fat milk 
powder/1 % (v/v) Tween-20 in PBS (pH 7.4).
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3. Antigenic studies of SIV nef  clones which express wild 
type and attenuated phenotypes in macaques
3.1. Introduction
There is strong evidence that a functional Nef protein of human and simian 
immunodeficiency viruses is a critical component in determining the rate of 
progression to disease. Disruption of the SIV nef gene alone is sufficient to attenuate 
infection significantly (Kestler et al, 1992, Rud et a l, 1994). Repair of attenuating 
mutations in vivo also appears to be responsible for the reversion to a wild type 
pathogenic phenotype (Whatmore et al, 1995). Furthermore, clinical studies of HIV-1 
positive patients have identified a proportion of long term non progressors (LTNPs) 
from whom only viruses attenuated in their nef genes have been isolated (Kirchhoff et 
al, 1995, Learmont et al, 1992). These attenuations appear to be responsible for 
these patients remaining clinically healthy.
The observation that small, yet stable genetic mutations in SIV nef are sufficient to 
disrupt key functions of the virus responsible for conferring a pathogenic phenotype 
could provide an invaluable tool for elucidating further information on functions of 
nef in vitro. It is now important to characterise the critical properties of nef that 
correlate with pathogenic phenotype in vivo.
Very little information exists on the structure of SIV Nef, whilst the crystal structure 
of HIV-1 Nef has been resolved (Lee et al, 1996). Nevertheless through the use of 
monoclonal antibodies, it is possible to investigate subtle changes in the structure and 
conformation of novel SIV Nef variants. This can reveal potentially important 
information regarding key regions of the Nef protein which are required for optimal 
viral replication in vivo. As a result it may be possible to make predictions regarding 
the structure of the SIV Nef protein.
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Previously, the structure of viral proteins from HIV envelope have been successfully 
characterised using monoclonal antibodies. Moore et al. (1993) extensively studied 
the structure of the HIV Envelope (Env) protein using monoclonal antibodies directed 
against Env proteins containing a series of deletions to elucidate key amino acid 
sequences important for antibody binding. Furthermore, as part of a program to design 
vaccines, Moore et al. (1994) identified which regions of the HIV Env protein are 
exposed on the surface, by investigating antibody binding to the SU subunit. Many of 
the complexities of the conformational structure predicted from these studies were 
proven once the crystal structure was resolved (Kwong et al, 1998).
To facilitate a comparable study of the structure of SIV Nef, mutant clones of SIV 
have been constructed that vary only in the nef gene (A. Jenkins, NIBSC). These nef 
sequences are derived from wild type J5, attenuated C8, or from passage of these 
viruses in vitro or in vivo (Figure 3.1.1 & 3.1.2). The various deletions and/or 
substitutions within these parental clones are known to have a dramatic effect on the 
pathogenic outcome of the viral infection (Rud et al, 1994, Almond et al, 1995, 
Whatmore et al, 1995). However, in addition it is necessary to have a panel of 
monoclonal antibodies such as those described by Arnold et al, (1999). These were 
generated in response to the immunisation of mice with wild type SIV Nef protein, 
were characterised by Western blot and their specificity determined based on their 
reactivity in an ELISA assay using recombinant proteins and synthetic overlapping 
peptides (Table 3.1.1). The MAbs were divided into five separate groups (I-V) which 
were confirmed through competition analysis using the recombinant baculovirus J5 
Nef as antigen, with all antibodies within the groups showing good reciprocal 
competition, with the exception of group I (Table 3.1.2). Two distinct epitopes were
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Figure 3.1.1. A schematic representation of SIV nef clones harbouring attenuations 
within the nef gene and the effect of these attenuations on mean virus load at 2 weeks 
post infection, as the number of infected PBMCs/10^. Results are the mean of a total 
of four animals within each group. Results are indicative of one scheduled 
experimental group. Animals used were cynomolgus macaques (macaca fascicularis). 
Expermental results were taken at 2 weeks post infection only.
Wild type J5 carries a full length nef gene and has a virus load of 560 infected 
PBMCs/10^. By contrast, the attenuated clones have a virus load that is decreased 
dramatically.
The red boxes denote deletions within the amino acid sequence of the clones. The 
asterix denotes a stop codon at amino acid 213 of VLA*del.
Courtesy of: N. Almond, Division of Retrovirology, NIBSC, personal
communication.
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ENV J
Virus/
Recom binant
Clone
LTR
J5 
C8 
GX2 
C8 del 
VLA*del
Î6QYMNTPW RNPAEEREKLAYR DMYL
143-146 191 213  249
K A
Mean virus load 
at 2 weeks pi.
(No. o f inf’d PBMC/10®)
2.75 +/- 0.87 
0.75 +/- 0.5
1.125 +/-0.48
1.125 +/-0.75  
0.8 +/- 0.57
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Figure 3.1.2. The 45R revertant clones. Recombinant virus was grown for less than 
28 days and propagated on CEMxl74 cells. Reisolated virus was derived by co­
culture of PBMCs taken from macaque 45R with C8166 cells and Facscan analysis 
performed. Sequence data was derived by PCR of the DNA in the cell pellet used in 
Facscan analysis.
Whatmore et al. (1995) used rhesus macaques for their studies, from which the 
reisolated virus was taken.
The deduced amino acid sequence of nef of virus taken from PBMCs at various time 
points after infection with SIVmacC8 is shown. The virus was observed to revert back 
to a nearly wild type sequence at 41 weeks post infection. The ability of two Nef 
specific monoclonal antibodies, KK70 and KK75 to bind to reisolated virus (from 
macaque 45R) and recombinant virus (generated by site directed mutagenesis) was 
investigated, by Facscan analysis.
A difference in monoclonal antibody binding between the two viruses was detected at 
25 weeks post infection. A spontaneous nucleotide change at position 191 was 
observed, to an aspartic acid (R191E), in the reisolated virus. Due to the coincidence 
of this position being mutated in C8 to a lysine residue (R191K) and that the mutation 
of R191E appeared to disrupt monoclonal antibody binding by Facscan analysis 
attention was focused upon this position as having an important role in protein 
conformation.
Red box denotes a deletion within the nef gene, p/i; post infection.
The linear epitope for Nef specific monoclonal antibody KK75, is shown between env 
and the 3’ LTR. The epitope for KK70 has not been defined.
45R revertant sequence data adapted from: Whatmore AM, Cook N, Hall GA, Sharpe 
S, Rud EW, Cranage MP (1995). Repair and evolution of nef in vivo modulates 
simian immunodeficiency virus virulence. J. Virol. 69 (8): 5117-23.
Recombinant virus and Facscan analysis: Courtesy of N. Almond, Division of 
Retrovirology, NIBSC, personal communication.
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ELISA end-point titre against indicated antigen
EVA777 Nef Peptides
Group MAb J5 Nef C8 Nef HIS-Nef Peptide 7 
(60-80)
Peptide 8 
(70-90)
I
KK71 3.3 2.8 - - -
KK76 3.7 3.0 - - -
II
KK78 3.3 2.2 3.3 - -
KK79 3.0 1.9 2.8 - -
KK80 3.9 2.8 3.5 - -
KK81 3.4 2.3 3.2 - -
III
KK70 3.2 - 2 . 1 - -
KK74 3.4 - 2 . 1 - -
IV
KK73 4.4 3.8 3.5 5.7 -
KK75 3.8 3.7 3.6 4.9 -
V
KK77 4.5 4.1 3.7 6.3
Table 3.1.1. The reactivity of monoclonal antibodies with recombinant Nef proteins 
and synthetic peptides.
J5 and C8 Nef proteins were derived from recombinant baculovirus, the HIS-Nef 
protein was purified from recombinant E. coli expressing BK-28 Nef and the EVA777 
Nef peptides were based on the sequence of SIVmac32H. Recombinant proteins were 
used at 1 pg/ml and peptides were used at 2.5 pg/ml. All antigens were prepared in 
distilled water. Results are expressed as logio end-point titres. -, ELISA end point 
<1.5.
Adapted from: Arnold C, Jenkins A, Almond N, Stott EJ, Kent KA (1999). 
Monoclonal antibodies recognise at least five epitopes on the SIV Nef protein and 
identify an in vzYro-induced mutation. AIDS Res. Hum. Ret. 15(12): 1087-1097
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Maximum percent inhibition by indicated unlabeled Mab
G rp I I G rp  I I I G rp IV Grp
V
Grp Biotin
ylated
M A b
G rp
la
(K K 7
1)
Grp
Ib
(K K 7
6)
K K 78 KK79 KK80 K K 8 I K K 70 K K 74 K K 73 K K 75 K K73
la K K 7I 100 0 100 90 100 60 0 0 0 0 0
Ib KK76 0 90 50 50 40 40 0 0 0 0 0
II KK81 100 100 100 100 100 100 100 70 0 0 0
III KK70 0 0 0 0 0 0 90 90 0 0 0
KK74 60 60 <10 <10 0 0 80 90 <10 <10 <10
IV KK75 0 0 0 0 0 0 0 0 90 90 90
V KK77 0 0 0 0 0 0 0 0 90 90 90
Table 3.1.2. The specificity of monoclonal antibodies based on competition analysis. 
Results are shown as the maximum percent inhibition of biotinylated antibody in the 
presence of unlabeled competitor. Group I to V are those defined by the reactivity of 
the MAbs with recombinant Nef proteins and synthetic peptides.
Adapted from: Arnold C, Jenkins A, Almond N, Stott EJ, Kent KA (1999). 
Monoclonal antibodies recognise at least five epitopes on the SIV Nef protein and 
identify an in vzïro-induced mutation. AIDS Res. Hum. Ret. 15(12): 1087-1097
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defined, using overlapping synthetic peptides, spanning amino acids 60-80 (group IV) 
and 70-90 (group V). The other epitopes recognised by the remaining groups of 
monoclonal antibodies were thought to be partially conformational due to their 
inability to react with any of the linear peptides (Arnold et ah, 1999).
As summarised in Figures 3.1.1 and 3.1.2 wild type J5 virus exhibits binding by 
KK70 and KX75 and a virulent in vivo phenotype, where the viral load is 560 infected 
cells per 10  ^PBMC. By contrast, C8 is not recognised by KK70 and has an attenuated 
in vivo phenotype, with a virus load 100-fold lower. This would suggest KK70 
recognised a conformational epitope which was disrupted by the attenuation in C8 
(Arnold et al., 1999).
The conformational structure of the KK70 epitope was confirmed when binding of 
KK70 was disrupted in the clone VLA*del (Arnold et al., 1999). This clone was 
constructed by site directed mutagenesis based upon reproducible changes in the nef 
gene sequence following passage of SIVmacJ5 on C8166 cells. In two independent 
experiments reported by Arnold et al, (1999), a premature stop codon was generated 
at amino acid 213, by a G>A change at nucleotide 9713, disrupting the ability of 
monoclonal antibody KK70 to bind. SIVmacJ5 virus with this reconstructed truncated 
Nef protein also exhibits an attenuated phenotype in vivo (Figure 3.1.1).
Clone C8del is a molecular clone derivative of C8 and carries only the four amino 
acid deletion between amino acids 143-146, with no additional nucleotide changes 
relative to J5. This deletion is sufficient to disrupt binding of KK70 by Facscan 
analysis of virus infected cells, indicating that amino acids 143-146 are an important 
part of, or are in close proximity to the conformational epitope that KK70 recognises 
(N. Almond, personal communication).
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Clone GX2 was isolated from macaque 1227 one month after challenge with an 
uncloned stock of virus known as the 11/88 stock of SIVmac32H. Relative to wild 
type J5 virus it contains a naturally occurring deletion between amino acids 62-83, 
which lies directly within the linear peptide sequence recognised by group IV and V 
monoclonal antibodies. This abolishes KK75 binding, but not that of KK70 (N. 
Almond, personal communication). The effect of the attenuation reduces average 
logio virus titre to 13 infected cells per 10  ^PBMC.
Additional clones of SIV Nef have been isolated from a rhesus macaque (45R) 
following infection with the attenuated C8 virus (Whatmore et ah, 1995). In this study 
a total of seven rhesus macaques were infected with the C8 virus (see section 1.9). Six 
of the animals remained healthy whilst the condition of one animal (45R) declined 
rapidly until it was sacrificed at 58 weeks post infection. Analysis of the nucleotide 
sequence of the nejlV  LTR region of PBMC associated provirus revealed that over a 
41 week period the sequence had evolved to near wild type, and in doing so the virus 
appeared to have regained the highly pathogenic disease characteristics of a wild type 
J5 phenotype (Figure 3.1.2, Whatmore et al, 1995). A flow cytometry based 
comparison of virus from macaque 45R re-isolated by co-culture on C8166 cells and 
of recombinant viruses generated by site directed mutagenesis in a J5 backbone 
revealed differences in the binding of monoclonal antibodies KK70 and KK75 (Figure
3.1.2) (K. Kent, A. Jenkins, C. Arnold, N. Almond, personal communication).
At 41 weeks post infection a discrepancy was revealed between re-isolated virus and 
recombinant virus. Whilst the re-isolated virus bound to KK70 and KK75 the 
recombinant virus, expressing the same motif, did not bind to KK70. The reasons for 
this discrepant pattern of antibody binding are unclear. However, as there are 
additional sequence differences between J5 and the reisolated EIYL variant, it is
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possible that one or more of these changes in the nef gene of the re-isolated virus co­
operate with the repair sequence EIYL at amino acids 143-146 and reconstruct the 
conformational epitope recognised by KK70.
Analysis of these sequences (Figure 3.1.3) revealed a mutation at position 191 (R>E). 
This amino acid location is intriguing since it is the location of one of the two other 
coding variations in the Nef protein that differentiate C8 and J5 (Figure 3.1.2).
The aims of this study were two fold. Firstly, to develop a quantitative method for 
characterisation of the binding of multiple recombinant SIV Nef proteins, derived 
from the clones described by Whatmore et a l (1995), to a panel of monoclonal 
antibodies (Arnold et a l, 1999). This assay required extensive experimentation to 
select a method where Nef protein could be expressed in a form that was suitable for 
use in this assay. The final assay format utilised glutathione-S-transferase tagged Nef 
protein, expressed by a bacterial system, in a 96-well ELISA-based format. The 
second aspect of the study was to apply this novel method to determine whether the 
mutation of amino acid R191E of J5 Nef would complement the amino acid motif 
EIYL at positions 143-146 and restore the conformational epitope recognised by 
KK70. The sequences of these SIV Nef proteins used in this study are shown in 
appendix 1, Figure 7.1.
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1 50
Recom-EIYL ------------------------- ---------------------------
Reiso-EIYL -------------------------  -------------------------
Consensus MGGAISRRRSKSAGDLRQRLLRARG ETYGRLLGEVEDGYSQSLGGLDKGL
51 100
Recom-EIYL ------------------------- ---------------------------
Reiso-EIYL --------------------------  n-----n-----
Consensus SSLSCEGQKYNQGQYMNTPWRNPAE EREKLAYRKQNMDDVDEEDDDLVGV
101 150
Recom-EIYL ------------------------- ---------------------------
Reiso-EIYL ----------------i-i---------------------------------
Consensus PVMPRVPLRTMSYKLAVDMSHFIKE KGGLEGIYYSARRHRILEIYLEKEE
151 200
Recom-EIYL ------------------------- ---------------------------
Reiso-EIYL --------------------------  e----h----
Consensus GIIPDWQDYTSGPGIRYPKTFGWLW KLVPVWSDEAQEDERHYLMQPAQT
201 250
Recom-EIYL ------------------------- ---------------------------
Reiso-EIYL --------------------------  a-
Consensus SKWDDPWGEVLAWKFDPTLAYTYEA YVRYPEEFGSKSGLPEEEVRRRLTA
251 263
Recom-EIYL -------------
Reiso-EIYL -------------
Consensus RGLLNMADKKETR
Figure 3.1.3. An alignment of the nucleotide sequence of reisolated virus (reiso-EIYL) from 
nacaque 45R at 41 weeks post infection with SlVmacCS, with virus generated by site directed 
nutagenesis (recom-EIYL) and wild type J5 virus. Dashes indicate 100% identity to wild type SIV 
i5 Nef. The R191E mutation is highlighted.
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3.2. Results
3.2.1. Analysis of nefDNA
PCR amplification of nef DNA templates GX2, C8del, VLA*del, J5(EIYL), 
J5(EIYL+R>E), J5(R>E), J5(EKIL) and J5(DIYL) (Table 3.2.1) generated products 
of approximately 800 base pairs when analysed by electrophoresis through a 1.75% 
(w/v) agarose gel (Figures 3.2.1a & 3.2.1b). A smaller band of approximately 730bp 
was obtained from the amplification of GX2. This was consistent with the 66 bp 
deletion within this clone (see section 3.1) compared with wild-type SIV J5. 
Hybridisation with a nef specific probe y^^P-SN9763C confirmed that the PCR 
products were derived from the SIV nef gene. The PCR product derived from the nef 
construct VLA*del did not hybridise in the presence of 20% (v/v) formamide at 42°C, 
presumably due to the deletion of a proportion of the sequence complementary to the 
radiolabelled probe. However, hybridisation of the probe in the absence of 
formaldehyde and at 29°C was found to permit hybridisation of the probe to this clone 
(data not shown).
The PCR-derived DNA was phenol/chloroform extracted and digested with the 
restriction enzymes EcoRl and BamRl. The digested DNAs were subjected to 
electrophoresis on a 1.75% (w/v) agarose gel to confirm that the DNAs were present 
(data not shown). PCR products were ligated into plasmid pGEX-4T3 overnight at 
16°C and transfected into E. coli strain XL-1 Blue. A number of recombinant clones 
were identified for each PCR product by colony hybridisation.
The identification of recombinant nef inserts in selected colonies for each construct 
was confirmed by restriction endonuclease analysis of a small scale preparation of
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Construct Attenuation/Mutation
J5 Wild type full length Nef
C8
Deleted between aa 143-146; R191K and T249A 
substitutions
C8del Deleted between aa 143-146
VLA*del
Mutation identified in J5 virus that lost the ability 
to bind to KK70 following passage on C8166 
cells (Arnold et al., 1999).
Is truncated by a premature stop codon at aa 213
GX2 66 nucleotide deletion between aa 66-88
J5(EIYL) Four amino acid substitution with sequence EIYL 
between aa 143-146
J5(EIYL+R>E) Four amino acid substitution with sequence EIYL 
between aa 143-146 and R191E substitution
J5(R>E) R191E substitution in a wild type backbone
Table 3.2.1. A list of the constructs used in the study and their various attenuations and 
deletions. All constructs, with the exception of GX2, were generated by the site directed 
mutagenesis of the wild type J5 clone. GX2 was generated from an M l3 clone containing 
an SIV nef insert derived by PCR from the blood of macaque 1225 one month after 
challenge with the 11/88 pool of SIVmac251.
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1 2 3 4 5 6 7 8 9 10 11 12
bp
1353
1078
872
603
Figure 3.2.1a. Agarose gel electrophoresis of products following amplification 
of SIV nef sequences by polymerase chain reaction. Products were resolved on a 
1.75% (w/v) agarose gel and visualised by staining with 1 pg/ml ethidium 
bromide andUV transillumination. Lanes 1-6,8,10,12; negative water eontrols, 
lane 7; product of SIVmacGX2, lane 9; product of SIVmacCSdel and lane 11; 
product of SIVmacVLA*del. The electrophoretic mobility of PCR products are 
compared with cpX174 DNA restricted with Haelll (unmarked left hand lane). 
Bands of specified sizes in base pairs are marked.
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Figure 3.2.1b. Agarose gel electrophoresis of products following amplification of SIV 
nef sequence by polymerase chain reaction. Conditions as stated for Figure 3.3.1a. 
Lanes 1-6, 8, 10, 12, 14 and 16; negative water controls, lane 7; product of 
SIVmacCSdel, lane 9; product of 15(EKIL), lane 11; product of 15(EIYL); lane 13; 
product of J5(EIYL+R>E), lane 15, product of J5(R>E), lane 17; product of J5(DIYL), 
lane 18; product of SIVmaeJ5 (positive control). The electrophoretic mobility of PCR 
products are compared with (pX174 DNA restricted with Haelll (unmarked left hand 
lane). Bands of specified sizes in base pairs are marked. The products towards the 
bottom of lanes 2,12,14,16 & 18 are thought to be residual primer product.
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DNA from 3 clones randomly selected for each construct (data not shown). One clone 
of each construct was selected for a larger scale DNA preparation and the presence of 
the appropriate nef DNA confirmed by restriction endonuclease analysis and gel 
electrophoresis (Figure 3.2.2).
3.2.2. Western blot analysis of GST-Nef recombinant protein
Triton X-100 soluble fractions of IPTG induced E. coli XL-1 Blue cultures 
transformed with the recombinant pGEX-4T3 plasmid containing the selected SIV nef 
genes were cleared by high speed centrifugation. Expression of the recombinant GST- 
Nef proteins for each construct was analysed by SDS-PAGE and immunoblotting 
using Nef specific monoclonal antibodies, KK70 or KK75. The analysis of selected 
clones is presented in Figure 3.2.3.
Recombinant fusion protein of the expected RMM of between 53-66 kDa was 
detected, reflecting the addition of GST (RMM 26 kDa) and Nef (RMM 27-35 kDa), 
for preliminary preparations of GST-GX2, GST-C8del and GST-VLA*del fusion 
proteins when Western blotting was performed with KK70 or KK75. However a 
significant proportion of the recombinant protein detected was degraded into multiple 
bands ranging from 30-60 kDa. Furthermore, in the absence of IPTG induction, the 
bacteria still expressed and degraded the fusion protein. Interestingly, for GST-GX2 
fusion protein, there appears to be more protein produced when the bacteria were not 
induced by IPTG (Figure 3.2.3a, lane 6) compared to those that were induced by 
IPTG. This indicates a very high basal level of protein expression. On some 
occasions, little protein was obtained, evident by the difficulty of detection even by 
immunoblotting (data not shown).
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Figure 3.2.2. Restriction endonuclease analysis of large scale preparation of pGEX- 
4T3-f2e/'DNA, ming BamRl and-EcoRI, run on a 1% agarose gel (w/v) and visualised 
by staining with 1 pg/pl ethidium bromide and UV transillumination. Lane 1; pGEX- 
4T3 undigested, lane 2; GX2 undigested, lane 3; C8del undigested, lane 4; VLA*del 
undigested, lane 5; J5(EIYL) undigested, lane 6; J5(EIYL+R>E) undigested, lane 7 
J5(R>E) undigested, lane 8; J5(EKIL) undigested, lane 9; GX2 digested, lane 10 
C8del digested, lane 11; VLA*del digested, lane 12; J5(EIYL) digested, lane 13 
J5(EIYL+R>E) digested, lane 14; J5(R>E) digested, lane 15; J5(EKIL) digested. The 
electrophoretic mobility of the DNA is compared with (pX174 DNA restricted with 
Haelll and A. DNA restricted with Hindlll (unmarked left hand lane). Bands of 
specified sizes in base pairs are marked.
The appropriate nef gene appears to be present in all clones at approximately 800 
bpwith the exception of GX2 (lane 9) that runs slightly faster due to the 66 nucleotide 
deletion within it. A band corresponding to nef at 800 bp in J5(EKIL) is absent. 
Attempts to re-clone this construct proved unsuccessful.
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Figure 3.2.3a. Western blot analysis of recombinant GST-GX2 fusion protein, 
produced in E. coli strain XL-1 Blue, using a Nef specific monclonal antibody KK70. 
Lane 1; GST-J5 protein, produced by IPTG induction, lanes 2-5; GST-GX2 protein, 
produced by IPTG induction, lane 6 ; GST-GX2 protein produced in the absence of 
IPTG induction. A high basal level of protein expression is observed when IPTG is 
not added to the system, suggesting the bacteria are switching on the promoter in the 
absence of IPTG to produce protein. Bands corresponding to GST-J5 and GST-GX2 
are present at approximately 60 kDa, reflecting the addition of GST (26 kDa) and Nef 
(27-35 kDa). Breakdown products are visible between 30-60 kDa. The GST-J5 
protein, in this Western blot, appears relatively stable, exhibiting no breakdown.
Figure 3.2.3b. Western blot analysis of recombinant GST-C8 del fusion protein, 
produced in E. coli strain XL-1 Blue, using a Nef specific monoclonal antibody 
KK75. Lane 1; GST-J5 protein, produced by IPTG induction, lanes 2-6; GST-C8 del 
protein, produced by IPTG induction. Bands corresponding to GST-J5 and GST-C8  
del are present at approximately 60 kDa, reflecting the addition of GST (26 kda) and 
Nef (27-35 kDa). In this Western blot, both GST-J5 and GST-C8 del proteins exhibit 
breakdown products, at 30-60 kDa
Figure 3.2.3c. Western blot analysis of recombinant GST-VLA*del fusion protein, 
produced in E. coli strain XL-1 Blue, using a Nef specific monoclonal antibody 
KK75. Lane 1; GST-J5 protein, produced by IPTG induction, lanes 2-6; GST- 
VLA*del protein, produced by IPTG induction. Lanes 7 & 8; wild type GST negative 
control. Bands corresponding to GST-VLA*del and GST-J5 are present at 
approximately 60 kDa, reflecting the addition of GST (26 kDa) and Nef (27-35 kDa). 
Breakdown products are visible between 30-60 kDa. On some occasions it proved 
difficult to isolate protein, as it was present in very small amounts (lane 3-6).
Overall, it is observed that the level of binding of the monoclonal antibodies to the 
various GST-Nef fusion proteins on each Western blot differs considerably. This is 
most likely due to the difference in the renaturation of the various recombinant GST- 
Nef fusion proteins on the blots after preparation.
115
1 2 3 4 5 6
46 — 
30 —
Figure 3.2.3a
kDa 1 2 3 4 5 6
66
46 —
30 — 
21.5 —
fSL.. = )
Figure 3.2.3b
1 2 3 4 5 6 7 8
66 — ; " y
46 — A  ^
30 — -
Figure 3.2.3c
116
To address the problem of degradation of GST Nef fusion proteins a number of
modifications were introduced into the protocol. These included:
i. Use of the E. coli BL21 strain, which is deficient in Ion and ompT genes 
encoding for bacterial proteases (Pharmacia Biotech, UK). The use of a strain 
carrying mutations which eliminate the production of proteases would be 
expected to reduce protein degradation.
ii. The addition of a protease inhibitor tablet (Roche, UK) containing a ‘cocktail’ 
mixture of protease inhibitors to cultures prior to preparation of bacterial lysates.
iii. The preparation of recombinant protein from small culture volumes 
(approximately 3 ml). Due to a high basal level of protein production, expression 
and breakdown of recombinant protein otherwise occurs over the extended 
periods of culture growth. By reducing the volume of overnight culture, the 
volume that is subcultured in fresh media the next day is also reduced, leading to 
a reduction in the amount of potentially degraded protein that is used.
iv. Optimisation of the growth period required for protein production after IPTG 
induction. Cultures were set up and samples were taken every hour for a total of 
4 hours after induction. These were taken through the protein production 
protocol and analysed by Western blot to determine which time period was 
optimum for growth. It was observed that 1 hour after IPTG induction yielded 
optimal levels of full length fusion proteins (data not shown).
V . Freeze thawing with dry ice to ensure complete cell lysis, allowing release of all 
the recombinant GST-Nef protein into the supernatant for purification.
vi. Optimisation of sonication time period, to ensure complete lysis of bacterial 
cells. Samples were sonicated for 1 minute, 2 minutes, 3 minutes and 4 minutes
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respectively, prior to analysis by SDS-PAGE and Western blotting. The 
optimum time period for sonication was determined to be 4 minutes. This was 
delivered as two bursts of 2 minutes of sonication, performed on ice to minimise 
heating of cultures and dénaturation,
vii. Growth of samples at room temperature. This would reduce the rate of growth 
and protein synthesis, therefore minimising protein misfolding and aggregation.
Initially, the E. coli strain XL-1 Blue was replaced with E. coli strain BL21. This was 
observed to have a marked increased effect on protein production (Figure 3.3.4). 
However protein was still being degraded as was evident by the presence of multiple 
bands for each recombinant GST-Nef fusion protein although they were not as strong 
as observed in the E. coli XL-1 Blue strain. The combined effect of the remaining 
modifications produced protein of a higher yield, higher quality and increased 
stability (Figure 3.3.5) when analysing crude GST-Nef protein supernatant and 
supernatant that had been purified onto glutathione sepharose 4B beads (section 
2.2.18). This was evident by the presence of a single band at the predicted molecular 
mass of between 53-66 kDa (Figure 3.3.5) when Western blotting was performed with 
a Nef specific monoclonal antibody, KK75, for GST-J5 and GST-C8. For each 
construct, the bands representing protein were very strong, indicating a good yield of 
recombinant protein. In contrast, an additional study that evaluated the quality of 
protein produced when the bacterial cultures were incubated at room temperature did 
not improve the quality of the protein (data not shown). All GST Nef protein samples 
used subsequently were made by the final modified protocol (section 2.2.12b).
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Figure 3.2.4. Western blot analysis of recombinant GST-Nef fusion protein, 
produced in A. coli strain BL21, using aNef specific monoclonal antibody KK75. 
Lane 1; wild type GST negative control, lane 2; GST-C8, lane 3; GST-J5, lane 4; 
GST-GX2, lane 5; GST-C8del, lane 6; GST-VLA*del, lane 7; GST-J5(EIYL), 
lane 8; GST-J5(EIYL+R>E), lane 9; GST-J5(R>E). GST-J5(EIYL) and GST- 
J5(EIYL+R>E) are present at approximately 45 kDa, which is smaller than the 
RMM of approximately 60 kDa for the addition of GST (26 kDa) and Nef (27-35 
kDa). Breakdown products, although still present appear to be minimised by the 
use of E. coli BL21, a strain which is deficient in bacterial proteases.
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Figure 3.2.5. Western blot analysis of recombinant GST-Nef fusion protein produced in 
E. coli strain BL21 after incorporation of the modifications described in section 3.3.2, 
using a Nef specific monoclonal antibody KK75. GST Nef fusion proteins were prepared 
either as crude supernatants after Triton X I00 solubilisation (section 2.2.13b) or purified 
onto glutathione sepharose 4B beads (section 2.2.18) and then prepared for SDS-PAGE 
Lane 1; wild type GST supernatant (negative control), lane 2; wild type GST bound to 
GS4B beads (negative control), lane 3; GST-J5 supernatant, lane 4; GST-J5 bound to 
GS4B beads, lane 5; GST-C8 supernatant, lane 6; GST-C8 bound to GS4B beads, lane 7; 
GST-J5(EIYL) supernatant, lane 8; GST-J5(EIYL) bound to GS4B beads, lane 9; GST- 
GX2 supernatant, lane 10; GST-GX2 bound to GS4B beads. The wild type GST is 
negative as expected as Western blotting was performed with a Nef specific monoclonal 
antibody. GST-J5 and GST-C8 are present at the expected RMM of approximately 60 
kDa. GST-J5(EIYL) is present at the smaller RMM of approximately 45 kDa. GST-GX2 
is not visible, as this protein contains a deletion within the linear epitope that KK75 
recognises.
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KK75 did not bind to recombinant GST-GX2, whilst it bound to the remainder of the 
GST-Nef constructs. This was expected due to the deletion within the GX2 Nef 
protein which encompasses the linear epitope recognised by KK75.
Protein expression from control bacterial cell lysates expressing only GST were 
confirmed to be negative when probed with KK75 (Figure 3.2.5).
In spite of the technical improvements, GST-J5(EIYL) and GST-J5(EIYL+R>E) 
recombinant proteins appeared reproducibly to be a smaller size (approximately 45 
kDa) than that predicted or observed for the remainder of the GST-Nef fusion protein 
constructs (Figures 3.2.4 & 3.2.5).
Western blotting was performed with rabbit anti-GST polyclonal antibody to confirm 
the expression of the recombinant proteins as GST fusions. A product for each 
recombinant GST-Nef protein was observed at a relative molecular mass of 53-60 
kDa (Figure 3.2.6). A breakdown product, for GST was also observed at 
approximately 26 kDa. Control samples of GST supernatant and GST purified onto 
GS4B beads also yielded a product of approximately 26 kDa. Again, GST-J5(EIYL) 
appears at a smaller size molecular weight of approximately 45 kDa.
3.2.3. Analysis of binding of anti-Nef monoclonal antibodies to GST-J5 Nef and 
GST-C8 Nef proteins by ELISA
The ability of SIV Nef alleles, expressed in bacterial cells as GST-fusion proteins, to 
bind selected anti-Nef MAbs was evaluated in a semi-quantitative 96 well microplate 
assay. Undiluted or three-fold step wise dilution of crude recombinant bacterial cell 
lysates (identified and characterised as described) were allowed to bind to glutathione 
coated plates and end point titres of binding by individual anti-SIV Nef monoclonal 
antibodies were determined. In each assay, the end point titre of antibody binding to
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Figure 3.2.6. Western blot analysis of recombinant GST-Nef fusion protein produced in 
E. Coli BL21 after incorporation of the modifications described in section 3.3.2, using an 
anti-GST polyclonal antibody. GST-Nef fusion proteins were prepared either as crude 
supernatants after Triton X I00 solubilisation (section 2.2.13b) or purified onto 
glutathione sepharose 4B (section 2.2.18) and then prepared for SDS-PAGE.
Lane 1 ; wild type GST supernatant, lane 2; wild type GST bound to GS4B beads, lane 3; 
GST-J5 supernatant, lane 4; GST-J5 bound to GS4B beads, lane 5; GST-C8 supernatant, 
lane 6; GST-C8 bound to GS4B beads, lane 7; GST-J5(EIYL) supernatant, lane 8; GST 
J5(EIYL) bound to GS4B beads, lane 9; GST-GX2 supernatant, lane 10; GST-GX2 
bound to GS4B beads. Wild type GST is present at the predicted RMM of 26 kDa. For 
GST-J5, GST-C8 and GST-GX2, a band corresponding to GST-Nef is present at 
approximately 60 kDa, with breakdown product of GST present at approximately 26 
kDa. GST-J5(EIYL) is present at the smaller RMM of 45 kDa as observed in Figure 
3.3.5.
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the Nef protein variant was compared to that of parental wild-type virus J5 and 
attenuated C8 fusion proteins and wild type GST protein alone. The results of initial 
studies using only GST, GST-J5 and GST-C8 are presented in Table 3.2.1. Only the 
anti-GST polyclonal antibody bound to the GST bacterial recombinant protein. None 
of the nef specific monoclonal antibodies bound to GST protein as predicted. All 
representatives from each group of monoclonal antibodies bound to wild type GST-J5 
recombinant protein (Table 3.3.1). By contrast, GST-C8 recombinant Nef bacterial 
protein only bound anti-GST and MAbs KK75 and KK77, representing competition 
groups IV and V respectively (Table 3.2.1).
3.2.4. Analysis of binding of anti-Nef monoclonal antibodies to GST-SIV Nef 
protein by ELISA
GST-VLA*del bound representative anti-SIV Nef MAbs of competition groups IV 
and V only. The pattern of binding was similar to that of GST-C8 (Table 3.2.2). By 
contrast, GST-GX2 recognised representative monoclonal antibodies of competition 
groups I, II & III, but not groups IV and V that are known to recognise linear peptides 
between amino acids 60-80 and 70-90 respectively of the SIV Nef protein (Table 
3.2.3).
GST-J5(EIYL) bound representatives of groups IV and V only, whereas GST- 
15 (R>E) bound representatives of each group of monoclonal antibodies in a pattern 
comparable to that observed for GST-J5 (Tables 3.2.4 & 3.2.5 respectively). GST- 
J5(EIYL+R>E) bound representatives of groups IV and V only (Table 3.2.6). None of 
the representative MAbs from groups I, II & III bound to this protein, as observed for 
GST-C8. This observation was also consistent for GST-VLA*del (Table 3.2.7).
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Ab
GST-SIV Nef fusion protein
GST
recombinant
protein
GST-J5
recombinant
protein
GST-C8
recombinant
protein
a-GST 2.24 2.12 2.07
KK76
(I)
<0.47 1.6 <0.47
KK79
(II)
<0.47 2.12 <0.47
KK80
(II)
<0.47 2.08 <0.47
KK70
(III)
<0.47 232 <0.47
KK75
(IV)
<0.47 235 2.35
KK77
(V)
<0.47 1.68 1.21
Table 3.2.2. The ELISA endpoint titres (logio) of the ability of representatives from 
the five groups of mXi-nef monoclonal antibodies and a-GST polyclonal antibody to 
bind to recombinant GST, J5-GST and C8-GST Nef fusion proteins. The binding of 
the recombinant proteins to the a-GST polyclonal antibody was used as an estimate at 
the amount of protein that was present in each preparation. However, the amount of 
protein was not accurately quantified as crude bacterial lysates of the recombinant 
proteins were used in these experiments.
The cut-off value was calculated as the mean of the negative values, + 3 standard 
deviations. A result equal to or less than this value is comparable to background 
values and is therefore negligible.
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Fusion
Protein
Antibody
a-GST KK76
(I)
KK79
(II)
KK80
(II)
KK70
(III)
KK75
(IV)
KK77
(V)
GST 1.64 <0.47 <0.47 <0.47 <0.47 <0.47 <0.47
J5 0.71 1.49 1.08 1.97 1.14 1.71 1.46
C8 1.22 <0.47 <0.47 <0.47 <0.47 1.84 1.66
GX2 1.25 1.69 1.46 1.84 1.43 <0.47 <0.47
Table 3.2.3. ELISA endpoint titres (logio) of the ability of representatives from each 
of the groups of anti-Nef monoclonal antibodies to bind to GST-GX2. The cut-off 
value was calculated as the mean of the negative values, + 3 standard deviations. A 
result equal to or less than this value is comparable to background values and is 
therefore negligible.
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Fusion
protein
Antibody
a-GST KK76
(I)
KK79
(II)
KK80
(II)
KK70
(III)
KK75
(IV)
KK77
(V)
GST 3.35 <0.47 <0.47 <0.47 <0.47 <0.47 <0.47
J5 239 2.26 233 2.07 3.29 1.93 2.57
C8 2.55 <0.47 <0.47 <0.47 <0.47 1.83 2.18
J5
(EIYL)
2.55 <0.47 <0.47 <0.47 <0.47 235 239
Table 3.2.4. ELISA endpoint titres (logio) of the ability of representatives from each 
of the groups of anti-Nef monoclonal antibodies to bind to GST-J5(EIYL). The cut­
off value was calculated as the mean of the negative values, + 3 standard deviations. 
A result equal to or less than this value is comparable to background values and is 
therefore negligible.
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Fusion
protein
Antibody
a-GST KK76
(I)
KK79
(II)
KK80
(II)
KK70
(III)
KK75
(IV)
KK77
(V)
GST 254 <0.47 <0.47 <0.47 <0.47 <0.47 <0.47
J5 2.22 1.03 239 1.66 2.02 2.67 1.94
C8 2.21 <0.47 <0.47 <0.47 <0.47 2.67 L88
J5+
(R>E)
2.49 1.68 2.77 2.2 2.73 3.46 2.45
Table 3.2.5. ELISA endpoint titres (logio) of the ability of representatives from each 
of the groups of anti-Nef monoclonal antibodies to bind to GST-J5+(R>E). The cut­
off value was calculated as the mean of the negative values, + 3 standard deviations. 
A result equal to or less than this value is comparable to background values and is 
therefore negligible.
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Fusion
protein
Antibody
a-GST KK76
(I)
KK79
(II)
KK80
(II)
KK70
(III)
KK75
(IV)
KK77
(V)
GST 2.24 <0.47 <0.47 <0.47 <0.47 <0.47 <0.47
J5 2.12 1.6 233 2.07 1.93 235 1.68
C8 2.07 <0.47 <0.47 <0.47 <0.47 1.84 1.21
J5+
(EIYL
R>E)
2.1 <0.47 <0.47 <0.47 <0.47 2.01 1.44
Table 3.2.6. ELISA endpoint titres (logio) of the ability of representatives from each 
of the groups of anti-Nef monoclonal antibodies to bind to GST-J5(EIYL+R>E). The 
cut-off value was calculated as the mean of the negative values, + 3 standard 
deviations. A result equal to or less than this value is comparable to background 
values and is therefore negligible.
128
Fusion
protein
Antibody
a-GST KK76
(I)
KK79
(II)
KK80
(II)
KK70
(III)
KK75
(IV)
KK77
(V)
GST 0.8 <0.47 <0.47 <0.47 <0.47 <0.47 <0.47
J5 1.14 1.94 2.46 222 2.1 2.6 2.49
C8 0.96 <0.47 <0.47 <0.47 <0.47 2.73 2.04
VLA*
del
0.76 <0.47 <0.47 <0.47 <0.47 2.19 1.63
Table 3.3.7. ELISA endpoint titres (logio) of the ability of representatives from each 
of the groups of anti-Nef monoclonal antibodies to bind to GST-VLA*del. The cut­
off value was calculated as the mean of the negative values, + 3 standard deviations. 
A result equal to or less than this value is comparable to background values and is 
therefore negligible.
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3.2.5. Binding of Group I & II monoclonal antibodies to GST-C8 and GST-C8del 
by ELISA
During these studies, a low level of binding was detected for GST-C8 and GST-C8del 
by representatives of the group I and II monoclonal antibodies. Previously no binding 
of GST-C8 to either of these groups had been observed as GST-C8 was included as a 
control on every plate. In order to eliminate the possibility of contamination between 
batches of protein samples new samples were generated. New glycerol stocks were 
also derived by re-cloning bacterial cultures used to produce the recombinant protein, 
to eliminate the possibility that the original glycerol stock may have become 
contaminated. Low levels of binding were still observed, which were approximately 
2-3 times greater than that for background binding.
These observations were in contradiction to previous experimental results which had 
shown consistently that these MAbs did not recognise GST-C8 recombinant fusion 
protein. However, the results agree with previous work by Arnold et a l (1999) which 
demonstrated binding by the group I and group II MAbs to GST-C8 Nef derived from 
recombinant baculovirus.
To investigate this discrepancy further, recombinant GST-C8 and GST-C8del fusion 
protein were affinity purified from bacterial lysates, quantified (Protein Assay Kit II, 
Bio-Rad, UK) and used as antigen in an ELISA.
The plates were coated with 200 pg/ml of recombinant fusion protein and a three fold 
dilution series performed to detect levels of binding. Levels of KK75 binding to GST- 
C8 and GST-C8del detected were comparable to the low levels obtained using the 
glutathione coated plates.
When a maximal concentration of approximately 1600 pg/ml of protein was used to 
coat the plates no significant levels of binding by the group I & II monoclonal
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antibodies to GST-C8 or GST-C8del was detected. Low levels of binding appeared to 
be non specific as there was no obvious pattern of binding that reflected the dilution 
of the coating protein (Figures 3.2.7 & 3.2.8).
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Figure 3.2.7. Analysis by ELISA of binding by representative monoclonal antibodies, 
KK76 (group I), KK79 (group II) and KK80) (group II) to recombinant GST-C8 Nef 
protein expressed in E. coli BL21 cells.
Recombinant protein was batch purified by using Glutathione Sepharose 4B beads, 
quantified and used to coat a 96 well plate.
The level of binding observed, even at the highest concentration of 1600 pg/ml is 
comparable to that of the baseline levels of antibody binding in the absence of Nef 
protein. Therefore, the ability of the group I, II & III monoclonal antibodies to bind to 
C8 was not reproducible in this system.
Figure 3.2.8. Analysis by ELISA of binding by representative monoclonal antibodies, 
KK76 (group I), KK79 (group II) and KK80) (group II) to recombinant GST-C8del 
Nef protein expressed in E. coli BL21 cells.
Recombinant protein was batch purified by using Glutathione Sepharose 4B beads, 
quantified and used to coat a 96 well plate.
The level of binding observed, even at the highest concentration of 1600 |ig/ml is 
comparable to that of the baseline levels of antibody binding in the absence of Nef 
protein. Therefore, the ability of the group I, II & III monoclonal antibodies to bind to 
C8del was not reproducible in this system.
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3.3. Discussion
The nef gene of human and simian immunodeficiency viruses is believed to be a 
critical component in the pathogenesis of infection. However, the mechanism by 
which nef carries out this process remains poorly understood.
Whilst the crystal structure of HIV-1 Nef has been resolved (Lee et al, 1996, Freund 
et al, 1994) relatively little information exists concerning the structure of the SIV Nef 
protein. By studying the antigenic structure of Nef it is hoped to gain an insight into 
the key regions of the protein that may play important roles in viral pathogenesis. The 
aim of this study of mutant SIV Nef proteins, differing only in a few base pairs that 
are known to confer significant changes to in vivo phenotypes (N. Almond, personal 
communication) was to utilise an immunological approach to determine whether the 
pattern of monoclonal antibody binding can predict the underlying protein structure.
This study revealed that there are two antigenically distinct regions of SIV Nef, 
characterised by clones GX2 and C8 respectively, that attenuate the virus if  either is 
disrupted. This study went on to analyse the effect on antigenic structure of repairing 
the four amino acid deletion in the C8 Nef protein in a manner similar to that 
observed in vivo (Whatmore et a l, 1995). The repair of the amino acid sequence 
DMYL between amino acids 143-146 with the repair sequence EIYL alone was 
observed to be insufficient to repair the epitope in Nef recognised by the monoclonal 
antibody KK70. Furthermore, the results indicate that substitution of the amino acid at 
position 191 (R191E) does not complement the EIYL motif to restore this epitope.
In order to evaluate the different nef alleles a relatively stable prokaryotic expression 
system was developed. Each nef allele was expressed as a C-terminal fusion protein
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with the stabilising protein partner glutathione-S-transferase in the vector pGEX-4T3. 
It was important to prove with key nef alleles that results obtained in this relatively 
novel system were in agreement with previously reported data (Arnold et al, 1999).
J5 exhibited the highest level of binding to representatives of all groups of Nef 
specific monoclonal antibodies. This would suggest that the full length recombinant 
fusion protein is stable in comparison with those that carry deletions and/or point 
substitutions. Furthermore, even conformation dependent epitopes within J5 were 
observed to be intact, which could result in more optimal expression as there are no 
disruptions within or surrounding important antigenic sites that could affect their 
presentation.
Arnold et a l (1999) (Table 3.1.1) previously demonstrated binding by the group I & 
II monoclonal antibodies to C8 Nef-GST baculovirus derived recombinant protein. 
The level of binding was approximately one log lower than that observed for J5 Nef- 
GST baculovirus derived recombinant protein. This was consistent for group IV and 
V monoclonal antibodies, which recognise linear epitopes. It is possible, that the 
deletion in C8 affects the protein folding and presentation of the epitope that the 
MAbs are recognising, resulting in a lower level of binding than that observed for 
wild type J5 protein in the baculovirus system.
Initially, no binding of the group I & II MAbs to GST-C8 was observed. However, 
during investigation of the binding of GST-C8del to the panel of MAbs, a low level of 
binding to the group I & II MAbs by GST-C8 and GST-C8del was detected. 
Investigation of this by production and purification of recombinant GST-C8 and GST- 
C8del fusion protein and coating of ELISA plates at high concentrations failed to 
demonstrate significant levels of binding by the group I & II MAbs to GST-C8 and 
GST-C8del. The binding observed by group I & II MAbs to GST-C8 and GST-C8del
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may be a true result, representing low levels of binding by the MAbs when high 
concentrations of protein are present. However, when the protein is titrated to lower 
concentrations binding by the MAbs is no longer observed (Figure 3.2.7). In 
retrospect, it would have been valuable to repeat these experiments with purified 
GST-J5 Nef protein on a separate plate to assess the degree of binding by the MAbs to 
the wild type protein as a positive control, to which the results for GST-C8 and GST- 
C8del could be compared. Also, binding by KK75 could have been used as an 
additional control. Analysis of the GST-C8 and GST-C8del by SDS-PAGE in this 
instance was not deemed necessary due to the sensitivity of the plate assay overall 
being greater than that of SDS-PAGE.
It is possible that the mutations in GST-C8 and C8del could be affecting the epitopes 
recognised by the group I & II MAbs even if the regions attenuated do not directly 
form part of the epitopes. The influence of surrounding amino acid residues on 
antibody binding has been documented for studies of HIV gpl20, whereby 
substitutions outside a linear sequence within a specific domain of gpl20 either 
abolished or significantly reduced the binding of MAbs specific for that domain 
(Moore et ah, 1993).
The differences in the observations from this study and those published by Arnold et 
al (1999) maybe attributable to the different expression systems employed. Arnold et 
a l (1999) used the baculovirus system to express proteins, whilst we utilised a 
prokaryotic approach. One of the drawbacks of utilising a prokaryotic system is the 
formation of inclusion bodies as the result of overexpression of the recombinant 
protein of interest. If the proteins being overexpressed are not completely soluble then 
they may fold incorrectly and this could conceal antigenic sites. The formation of 
inclusion bodies does not occur in the baculovirus system, therefore the proteins
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produced retain their full biological activity. Where on occasion low levels of binding 
were observed, this may have been due to the protein folding properly or closer to its 
correct conformation, resulting in the expression of antigenic sites for detection. 
Nevertheless, there was no direct evidence within this study that any of the 
recombinant fusion proteins produced formed inclusion bodies. Furthermore, the 
production of these recombinant proteins as a fusion with the C terminus of GST 
should facilitate the production of fusion proteins which are soluble in aqueous 
solutions (Smith & Johnson 1988).
The baculovirus system has the capacity to perform post translational modifications 
on the recombinant proteins produced, whilst the prokaryotic system does not. Nef is 
myristoylated at its N terminus by the addition of a myristoyl group (Allan et al, 
1985). It is possible that the myristate moiety may affect the ability of the group I and 
II monoclonal antibodies to bind, possibly by altering the conformation of the protein, 
which may make antigenic sites more accessible. This could be investigated by 
producing a non-myristoylated recombinant SIV Nef fusion protein using the 
baculovirus system and myristoylated SIV Nef fusion protein within the prokaryotic 
system. By analysing the ability of the different groups of monoclonal antibodies to 
bind, the effect of mysristoylation on antigenic structure could be determined. If the 
pattern of binding was identical to that observed previously then it could be concluded 
that the myristoyl group within this system has no effect on protein conformation. The 
production of HIV-1 Nef recombinant protein in bacterial cells which is myristoylated 
by co-expression with n-myristoyltransferase has been successful (M.Harris, personal 
communication). It has also been described that a non-myristoylated HIV-1 Nef has a 
different structure to that of a myristoylated Nef, in that it has an extended 
conformation (Geyer et al, 1999).
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The use of the bacterial expression system for the production of SIV Nef proteins 
appears to be robust enough for use in epitope mapping studies. SIV Nef, when 
expressed as a C-terminal fusion partner with glutathione-S-transferase is particularly 
valuable. HIV-1 and SIV Nef are myristoylated at the amino terminus when expressed 
in eukaryotic cells (Harris & Coates 1993, Harris & Neil 1994). This myristoylation is 
essential for association of a Nef protein with the plasma membrane, but whether this 
is a direct association of the myristoyl with the membrane, or a result of 
conformational changes that occur at amino terminus of the Nef protein following 
myristoylation remains to be determined (Harris & Coates 1993, Harris & Neil 1994). 
Nevertheless, it has been demonstrated by others (Azad et al., 1994), that bacterially 
expressed recombinant HIV-1 Nef protein can be transfected into mammalian cells 
and function in a predictable manner indicating that it is capable of folding 
sufficiently to mediate selected functions, regardless of the myristoylation state. Our 
confidence of the predictive value of this bacterially expressed Nef protein, however, 
is based upon parallel data obtained from binding of antibodies to recombinant 
bacterial protein, as well as recombinant viruses that express the same set of Nef 
alleles. The equivalent of antibody binding in both systems for a number of alleles 
provides good supporting evidence for the predictive value of this approach of the 
antigenic structure for novel epitopes such as J5(EIYL) and J5(EIYL+R>E).
Initially problems were encountered in the production of bacterially expressed 
recombinant SIV Nef that did exhibit evidence of degradation during expression on 
subsequent purification. The production of recombinant SIV Nef protein in the 
presence and absence of IPTG, suggests the bacteria were able to drive expression of 
the promoter and as a consequence, expression of the GST-nef genes without the need 
for induction. Unless the promoter is tightly regulated, growing large cultures of
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bacteria transformed with toxic genes for extended periods or high density will 
frequently lead to the synthesis of the protein and its subsequent degradation.
This effect was controlled by using smaller culture volumes for protein production. 
Less protein degradation was observed when 30 pi volumes of 3 ml overnight cultures 
were used to inoculate fresh media (3 ml) prior to induction for 1 hour. The reason for 
this may be that if the bacteria have been synthesising and degrading protein (during 
the course of the overnight incubation), only a small volume of this is used to grow a 
fresh culture. By harvesting after two hours of growth (1 hour before and 1 hour after 
EPTG induction), it minimised the extent of protein degradation. In retrospect, the use 
of a large culture of bacteria inoculated from glycerol stocks but harvested after just a 
total of 2 hours of growth may have produced protein of a reasonable quality which 
was not degraded due to the shorter incubation period. This approach could be 
adopted for future studies.
The use of a vector containing a more tightly regulated promoter designed for the 
production of toxic proteins may also be of benefit. The use of the T7 promoter for 
this purpose has been described extensively (Brown & Campbell 1993, Doherty et al, 
1993). The over expression of the E. coli primase enzyme, required for DNA 
replication of E. coli has been performed successfully using the T7 promoter (Godson 
1991). By cloning the dnaG gene after various modifications into the T7 polymerase- 
transcribed expression vector pET-3d, the production of this primase was tightly 
regulated and cells which contained the constructed plasmid were able to express 30% 
of the cellular protein as primase. It would be a possibility to investigate the use of the 
T7 promoter for production of these SIV Nef proteins, as tight control of the 
expression of the recombinant proteins the potential problems of toxicity of SIV Nef 
to the bacteria could be minimised.
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In spite of the modifications still introduced to minimise protein degradation a certain 
degree of protein breakdown was still observed for clones GST-15 (EIYL) and GST- 
J5(EIYL+R>E). On SDS-PAGE gels, these recombinant proteins appear at a 
consistently smaller size than that predicted for the GST-Nef proteins (between 40-45 
kDa). This degradation is occurring at the carboxy terminus of the protein as Western 
blotting performed with KK75, which recognises a linear peptide sequence at the 
amino terminus of SIV Nef, showed evidence of binding to the recombinant proteins. 
It is possible that the amino acid substitutions in these two constructs are particularly 
toxic to the bacteria. Proteolytic enzymes are known to remove abnormal proteins 
from bacterial systems, including those with mutations caused by amino acid 
substitution (Goldberg et ah, 1986). Therefore, despite attempts to minimise 
degradation, protein will still be broken down. The DNA sequence of these proteins 
has been confirmed to be intact as these sequences were subcloned into the yeast 
episomal vector and sequencing performed to confirm the correct sequence for each 
construct (Chapter 4). Therefore the truncation of these clones must be occurring once 
the proteins are synthesised.
It has been described during synthesis of recombinant proteins, that E. coli shows a 
bias in its utilisation of codons between genes. This bias differs between E. coli and 
mammalian cells, suggesting that a mammalian gene expressed in E. coli will have an 
inappropriate distribution of codons. If bacteria encounter codons for a sequence for 
which they are not biased, a longer time is taken to synthesise the amino acids, which, 
as a result, leaves the protein open to proteolytic cleavage. Optimisation of codon 
usage will prevent this. Codon optimisation of specific genes has been documented to 
improve the level of expression of recombinant protein in E. coli (Hale & Thompson 
1998). Optimisation of the codons for the sequence J5(EIYL), therefore, could result
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in more efficient synthesis of the recombinant proteins and reduce its susceptibility to 
breakdown.
Since breakdown of recombinant SIV Nef was restricted to selected alleles it would 
be of interest to use mass spectrometry to elucidate the exact region at which these 
recombinant proteins are being degraded. It would be expected that a specific region 
of these proteins is particularly unstable, resulting in the proteins being degraded until 
the minimal stable domain of the protein is encountered. This stable domain could be 
determined and it would be interesting to observe if wild type Nef protein, grown in 
culture for an extended period of time such as 12 hours, would breakdown to the same 
size as J5(EIYL) and J5(EIYL+R>E) and thus determine whether these sizes do 
indeed represent a stable domain of the protein.
The data obtained firom this study is in general agreement with previously 
unpublished studies from the Division of Retrovirology at NIBSC, in which the 
selective repair mutants of SIV Nef (Whatmore et a l, 1995) have been re-introduced 
into the parental molecular clone SIVmacJ5 and the binding of anti-SIV Nef 
monoclonal antibodies analysed by flow cytometry. It suggests that, in spite of the 
technical difficulties encountered in the production of recombinant bacterial Nef 
fusion protein, due its relative instability, the protein produced is capable of binding 
glutathione and is folded in a conformation that is indistinguishable from native viral 
proteins. Thus, the approach developed and applied in this study may be suitable for 
exploring further the effects of sequence changes in Nef on epitopes that appear to be 
critically associated with a pathogenic phenotype to the virus. The development of 
this relatively rapid method to map the structurally important epitopes of SIV Nef will 
facilitate research to elucidate the key activities of Nef that are essential for its 
functions in vivo.
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The mapping of protein structures with monoclonal antibodies has been proven to be 
a valuable technique employed in the study of other HIV-1 proteins. John Moore and 
colleagues (1993a, 1994) used monoclonal antibodies to investigate the structure of 
the HIV envelope glycoprotein before the X-ray crystal structure of gp 120 was 
resolved (Kwong et al., 1998). Moore et al. (1993) performed studies using 
monoclonal antibodies directed against various domains of the HIV gp 120 molecule 
to predict its conformation. Monoclonal antibodies that were dependent on a specific 
domain of gp 120 were found to be sensitive to changes within this region, indicating 
that their ability to bind was dependent upon the native structure of the protein. 
Substitutions outside the epitopes could also significantly affect the ability of 
monoclonal antibodies to bind, demonstrating the importance of neighbouring amino 
acid sequences on the structure of important epitopes. Some amino acid substitutions 
also increased the binding of one particular antibody, possibly by improving the 
accessibility of the epitope.
X-ray crystallography has now proven that the HIV-1 envelope is heavily dependent 
upon conformation to yield a functional protein (Kwong et al., 1998). From the 
information obtained by direct structural analysis it was revealed that many of the 
features of envelope were accurately predicted from the antibody mapping studies 
performed a number of years previously by Moore and colleagues. We should, 
therefore, move forward and evaluate the implications of the binding data on the 
potential roles of Nef in bringing about the high level replication of the virus in vivo.
It would be valuable to have some structural information of SIV Nef to ascertain the 
relative distance between the two non-overlapping epitopes of SIV recognised by the 
two competition groups represented by KK70 and KK75. HIV-1 Nef consists of two
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domains, a small N-terminal domain and a larger C-terminal domain. The N terminal 
domain contains a myristoylation motif and is highly susceptible to degradation. The 
C-terminal is highly conserved amongst isolates and forms a well-defined and 
relatively stable structure (Lee et al., 1996). By superimposing and modelling the 
structure of the C-terminal portion of SIV Nef onto the crystal structure of HIV-1 Nef 
(Figure 3.3.1) we can test the predictions of the antibody data. It is clear that the 
deletion of four amino acids in the alpha helical domain, similar to the deletion of 
amino acids 143-146 in SIVmacCS, would have extensive effects on the structure of 
the carboxy terminus of the protein. Interestingly, position 213, truncated in 
VLA*del, is closely juxtaposed to the alpha helical region of SIV Nef. It is intriguing 
that the same epitope recognised by KK70 is disrupted if the Nef protein prematurely 
truncates at this region. By contrast, the region surrounding amino acid 191 would not 
be predicted to be closely associated with the epitope recognised by KK70, as our 
results indicate, as it is not predicted to be in close juxtaposition to the alpha helical 
region.
This study has shown that there are two regions of SIV Nef that are antigenically as 
well as genetically distinct. These result in attenuation of the virus in a broadly similar 
manner when they are deleted, as observed by previous in vivo experiments (Figure 
3.1.1). This suggests that Nef may be mediating two or more distinct activities in 
order to facilitate high level replication of SIV. What these may be, remains to be 
determined. Furthermore, mutations that arise spontaneously are an intriguing 
phenomenon. The mutant clone VLA*del arose spontaneously in tissue culture, 
abrogating the ability of KK70 to bind and resulting in a reduced virus load in vivo 
(N. Almond, personal communication).
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Figure 3.3.1. A protein homology model of SIV Nef based upon the known structure 
of the HIV-1 Nef protein. Due to poor homology, structural information between 
amino acids 85-233 only is available. Amino acids 143-146, the region which is 
deleted in C8 Nef, is highlighted. This region is postulated to form part of the 
conformational epitope recognised by monoclonal antibody KX70 and sits within an 
a-helical structure. The tyrosine at position 213, at which the Nef protein is truncated 
in VLA*del is located in close proximity to amino acids 143-146.
Figure computed and prepared by M. Forster, NIBSC.
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Clone GX2 arose spontaneously in a macaque infected with SIVmac32H one month 
after infection and exhibits a reduced viral load in vivo. Could it be that the virus 
evolves in such a way, in vivo, to escape detection by the immune system, by 
removing epitopes that are the target of effective anti-viral immunity. Although viral 
titres are reduced by the removal of selected regions of the protein, if it can lead to 
effective escape from the immune system, then it could result in the virus persisting in 
the host for longer. There is evidence that Nef can be the target of protective 
immunity since Nef-specific CTLs, in vivo, have been observed to confer protection. 
Immunisation with recombinant vaccinia virus expressing SIV Nef conferred partial 
protection against SIV challenge, with high levels of Nef-specific CTLs on the day of 
challenge correlated with a low virus load after challenge (Gallimore et al, 1995). 
Moreover, in the study by O’Connor et a l (2002) evidence for CTL immune escape 
by selected sequence variation at regions closely flanking the epitopes recognised by 
KK70 and KK75 monoclonal antibodies was observed. Thus the fortuitous 
association of T cell and B cell epitopes in SIV Nef enables us to use monoclonal 
antibodies to study immunological pressure created by T cell immunity in vivo.
In the case of C8 and VLA*del these were viral variants that were selected following 
culture in C8166 cells (Rud et al., 1992, Arnold et a l, 1999). Presumably the loss of 
the epitope recognised by ICK70 is advantageous for the replication of SIV in this cell 
line and these epitopes may coincide with functionally important regions of the Nef 
protein that may be dispensable under certain conditions in vitro or in vivo. In that 
situation then it may be more valuable to try to elucidate functional changes that result 
from mutation of SIV Nef at these specific regions. This is the goal of the next 
chapter.
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4. The ability of SIV nef  clones which express wild type or 
attenuated pheotvpes in macaques to interact with adaptor 
proteins. TCRC and members of the Src family of protein
tyrosine kinases
4.1. Introduction
Protein/protein interactions are an essential feature of most biological processes. 
Identification of critical interactions and definition of the epitopes involved may lead 
to a situation where it is possible to predict the influence that changes in protein 
sequences and/or structure may have upon biological processes. This is particularly 
important in the characterisation of the pathogenesis of viral infections. A better 
definition of the protein interactions that are essential for, or that facilitate virus 
replication may permit the rational selection and development of novel antiviral 
drugs.
Examples of interactions that may influence viral pathogenesis have been described in 
the context of human and simian immunodeficiency virus replication. The viral Tat 
and Rev proteins of these viruses bind to regions of the LTR and env mRNA 
respectively. However, host cell proteins that bind to the viral LTR region are 
required for effective viral transcription and replication, particularly in macrophages. 
Furthermore, viral structural proteins. Gag and Env are only able to assemble into 
viable structural particles by making appropriate interactions with host proteins 
(Zhang et al, 1994). Most intriguing and perhaps least well understood are the protein 
interactions of Nef that have been demonstrated in the SIV macaque model to be 
essential for high level viral replication, observed prior to the induction of disease. 
The importance of Nef in pathogenesis has been confirmed with the identification of 
selected HIV infected long term non progressors in which a nef defective HIV-1 has 
established infection.
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The Nef proteins of SIV, HIV-1 and HIV-2 have been demonstrated to interact with a 
number of cellular partners that may contribute to the influential role of this protein in 
pathogenesis. For example, sequence analysis has identified a PXXP motif that 
enables Nef to interact with the SH3 domain of members of the Src family of protein 
tyrosine kinases. Attempts to delete this motif from SIV isolates have led to rapid 
reversion indicating a strong selective pressure to maintain this peptide motif (Saksela 
et al., 1995). This motif is well conserved amongst n e /isolates, suggesting that this 
specific interaction is beneficial to the virus in vivo. Other studies have identified a 
dileucine motif (L 4 1 3 L 4 1 4 ) within the cytoplasmic domain of Nef as essential for down 
regulation of cell surface CD4 (Aiken et ah, 1994). Down regulation of CD4 may be a 
mechanism by which the viruses can escape the immune system or avoid 
superinfection of cells.
Furthermore, the region between amino acids 45-127 has been described to be 
important for the association of Nef with a Nef associated kinase (NAK) (Sawai et al., 
1994). This region consists of several amino acid motifs that are conserved 
throughout HIV-1, HIV-2 and SIV Nef. The conservation of the sequence in this 
region of Nef indicates that interaction with a kinase may be beneficial for viral 
replication in vivo.
None of the interactions described above fully account for the effect brought about by 
the disruption of Nef through deletion of amino acids 143-146, as in the attenuated 
virus SIVmacCS or amino acid 66-88 as in SIVmacGX2. This indicates that Nef may 
he involved in further protein interactions required for virus replication, or that these 
changes within Nef could have far reaching effects on the interactions previously 
documented.
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A number of methods have been described for investigation of protein/protein 
interactions. One of them, the yeast-2-hybrid system utilises yeast in a genetic assay 
designed to detect protein/protein interactions in vivo (Fields and Song, 1989). This 
system can either be used to confirm interactions between two known proteins or 
alternatively to search a genomic cDNA library for proteins that interact with a 
particular target protein of interest. Furthermore, this assay can be used to define the 
critical domains that mediate an interaction and identify specific residues that are 
involved.
The yeast-2-hybrid system exploits the properties of the GAL4 protein of the yeast 
Saccharomyces cerevisiae. GAL4 is a transcriptional activator required for the 
expression of genes encoding enzymes of galactose utilisation (Johnston, 1987). It 
consists of two distinct domains, an N-terminal domain (the DNA binding domain) 
which binds to specific DNA sequences (UASg) and a C-terminal domain (the 
activating domain) which is required for transcriptional activation.
In order to use the yeast-2-hybrid system, two plasmids are cloned each with a 
selected protein fused to a domain from GAL4. The plasmids are designed to express 
either the GAL4 DNA binding domain fused to a protein designated ‘X’ or the GAL4 
activating domain fused to a protein designated ‘Y’. The two separate plasmids are 
introduced into a yeast strain. If there is an interaction between proteins X and Y the 
GAL4 domains are bought into contact with each other and transcription of a gene 
regulated by UASq takes place (Figure 4.1.1). The transformants can then be 
identified by the blue staining of colonies following the conversion of the 
chromagenic substrate X-gal by the galactosidase produced in cells where interactions 
occur. Alone, the native GAL4 protein, containing both domains can activate 
transcription when yeast cells are grown on galactosidase supplemented media.
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Figure 4.1.1. The yeast-2-hybrid system, an assay designed to detect protein-protein 
interactionswhich may occur in vivo by utilising the GAL4 protein of the yeast strain 
Saccharamyces cerevisae. a, The native GAL4 protein consists of both DNA binding and 
activating regions and induces GALl-lacZ transcription, b, Hybrids consisting of either 
the DNA-binding domain or activating region cannot induce transcription alone, c, A 
protein-protein interaction between proteins X and Y brings the GAL4 domains into 
close proximity and results in transcriptional activity.
Adapted from; Fields S & Song O (1989). A novel genetic system to detect protein- 
protein interactions. Nature340:245-246
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However, although the N-terminal domain of GAL4 can bind to DNA it cannot 
activate transcription. The C-terminal DNA, containing the activating regions cannot 
activate transcription alone, as it is unable to bind to the specific DNA sequence 
UASg.
Within the system utilised in this study, the P-gal reporter gene in the pASI/CYHII- 
BssRll.l plasmid is chromosomal and under the control of the GALl promoter 
(Appendix 2, Figure 8.3). GAL4 transcription factor activates the GALl promoter and 
drives the expression of the p-gal gene. Active GAL4 is reconstituted by a positive 
yeast-2-hybrid interaction bringing together the GAL4 activation domain and the 
GAL4 DNA binding domains present in the yeast-2-hybrid proteins.
The yeast-2-hybrid system has been applied in the analysis of protein interactions by 
selected SIV nef alleles, including SIVmacJS and SIVmacCS (Bell et al., 1998). 
These studies revealed differential binding of the two alleles of nef for selected 
proteins, including TCRÇ. The interaction of wild type SIV Nef with TCRÇ was also 
confirmed independently by Howe {et al, 1998) using the nef allele of the wild type 
clone SIVmac239.
If the interaction with the TCRÇ is important for viral pathogenesis it would be 
valuable to confirm whether the revertant SIV Nef proteins (J5(EIYL), 
J5(EIYL+R>E) and J5(R>E)) also interact with the protein. Furthermore, it may be 
possible to gain an insight into which of these sequences is responsible for restoring 
the ability of the SIV Nef protein to regain a wild type-like function and ultimately to 
enhance infection.
Previously, it was demonstrated that the premature truncation of Nef at amino acid 
213 disrupts the binding of monoclonal antibody KK70, which indicates that a major
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conformational structure has been disrupted (Chapter 3). It would be valuable to 
elucidate whether the disruption of the epitope recognised by KK70 disrupts the 
protein/protein interactions of Nef in a similar manner to that observed for deletion of 
amino acids 143-146 in C8.
The GX2 nef allele is disrupted in a genetically distinct region of the protein 
compared with the changes from wild type sequence observed in C8 Nef and is also 
associated with a similar level of virus replication as C8 (Chapter 3, Figure 3.1.1). It 
is possible that the GX2 Nef protein could display a discrete pattern of protein/protein 
interactions, that differs from the range of proteins shown to interact with C8 Nef. 
This hypothesis could be tested using yeast-2-hybrid technology.
The proteins selected to be tested for their ability to interact with SIV Nef in this 
study are listed below. In each case, they were selected on the basis of previous 
evidence that differential properties may exist between the J5 and C8 clones.
(i) The medium chains AP47 and AP50 of AP-1 and AP-2 respectively (section 
1.10a), which play an important role in the transport of clathrin coated vesicles during 
endocytosis. These proteins have been described to interact with a specific class of 
sorting signal, containing tyrosine based motifs within the cytoplasmic domain of 
some membrane proteins (Ohno et ah, 1995). The N terminus of certain Nef proteins 
contain such endocytic motifs (Piguet et al., 1998). Previous studies have described 
an interaction between either HIV-2rod Nef or SIVmac239 Nef protein with full 
length or truncated AP50 chain of the adaptor proteins (Piguet et al., 1998). These 
interactions appeared to depend upon specific C-terminal sequences (Bresnahan et al., 
1998).
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(ii) Lck is a member of the Src family of protein tyrosine kinases, which are involved 
in cellular signalling and cytoskeletal organisation. The ligand for these proteins is a 
minimal PXXP motif. Such a motif is well conserved amongst Nef isolates (section 
1.1 le). A variety of interactions have been described between various Nef isolates and 
proteins containing Src homology domains.
(iii) The Ç chain of the T cell receptor is an important component of the immune 
system. SIVmacJS and SIVmacCS have previously been investigated for interactions 
with TCRÇ. SIVmacJS was found to interact with TCRÇ whilst SIVmacCS did not. 
Two clones of TCRÇ will be investigated, TCRÇi.n, which expresses the entire 
cytoplasmic domain and TCRÇ2 .2 1 , which expresses only the C-terminal 56 amino 
acids (Bell et al, 1998). The TCRÇ2.21 clone contains only the two distal 
immunoreceptor tyrosine-based activation motif (ITAM), whilst the TCRÇi.n clone 
contains all three IT AMs (Figure 4.1.2).
Due to previous studies describing interactions between various Nef isolates and the 
proteins mentioned above, it was reasoned that it would be intriguing to investigate 
the interactions between these proteins and the various SIV Nef proteins that have 
been described within this thesis. C8 and VLA*del are both proteins mutated in 
different ways, one by a premature stop codon, the other by a four amino acid deletion 
and other nucleotide substitutions. Both types of mutations, however, have an overall 
affect on the same a-helical region within the Nef protein with regards to shape. 
Studying the interactions of these SIV Nef proteins will provide insight into the effect 
a change in the overall shape of the Nef protein has on its various functions. 
Furthermore, with regards to the repair mutations (JS(EIYL), JS(EIYL+R>E) and 
JS(R>E)), it would be particularly interesting to see which of these interactions, if
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Figure 4.1.2. A schematic representation of the TCRÇ. The tyrosines (Y) are indicated within 
the immunoreceptor tyrosine-based activation motifs (ITAMs). Regions of the TCRÇ 
contained in cDNA clones used in the study are indicated by the black lines. TM; trans­
membrane domain.
Adapted from: Bell I, Ashman C, Maughan J, Hooker E, Cook F, Reinhardt T (1998). 
Association of simian immunodeficiency virus Nef with the T-cell receptor (TCR) Ç chain 
leads to TCR down-modulation. J. Gen. fzro/. 79:2717-2727
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any, are regained as the virus evolves closer to a wild type sequence. This may 
provide an insight into the mechanism which drives the selective pressure for the 
virus to maintain a wild type sequence and increase our understanding of whether this 
is associated with the virus regaining certain functions, which may contribute to 
disease progression.
These proteins had been previously introduced into the pACTII plasmid (Molecular 
Immunology Unit, GlaxoSmithKline, Appendix 2) as a GAL4 activation domain 
fusion, whilst the SIV Nef proteins were introduced into the pASI/CYHII-R^^HII.I 
plasmid (Molecular Immunology Unit, GlaxoSmithKline, Appendix 2) as a GAL4 
DNA binding domain fusion.
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4 .2 .  Results
4.2.1. Analysis of pASI/CYHII-^yyHlI.I DNA
A large scale preparation of yeast episomal plasmid pASI/CYHII-R^^HII.I was 
performed using a commercial maxi-prep kit. The plasmid DNA was digested 
sequentially using restriction endonucleases BamHI and Sail and the digested DNA 
de-phosphorylated by incubation at 37°C with 1 pi calf intestinal phosphatase. 
Analytical gel electrophoresis on a 1.75% (w/v) agarose gel containing 5 pg/ml 
ethidium bromide confirmed the presence of the pASI-CYHII/R^^HII.I DNA at the 
correct size of 8.5 kb. The DNA fragments were excised from the gel and the plasmid 
DNA extracted using a commercial kit.
4.2.2. Analysis of nefPNA
Restriction endonuclease analysis of small and midi scale preparations of each of the 
various pGEX-4T3-nef clones revealed a product of approximately 800 bp 
corresponding to the expected size for SIV nef. Clone pGEX-4T3-GX2 was found to 
be smaller, as expected, due to the 66 nucleotide deletion within it. The various DNA 
fragments were excised out of gels, the DNA extracted using a commercial kit and 
ligated into the yeast episomal vector pASI-CYHIE^^^HII.I using restriction sites 
BamHI and Sail. Ligations were performed with multiple controls, to ensure that the 
clones being isolated were likely to be positive for the appropriate nef insert (section 
2 .2 .8).
Each vector DNA, ligated with an appropriate nef DNA  insert was used to transform 
F. coli DH5a cells. Plasmid pUC19 (at a concentration of 1 ng/pl) was used as a 
control to estimate the efficiency of transformation, which was calculated to be 
between 500-800 colony forming units per jUg of control plasmid. This was sufficient
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for our purposes. Six transformants for each SIV nef clone were picked for small scale 
preparation of DNA. Restriction endonuclease analysis, using BamHI and Sail, and 
electrophoresis on a 1% (w/v) agarose gel containing 5 pg/ml ethidium bromide, 
revealed the presence of each appropriate SIV nef gene at the expected size of 800 bp 
in the majority of clones. Clone GX2 gave a product which was slightly smaller due 
to the presence of a 66 nucleotide deletion within this gene (data not shown).
One positive transformant was picked for each SIV nef clone and the appropriate 
glycerol stock used to perform a large scale preparation of DNA. The presence of the 
appropriate nef gene was confirmed by restriction endonuclease digestion using 
BamHI and Sail (Figure 4.2.1) and electrophoresis on a 1% (w/v) agarose gel 
containing 5 pg/ml ethidium bromide.
4.2.3. Sequence analysis o f pASI-CYHII/^syHII.I-figf clones
All pASI-CYHH/^jiyHII.I-Mg/" clones were shown to be a match to the expected SIV 
Nef sequence except where the mutations had been introduced, where sequences were 
confirmed to be as expected.
4.2.4. Expression o f Nef-BD fusion proteins
Protein was prepared from yeast cells transformed with the BD-Nef constructs. 
Protein preparations from cells transformed with pASI-CYHII/5.S5HILI vector alone 
or untransformed Y190 cells were prepared to serve as controls during Western 
blotting. Analysis of these samples on a 4-20% tris-glycine gradient gel (Novex, UK) 
followed by Western blotting and probing with anti-HA antibody which recognises 
the HA tag in the pASI-CYHII/^jjHII.I vector is presented in Figure 4.2.2. No 
binding to preparations of parental Y190 cells was detected, whereas the MAb binds
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2 0 2 7
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109 8
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pAST-CYHII/BSSHII.I DNA
nef DNA
Figure 4.2.1. Restriction endonuclease analysis of large scale preparation of pASI- 
CYHII/^YsHII.I-wq/DNA on a 1% agarose gel containing 5 pg/ml ethidium bromide. 
Lane 1; pASI-CYHII/5yyHII.I, lane 2; pASI/CYHII/55YHII.I-J5, lane 3; pASI- 
CYHII/55YHII.I-C8, lane 4; pASI-CYHII/555HII.I-GX2, lane 5; pASI- 
CYHII/5Y5HII.I-VLA*del, lane 6; pASI-CYHII/5yyHII.I-J5(EIYL), lane 7; pASI- 
CYHII/5yyHILI-J5(EIYL+R>E), lane 8; pASI-CYHII/toHII.I-J5(R>E). The size of 
the restriction fragments were compared with fragments of 1 À DNA digested with 
Hindlll and (pX 174 DNA digested with Haelll.
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Figure 4.2.2. Western blot analysis of recombinant Nef-BD protein performed using 
anti-HA monoclonal antibody on a 4-20% Tris-Glycine gel (Novex, UK). Gel A: lane 
1; control Y190 cells, lane 2; pASI-CYHII/5yyHILI, lane 3; J5-Nef-BD, lane 4; C8- 
Nef-BD, lane 5; VLA*del-Nef-BD. Gel B: lane 1; control Y190 cells, lane 2; pASI- 
CYHII/5yyHII.I, lane 3; VLA*del-Nef-BD, lane 4; J5(R>E)-Nef-BD, lane 5; GX2- 
Nef-BD, lane 6; J5(EIYL+R>E)-Nef-BD, lane 7; J5(EIYL)-Nef-BD. The relative 
molecular mass of protein bands bound by the anti-HA antibody was calculated by 
comparison with protein standards (Gibco BRL, UK). Protein product corresponding 
to pASI-CYHII/5yyHII.I is present at the predicted size of between 16-20 kDa. An 
additional band, a ‘doublet’ is present at approximately 50 kDa. This is also present in 
the lanes corresponding to Nef-BD protein.
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to pASI-CYHII/^jjHII.I vector protein at the expected weight of between 16-20 kDa. 
Of interest, a second faint band was detected of an RMM of 52 kDa. For each of the 
recombinant Nef constructs, a band of RMM 55 kDa would be predicted as the RMM 
of Nef is between 27-35 kDa. This was the case for J5 and C8 Nef fusion proteins. 
VLA*del Nef fusion protein appears to be smaller, presumably due to the truncation 
of the Nef protein. The remaining fusion proteins appeared to have an RMM of 
approximately 55 kDa, with the notable exception of J5(EIYL) which appeared to 
have an RMM of approximately 36 kDa. This confirms that the appropriate Nef 
protein was being expressed by each of the constructs.
Parallel analysis of these protein preparations by Western blotting and probing with 
the SIV Nef specific MAb KK75 is presented in Figure 4.2.3. No binding of this 
antibody was observed to protein preparations derived from the yeast cells or cells 
transformed with the parental plasmid pASI-CYHII/5.s5HILI as there are no nef 
sequences present. By contrast, J5-Nef-BD and C8-Nef-BD are present at the 
predicted relative molecular mass of 55 kDa, as is J5(R>E)-Nef-BD. Two 
preparations of VLA*del-Nef-BD are present at approximately 50 kDa. GX2-Nef-BD 
is not recognised by KK75 due to the amino terminus of this protein harbouring a 
deletion that encompasses the linear epitope recognised by KK75. Surprisingly, the 
J5(EIYL+R>E) and J5(EIYL) recombinant proteins appear at the smaller size of 50 
and 40 kDa respectively.
The presence of the appropriate Nef protein, in each construct is confirmed as 
Western blotting was performed with a Nef specific MAb, KK75. However, 
J5(EIYL+R>E)-Nef-BD and J5(EIYL)-Nef-BD are not present at the predicted size, 
as observed for all other clones. The possible reasons for this are discussed in section
4.3.
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Figure 4.2.3. Western blot analysis of recombinant Nef-BD protein performed using 
KK75 on a 4-20% Tris-Glycine gel (Novex, UK). Lane 1 ; pASI-CYHII/5yyHII.I, lane 2; 
J5-Nef-BD, lane 3; C8-Nef-BD, lane 4; VLA*del-Nef-BD, lane 5; VLA*del-Nef-BD, 
lane 6; GX2-Nef-BD, lane 7; J5(R>E)-Nef-BD, lane 8; J5(EIYL)R>E-Nef-BD, lane 9; 
J5(EIYL)-Nef-BD. The relative molecular mass of protein bound by anti-Nef 
monoclonal antibody was calculated by comparison with a protein standards (Gibco 
BRL, UK). The doublet, previously observed in Figure 4.2.2 in the lanes corresponding 
to SIV Nef protein, is absent.
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4.2.5. B-Galactosidase assays
a. Interaction o f Nef-BD proteins with members o f the endocytic pathway
An interaction between the two proteins is denoted by a +, indicating that the yeast 
colonies were blue. A negative interaction (denoted by - ), indicates the colonies were 
white. Differences in the number of blue colonies were observed on different plates. 
This may be a result of different transfection efficiencies, or the potential toxicity of 
the proteins to the yeast they are being transformed with.
The interaction of the Nef-BD proteins with the parental activation domain plasmid 
pACTII-AD not containing any additional sequences was used as a control in every 
set of assays. No specific interactions of parental pASI-CYHII/R^^HII.I plasmid was 
observed with this plasmid.
A positive interaction was detected between pASI-CYHII/.^^.s'HILI expressing J5 Nef 
as a fusion partner with the BD and AP47-AD and AP50-AD. This was apparent by 
large numbers of blue colonies (Table 4.2.1). The interaction with pACTII-AD was 
negative, as expected. Intriguingly, the interaction with AP47-AD consistently 
revealed a high number of white colonies amongst those that had developed blue. 
Although these types of white breakthrough colonies were evident in a number of 
other transformations, they appeared in relatively small numbers in comparison with 
this specific interaction of J5-Nef-BD + AP47-AD where they constituted 
approximately 50% of the colonies grown. The number of blue colonies in the 
interaction of J5-Nef-BD with AP50-AD was greater than that observed for AP47- 
AD.
C8-Nef-BD exhibited no interaction with AP47-AD or AP50-AD, neither did clone 
VLA*del-Nef-BD.
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N ef allele expressed in 
pASI-CYHII/5ssHII.I
Gene expressed in pACTII-AD
pACTII AP47 AP50
pASI-CYHII/R^^HILI - ND ND
J5 - + +
C8 - - -
VLA*del - - -
GX2 + + +
J5(EIYL) - + +
J5(EIYL+R>E) - - -
J5(R>E) + + +
Table 4.2.1. The interaction of the Nef-BD DNAs with AP47-AD and AP50-AD. 
Data is representative of three independent experiments. The interaction of the various 
Nef-BD DNAs with the pACTII-AD was used as a negative control in each 
experiment, as well as that of the pASI-CYHII/Ri'j'HII.I vector with pACTII-AD. - , 
negative, no blue colonies, + , positive, blue colonies present.
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An interesting feature was observed for the interactions of GX2-Nef-BD and 
J5(R>E)-Nef-BD. Although these clones exhibited a strong interaction with AP47-AD 
and AP50-AD fusion proteins, interactions were also observed with pACTII-AD. This 
was observed reproducibly. A low level of interaction was observed between 
J5(EIYL) Nef-BD and pACTII-AD, although this was less than that observed for 
GX2-Nef-BD and J5(R>E)-Nef-BD (Table 4.2.1).
In order to investigate this observation further, a kinetic assay was performed to 
determine if there was any differential rate of p-galactosidase production in the 
+pACTII-AD interactions.
Double transformations of yeast Y190 either with J5-Nef-BD, J5(EIYL)-Nef-BD, 
GX2-Nef-BD or J5(R>E)-Nef-BD DNA, alongside one of pACTII-AD, AP47-AD or 
AP50-AD were performed. All three interactions were plated onto one plate, divided 
into three segments, in triplicate (Figures 4.2.4a, b & c). After lysis of the yeast 
colonies by liquid nitrogen the discs were incubated, with Z buffer/ONPG/p- 
mercaptoethanol (section 2.2) for a period of 1, 2 or 6 hours for colour development 
and allowed to dry.
The one hour incubation plates (Figure 4.2.4a) reveal a faint blue colour for the 
interaction of GX2-Nef-BD and J5(R>E)-Nef-BD with pACTII-AD. It appeared there 
were fewer blue colonies in the pACTII-AD interaction, by comparison to the AP47- 
AD and AP50-AD interactions. However, it was difficult to determine unequivocally 
whether the blue colonies present in the +AP47-AD and +AP50-AD interactions were 
indicators of true interactions or were partially due to trans-activation of pACTII-AD. 
By two hours of incubation (Figure 4.2.4b) it was not possible to distinguish between 
the pACTII-AD and the AP47-AD or AP50-AD interactions with GX2-Nef-BD and 
J5(R>E)-Nef-BD. This was consistent after 6 hours of development (Figure 4.2.4c).
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J 5 -N e f -B D G X 2-N ef-B D
J 5  (R > E )-N e f  BD J 5  (E IY L)-N ef BD
Figure 4.2.4a. p-galactosidase disc assay of the interactions of Nef-BD proteins with pACTII- 
AD (A), AP47-AD (B) and AP50-AD (C), after 1 hour incubation with the chromogenic 
substrate. A positive interaction is denoted by the production of p-galactosidase, which results in 
the colonies producing a blue colour after lysis and incubation with the chromogenic substrate. A 
negative interaction is denoted by the colonies remaining white. The interaction with pACTII- 
AD alone serves as a negative control.
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J 5 -N e f -B D
J 5  (R > E )-N e f  BD J 5  (EIY L)-N ef BD
Figure 4.2.4b. p-galactosidase disc assay of the interactions of Nef-BD proteins with pACTII- 
AD (A), AP47-AD (B) and AP50-AD (C), after 2 hours incubation with the chromogenic 
substrate. A positive interaction is denoted by the production of p-galactosidase, which results in 
the colonies producing a blue eolour after lysis and incubation with the chromogenic substrate. A 
negative interaction is denoted by the colonies remaining white. The interaction with pACTII- 
AD alone serves as a negative control.
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J 5 -N e f -B D G X 2-N ef-B D
J 5  (R > E )-N e f  BD J 5  (EIY L)-N ef BD
Figure 4.2.4c. p-galactosidase disc assay of the interactions of Nef-BD proteins with pACTII- 
AD (A), AP47-AD (B) and AP50-AD (C), after 6 hours incubation with the chromogenic 
substrate. A positive interaction is denoted by the production of p-galactosidase, which results in 
the colonies producing a blue colour after lysis and ineubation with the ehromogenie substrate. A 
negative interaction is denoted by the colonies remaining white. The interaction with pACTlI- 
AD alone serves as a negative control.
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Previously, some p-galactosidase production for the interaction of J5(EIYL)-Nef-BD 
with pACTII-AD had been observed. However, in this set of experiments, the 
interactions of J5-Nef-BD and J5(EIYL)-Nef-BD with pACTII-AD were negative. 
J5(EIYL)-Nef-BD revealed a positive interaction with AP47-AD and AP50-AD, that 
was comparable to that of 15-Nef-BD with AP47-AD and AP50-AD (Figure 4.2.5, 
Table 4.2.1). By contrast, J5(EIYL+R>E)-Nef-BD did not interact with AP47-AD and 
AP50-AD, as observed for C8-Nef-BD (Table 4.2.1, Figure 4.2.5).
b. Interaction of Nef-BD proteins with Lck, a member of the Src family of 
protein tyrosine kinases
An interesting phenomenon was observed for the interaction of Lck-SH3-AD protein 
with J5-Nef-BD, C8-Nef-BD and VLA*del-Nef-BD proteins. The number of 
colonies, in contrast to those of other interactions of the Nef-BD proteins, were very 
low, never being more than 10 and on some occasions as few as 2. Only on one 
occasion was a single positive colony observed, for J5-Nef-BD + Lck-SH3-AD, 
amongst negative white colonies. This made interpretation of this set of experiments 
difficult. The results of this set of experiments cannot be taken as an accurate 
reflection of this interaction (data not shown).
c. Interaction of Nef-BD proteins with TCRC proteins
All of the Nef-BD clones were investigated for interactions with TCRÇi.n and 
TCR«;2 .2 i (Table 4.2.2).
Wild type J5-Nef-BD interacted with both TCRÇi.n and TCRÇ2.21 clones. The 
attenuated C8-Nef-BD clone did not interact with either of the TCRÇ clones, an 
observation which was consistent for VLA*del-Nef-BD.
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J 5 -N e f -B D C 8 -N ef-B D
J 5  (E IY L)-N ef - BD J 5  (E IY L + R > E )-N ef  - BD
Figure 4.2.5. p-glalactosidase dise assay to show the interactions of J5-Nef-BD, C8-Nef-BD, 
J5(EIYL)-Nef-BD and J5(EIYL+R>E)-Nef-BD with AP47-AD (A) and AP50-AD (B). Repair 
of the deletion in C8 with the sequence EIYL repairs the ability to interact with the adaptor 
proteins, in a manner similar to that of J5. By contrast, when the point mutation R191E is 
presented in conjunction with the EIYL sequence, the interaction is disrupted. All proteins were 
tested for an interaction with pACTII-AD, as a negative control. In all instances, this was 
negative (data not shown).
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Nef allele expressed in 
pASI-CYHII/5ssHII.I
Gene expressed in pACTII-AD
pACTII TCRÇ1.11 TCRÇ2.21
pASl-CYHll/5^5HIl.I - ND ND
J5 - + +
C8 - - -
VLA*del - - -
GX2 + + +
J5(E1YL) - + +
J5(E1YL+R>E) - - -
J5(R>B) + + +
Table 4.2.2. The interaction of the Nef-BD DNAs with TCRÇi.n-AD and TCRÇ2.21- 
AD. Data is representative of three independent experiments. The interaction of the 
various Nef-BD DNAs with the pACTII-AD was used as a negative control in each 
experiment, as well as that of the pASl-CYHll/555HlLI vector with pACTlI-AD, - , 
negative, no blue colonies, + , positive, blue colonies present.
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GX2-Nef-BD and J5(R>E)-Nef-BD were observed to cause trans-activation of 
pACTII-AD. A time course was not carried out for this set of experiments; instead the 
assay was observed during the course of incubation with the Z buffer/ONPG/p- 
mercaptoethanol to determine if  there was any delay in p-galactosidase production for 
the interactions with pACTIl-AD. Although a slight delay was observed, it was not 
long enough to determine whether the subsequent interactions with the TCRÇ clones 
were true interactions and not partially or completely due to trans-activation of 
pACTll-AD.
J5(B1YL)-Nef-BD revealed a positive interaction with TCRÇi.n and TCRÇ2.21 that was 
comparable to that of J5-Nef-BD. J5(B1YL+R>B)-Nef-BD did not interact with any of 
the TCRÇ clones, as observed for C8-Nef-BD (Table 4.2.2, Figure 4.2.6).
4.2.6. Liquid assay
To obtain more quantitative data for each of the interactions described, semi- 
quantitative liquid p-galactosidase assays were attempted. However, difficulty was 
experienced in growing yeast cultures to the appropriate density required for these 
experiments. The possible reasons for this are discussed in section 4.3.
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J 5 -N e f -B D
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C 8 -N ef-B D
A 5
x °
J 5  (E IY L)-N ef - BD
B
J 5  (E IY L + R > E )-N ef  - BD
Figure 4.2.6. p-glalactosidase disc assay to show the interactions of J5-Nef-BD, C8-Nef-BD, 
J5(EIYL)-Nef-BD and J5(EIYL+R>E)-Nef-BD with TCRÇ^^rAD (A) and TCRÇ,,,-AD (B). 
Repair of the deletion in C8 with the sequence EIYL repairs the ability to interact with the adaptor 
proteins, in a manner similar to that of J5. By contrast, when the point mutation R191E is 
presented in conjunction with the EIYL sequence, the interaction is disrupted. All proteins were 
tested for an interaction with pACTII-AD, as a negative control. In all instances, this was 
negative (data not shown).
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4.3. Discussion
The ability of Nef to interact with a range of cellular partners represents a unique 
opportunity to subvert normal cell function to the benefit of the virus. The aim of this 
part of the project was to utilise yeast-2-hybrid technology to investigate the 
interaction of selected cellular components with novel SIV nef clones. The selected 
SIV nef clones had been characterised as having the ability to affect the level of virus 
replication observed either in vitro or in vivo (Whatmore et al., 1995, Arnold et a l, 
1999, N. Almond, personal communication). The aim was to identify the domains of 
Nef which mediate these interactions.
Protein analyses indicated that the SIV Nef proteins were being expressed as fusions 
with the GAL4 BD (Figure 4.2.2) as well as confirming that the proteins were indeed 
SIV Nef (Figure 4.2.3). Western blotting with the anti-HA MAb revealed the presence 
of an additional band at approximately 52 kDa in all of the protein preparations 
(Figure 4.2.2). This band was present in the control lane of vector only (Figure 4.2.2, 
Gels A & B, lanes 2), but absent when Western blotting was performed with Nef 
specific MAb KX75 (Figure 4.2.3). This is most likely to be a protein expressed by 
the transformed yeast that contains a peptide sequence similar to the HA tag. The 
exact identity of this protein is unknown although it has been observed previously (M. 
Morse, personal communication). However, as the control lane of the Y190 cells 
remained negative and no cross reactivity with the anti-Nef Mab was observed it was 
not considered that it was likely to have any adverse effects on the results obtained. 
Whilst the majority of Nef-BD fusion constructs were expressed as relatively stable 
proteins of the predicted RMM, clones J5(EIYL)-Nef-BD and J5(EIYL+R>E)-Nef-
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BD resolved to approximately 36-40 kDa and 48-50 kDa respectively. This result is 
remarkably similar to observations in the previous chapter where expression of GST- 
J5(EIYL) and GST-J5(EIYL+R>E) in a bacterial expression system also yielded 
proteins of distinct sizes which did not correlate with the predicted RMM of GST-SIV 
Nef. For GST-J5(EIYL) and GST-J5(EIYL+R>E), the proteins had relative molecular 
masses of 40-44 kDa (Figures 3.2.4 & 3.2.5), and 44 kDa (Figure 3.2.4) respectively. 
The reason for this reproducible aberrant RMM of these two Nef alleles is unclear. 
Substitution of the wild type sequence by these repair sequences could affect protein 
folding such that sites recognised by proteases are more accessible and the proteins 
are cleaved at specific sites into these smaller fragments. It is also possible, as 
discussed in section 3.2, that these recombinant proteins are particularly unstable and 
so are degraded by proteases until the minimal stable domain of the protein is 
encountered. However if these proteins of smaller RMM than predicted represented 
partially degraded proteins then the binding data becomes more significant, as regions 
of the protein which may influence the binding capacity of the Nef protein have 
potentially been altered.
The J5-Nef-BD and C8-Nef-BD clones had previously been tested in the yeast-2- 
hybrid system (Bell et al, 1998). J5-Nef-BD had been observed to interact with the 
same TCRÇ-AD and AP-AD clones that were utilised in these studies, allowing the 
interactions of J5-Nef-BD with each of the activation domain fusion proteins to be 
used as a positive control.
Wild type J5-Nef-BD protein was found to interact with AP47-AD, AP50-AD, 
TCRÇi.ii-AD and TCRÇ2 .2 1-AD. These observations are in agreement with those 
previously published by Bell et a l (1998), and are consistent with observations for the
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interaction of SIVmac239 Nef with AP47 and AP50 as demonstrated by Piguet et al.
(1998) and Le Gall et al. (1998).
Interestingly, the interaction of J5-Nef-BD with AP47-AD consistently gave rise to a 
high number of white colonies, which appear to have lost one or both of the plasmids 
and have overcome the nutritional selection of the plates. In the case of the interaction 
between J5-Nef-BD + AP47-AD, colonies of this type constituted approximately 50% 
of those present. Although white colonies were detectable in other interactions, they 
were not so abundant. The reason for their prevalence in this particular interaction 
remains unclear.
A greater number of blue colonies were present following the interaction of J5-Nef- 
BD with AP50-AD than that of J5-Nef-BD with AP47-AD. Although parameters, 
including the transfection efficiency and the toxicity of the Nef protein to the yeast 
could be affecting the number of yeast colonies which are transformed with both 
proteins, these differences may also be attributable to differences in the ability of Nef 
to interact with these two proteins.
The adaptor proteins are present at different locations in the cell. AP47 attaches to the 
trans golgi network (TGN) and AP50 attaches to the plasma membrane. Nef is post 
translationally modified by the addition of a myristoyl group at its N terminus, which 
is essential for its association to the cytoplasmic face of the plasma membrane (Yu & 
Felsted, 1992). A myristoylated Nef may interact with AP50 to a greater extent than 
AP47 due to its tendency to localise to the plasma membrane. It is not known whether 
the Nef proteins produced in these experiments were myristoylated or not. However, 
the yeast strain Saccharomyces cerevisiae has been described to post translationally 
modify the amino terminus of the HIV-1 gag gene product by myristoylation
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(Bathurst et ah, 1989). This has a direct effect on the cellular localisation of the gag 
precursors. HIV-1 Nef has also been described to be myristoylated in Saccharomyces 
cerevisiae (Macreadie et al., 1993), although this was in a system where yeast 
transformants were grown in selective media containing myristic acid, which was not 
the case in the experiments described. Alternatively, subtle differences in the point of 
contact with Nef of these two proteins may make AP47-AD binding less stable.
SIV and HIV Nef have been described to downregulate the CD4 receptor possibly as 
a result of interacting with the cellular trafficking machinery. Nef directs CD4 to the 
endosome, by transport through clathrin coated pits (CCPs), a process which occurs 
primarily at the plasma membrane, and increases the rate of CD4 endocytosis. This 
process also occurs at the TGN, although to a lesser extent. This could also account 
for the differences observed in the ability of wild type J5 Nef to interact with AP47 
and AP50, since, if  the downregulation of CD4 by Nef involves the TGN to a lesser 
extent than the plasma membrane then Nef may interact with AP47 (which attaches to 
the TGN) less so than AP50 (which attaches to the plasma membrane).
The interaction of J5-Nef-BD with AP47-AD also correlates with observations that 
HIV-1 Nef induces the endocytosis of MHC class I complexes by internalisation in 
vesicles that accumulate at the TGN, sorting them into lysosomes and degrading 
them. This process involves AP-1, of which AP47 is the medium chain. These 
interactions allow Nef to reduce surface expression of CD4 receptors and MHC class 
I molecules and create an environment within which the virus can thrive.
The interaction of Nef with the adaptor proteins, (particularly with AP50), could serve 
as a bridge for Nef to associate with the plasma membrane and hence with TCRÇ.
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This is consistent with the observation that the Nef-BD proteins shown to associate 
with the TCRÇ also associate with the adaptor proteins. It would be interesting to 
elucidate whether the interaction of Nef with TCRÇ affects either of the two specific 
signal transduction pathways that are activated by the TCR upon stimulation. All the 
components of the TCR are required for efficient plasma membrane expression of the 
receptor (Weiss, 1993). By interacting with the Ç chain Nef could prevent the normal 
signal transduction through the T cell receptor, which could reduce the ability of the 
host to mount an effective immune response against the virus.
It appears that the cytoplasmic domain of the TCRÇ is sufficient for the interaction 
with the various Nef proteins and the membrane proximal IT AM (present in 
TCRÇi.ii) is not required. ITAM motifs are required for interactions with Src 
homology 2 (SH2) domain containing proteins, such as ZAP70 kinase, involved in the 
T cell signalling pathway (Wang & Samelson, 1996). Previously, Bell et al. (1998) 
showed subtle differences between different nef alleles interacting with these TCRÇ 
clones through the liquid assay, which was thought to be due to the presence of the 
different ITAM motifs. Within these experiments, this observation was not 
reproducible, due to the non-quantitative nature of the P-galactosidase assay.
Bell et al. (1998) reported that J5-Nef-BD did not interact with Hck-SH3, a member 
of the Src family of protein tyrosine kinases. In this study the interactions of SIV Nef 
with Lck-SH3 were investigated. Analysis of J5-Nef-BD, C8-Nef-BD and VLA*del- 
Nef-BD proved problematic, with very few colonies being generated by this 
interaction by comparison with the others described. The great reduction in the 
number of colonies suggests that the interaction of the Nef-BD proteins with Lck- 
SH3-AD may be toxic to the yeast, preventing their growth despite the availability of
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nutrients. It is impossible to conclude whether any of the SIV-Nef-BD proteins 
investigated interact with Lck-SH3-AD. In future, it may be beneficial to repeat these 
experiments, using an inducible promoter such as that described by Macreadie {et al., 
1993) to regulate expression of toxic proteins in yeast cells, which could overcome 
the problems encountered in these experiments.
Previously, Harris et al. (1995) described an interaction between a baculovirus 
derived myristoylated HIV-1 Nef-GST fusion protein and baculovirus expressed Lck 
by taking lysate from Sf9 cells infected with Lck and incubating with myristoylated 
Nef-GST immobilised on glutathione agarose beads and subsequent analysis by 
immunoblotting. In this situation, where interactions of over expressed proteins may 
be toxic to the cell, the use of a purely biochemical method to look for interactions 
may also be advantageous.
By contrast to J5-Nef-BD, no specific interactions were observed between C8-Nef- 
BD and any of the cellular partners (Figures 4.2.5 & 4.2.6, Tables 4.2.1 & 4.2.2). This 
data is in agreement with that of Bell et al. (1998), who similarly observed no 
interaction of C8-Nef-BD with the TCRÇ clones and the Hck-SH3-AD clone. 
However, Bell et al. (1998) showed, through the quantitative liquid assay, that C8- 
Nef-BD interacted with AP50-AD at a level approximately five fold less than that of 
J5-Nef-BD. A low level of p-galactosidase production observed for the interaction of 
C8-Nef-BD with AP47-AD and AP50-AD was revealed to be a basal level of 
production as it was comparable to the level of p-galactosidase produced when the 
yeast were transformed with pASI-CYHII/R^^HII.I vector and AP47-AD and AP50- 
AD (data not shown). It is possible that there is a low level of interaction of C8-Nef- 
BD with AP50-AD within this system that is detectable only through a quantitative 
assay. It is difficult to deduce whether C8 Nef may still downregulate CD4, despite
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showing little or no interaction with the adaptor proteins in these experiments. 
Previously, Bell et al. (1998) failed to show any significant levels of CD4 
downmodulation by C8 Nef. Therefore, attenuated SIV Nef proteins, exhibiting a 
reduced ability to interact with the adaptor proteins may also display an inability to 
down modulate cell surface levels of CD4.
VLA*del-Nef-BD revealed a pattern of interactions identical to that of C8-Nef-BD. 
Previously, VLA*del had been shown to exhibit an identical pattern of MAb binding 
to C8 (Chapter 3). The similarity of these observations can be explained by reference 
to the putative structure of SIV Nef (Figure 3.3.1). The truncation of VLA*del begins 
at position 213 which is in close proximity to the alpha helical region that is deleted in 
C8. The alpha helical region around which the attenuations in C8 and VLA*del are 
centralised may form a critical part of the Nef protein structure that is important for 
mediating cellular interactions and protein antigenicity. These sequence changes 
could also be affecting the overall folding of the protein, making the regions 
recognised by interacting partners or monoclonal antibodies inaccessible.
The ability of clones GX2-Nef-BD and J5(R>E)-Nef-BD to interact with the native 
activation domain of GAL4 when it is not fused to additional peptides/proteins makes 
analysis of the results gained for the interactions with AP47-AD, AP50-AD and the 
TCRÇ-ADs difficult. This phenomenon was observed consistently for these two 
particular Nef-BD proteins, on multiple independent occasions. It is unclear as to why 
this non specific interaction is limited to these two mutant SIV Nef clones. Possibly, 
the overall shape of these clones exposes a region of the proteins that can bind to the 
GAL4 activation domain. Interestingly, the attenuations within these two clones are at
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opposite ends of nef relative to each other. The 66 nucleotide deletion in GX2 is at the 
5’ end of nef whilst the R191E mutation is at the 3’ end. Little is known about the 
crystal structure of SIV Nef (Chapter 3). Homology mapping of the structure of SIV 
Nef based on HIV-1 Nef (M. Forster, personal communication, NIBSC) has predicted 
a putative structure of SIV Nef (Figure 3.3.1). This structure extends from amino acid 
85-233 which does not include the deletion in GX2. Although position 191 is present 
in this putative structure, its location is in a region where relatively little spatial 
information is available. Therefore there is little or no relevant structural knowledge 
concerning the regions of these mutations that could help explain the mechanism of 
trans-activation to be mediated by the GX2 and J5(R>E) Nef proteins.
Attempts to further investigate the yeast-2-hybrid assay results using the semi- 
quantitative liquid assay failed. Problems were encountered at the preliminary stage of 
growing overnight cultures of the yeast transformed with the various Nef-BD and AD 
genes. Many of the cultures did not grow at all, or not to the appropriate density 
required to perform the liquid assay. This may be an issue of toxicity caused by the 
nef gene to the yeast. Whilst the yeast are growing on the selection media plates, it is 
possible that they may selectively delete regions of nef associated with toxicity, whilst 
retaining parts of the plasmid that confer the ability to grow on the selection media. 
By the time the yeast colonies are picked for the liquid assay they may be missing the 
parts of the DNA that are required for the yeast to grow in the selection media, or the 
regions of the gene that are required for the parts of the protein to interact. Problems 
associated with the toxicity of nef in the expression system used have been 
encountered previously (Chapter 3). For future studies, this should be taken into 
consideration when choosing an expression system within which to express SIV nef
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Interpretation of the yeast-2-hybrid data would be improved if information on the 
oligomeric states of Nef in vivo was known. If Nef forms dimers or trimers in vivo 
then the results from the p-galactosidase assays could be very revealing. It has been 
reported recently that the core domain of HIV-1 Nef forms stable homo-dimers and 
trimers in solution (Arold et al., 2000). The non-specific trans-activation of GAL4- 
AD observed by clones GX2-Nef-BD and J5(R>E)-Nef BD could be a consequence 
of the structural status of the SIV Nef protein carrying these attenuations. Arold et al. 
(2000) investigated the accessibility of amino acids involved in interactions. It was 
observed that the configuration of the dimeric and trimeric states of the Nef core 
domain did not interfere with the ability to interact with the SH3 binding site, the 
protease cleavage site and the acidic cluster between the PXXP motif. However, Liu 
et al. (2000) reported that a mutation at position D 123, in the HIV-1 Nef core domain 
(located on the oligomer interface) abrogated the ability of the protein to 
downregulate MHC class I resulting in enhanced viral infectivity and affecting the 
ability of Nef to form dimers. Thus, the oligomerisation of N ef could have an 
important effect on its ability to interact with other proteins. It is possible that, in 
GX2-Nef-BD and J5(R>E)-Nef-BD the attenuations are destabilising the oligomeric 
state of Nef and exposing surfaces that can interact with the GAL4-AD. In the 
absence of structural data on SIV Nef this is difficult to confirm or investigate further. 
The observation that repair of the last two amino acids to wild type sequence in 
J5(EIYL)-Nef-BD was sufficient to restore the interactions of Nef with AP47, AP50 
and TCRÇ is highly significant. This suggests the folding of the protein, when this 
repair sequence is present, is restored to its native structure. The observation that the 
pattern of interactions of J5(EIYL)-Nef-BD was similar to that for wild type J5 Nef- 
BD suggests that as the sequence within the initially attenuated virus (C8) reverts
181
back to wild type (J5(EIYL)), Nef regains the ability to exploit cellular processes, an 
observation which highlights the selective pressure for specific sequences within Nef 
to be intact. There are no premature stop codons within J5(EIYL) (Appendix 1, Figure 
7.1). This is in agreement with the observations of Whatmore et al. (1995) who 
reported that repair of the deleted sequence in C8, (that one macaque (45R) was 
infected with), was associated with progression to disease and a wild type phenotype. 
Intriguingly, the repair sequence J5(EIYL) did not regain the ability to bind 
monoclonal antibody KK70 (Chapter 3). This indicates that whilst the binding of 
KK70 has been a useful surrogate marker for wild type Nef function, it may not be an 
absolute correlate.
By contrast, when the repair sequence, J5(EIYL+R>E)-Nef-BD is present the ability 
to interact with the cellular components is disrupted, an observation which is 
consistent with previous results (Chapter 3) where the binding of KK70 to this repair 
sequence was also disrupted. This focuses attention on the point mutation R191E as 
being a key factor in disrupting the interaction with cellular machinery. However, as 
previously discussed, the point mutation in J5(R>E) is one which caused trans­
activation of the native GAL4-BD and therefore its interactions with the cellular 
components could not be determined.
The observation that the J5(EIYL) and J5(EIYL+R>E) proteins are smaller than the 
predicted size makes these results more intriguing. It may be that the combination of 
the repair sequence and the smaller size of the J5(EIYL) Nef protein contribute to 
exposure of the region that is involved in cellular interactions. Subsequently, the 
R191E mutation in J5(EIYL+R>E) maybe obscuring this region.
1 8 2
The analysis of interactions between SIV Nef variants and components of the signal 
transduction pathway has proven illuminating particularly with regards to the various 
sequences across amino acids 143-146 which could potentially restore wild type 
function in vivo. These predictions require further investigation.
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5. General Discussion
5. General Discussion
An intact nef gene is important for pathogenicity of HIV and SIV but the mechanisms 
by which it exerts effects on virus replication in vivo remain poorly understood. 
Molecular studies have identified a number of cellular activities by which the Nef 
protein may alter viral pathogenesis, either by modulating virus replication (either 
increasing or decreasing) or by facilitating escape from the immune system (Fackler 
& Baur 2002, Johnson & Desrosiers 2002, Collins & Baltimore 1999). However, it 
has been difficult to determine which of the interactions mediated by HIV-1 Nef are 
most critical in vivo. The work presented in this study applied a model system that 
permitted comparison of results generated from in vitro observations with results from 
experiments designed to investigate the in vivo replication of SIV. In particular these 
studies focused on the in vitro characterisation of a panel of five SIV nef clones 
whose influences on the in vivo replication of SIVmacJS have been characterised 
previously (Table 5.1, column 2) (Arnold et a l, 1999, N. Almond, personal 
communcation).
A further set of three nef alleles identified during the phenotypic reversion of 
attenuated SlVmacCS to a virulent phenotype in vivo were also studied (Whatmore et 
al, 1995). These mutants represented selected SIVmacCS revertants isolated over 41 
weeks post infection from macaque 45R. By 41 weeks post infection, the initially 
deleted four amino acid region in SIVmacCS Nef had been repaired and evolved to 
the sequence DIYL. This sequence is very similar to the sequence of wild type 
SrVmacJ5 (DMYL) and the motif is identical to that in the pathogenic clone 
SIVmac239, associated with the ability of the virus to cause disease. These data
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provide strong support to the proposal that the four amino acid region, amino acids 
143-146, that is deleted in SIVmacCS, abrogates the capacity of Nef to mediate 
critical functions that result in the virus causing disease.
The purpose of these studies was to characterise the range of Nef alleles in order to 
identify if any correlations existed between selected in vitro biochemical properties 
and their defined in vivo phenotypes. Two types of analyses were performed. The first 
approach was to apply monoclonal antibodies to investigate the structure of SIV Nef. 
This required the development of a semi-quantitative assay to measure the capacity of 
selected specific MAbs to bind SIV Nef. The second approach was to apply yeast-2- 
hybrid analysis to probe interactions between the Nef variants and selected cellular 
components that have been observed to bind differentially between wild type and 
attenuated isolates of SIV Nef (Bell et al, 1998, Howe et al, 1998). Studies by other 
groups have been performed looking at related isolates of Nef in a variety of 
functional assays. The results of these and relevant data from other groups will be 
discussed in the context of data presented in this study.
A summary of the results obtained by the two analyses of SIV Nef described above is 
presented in table 5.1. It demonstrates clearly that there is a strong association 
between the antigenic structure of the carboxy terminus of Nef and the ability of the 
Nef protein to interact with TCR( ,^ AP47 and AP50 proteins. Thus, it confirms the 
importance of the four amino acid motif DMYL, that extends a proposed a-helical 
region encompassing surrounding amino acids 143-146, to create the structure 
necessary for Nef to bind KK70 and these specific cellular proteins. Nevertheless, the 
four amino acid motif itself is not directly involved in these interactions since the loss 
of the KK70 epitope by premature truncation of Nef at amino acid 213 (as in
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Table 5.1. A summary of the results obtained for the panel of SIV Nef clones from in 
vivo, antigenic and yeast-2-hybrid analysis.
SD; standard deviation, +; a positive interaction / binding exhibited by the appropriate 
MAb, a negative interaction / no binding exhibited by the appropriate MAb, ND; 
not done, NI; non-interpretable.
In vivo data, courtesy of N. Almond (personal communication).
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VLA*del) also disrupts the binding of TCRÇ, AP47 and AP50. Thus it would suggest 
that it is some aspect of the conformation of the carboxy terminus of Nef that is 
important in protein interactions rather than the specific amino acids delineated by 
these mutations.
Analysis of C8 revertant clones demonstrated that replacement of the deletion of 
amino acids 143-146 with the sequence EIYL disrupted the conformational dependent 
epitope recognised by KK70. Furthermore, the KK70 epitope was not reconstructed 
when the EIYL motif was expressed in the presence of an aspartic acid residue at 
amino acid 191 (R>E), as may have been predicted from the analysis of virus 
recovered from macaque 45R at 41 weeks post infection and maintained on C8166 
cells for 28 days (A. Jenkins & C. Arnold, NIBSC, personal communication).
The results outlined in this thesis draw interesting parallels with those of Carl et al.
(1999). This group utilised similar SIV Nef clones in their studies that contained the 
repair motifs that had been observed by Whatmore {et ah, 1995) during infection of 
these animals with SIVmacC8. However, these motifs were engineered into the 
SIVmac239 backbone. Their experimental system used stocks of virus (generated by 
transient transfection of 293T cells) to infect CEMxl74 cells. Infection with wild type 
SIVmac239 produced much higher amounts of Nef when compared with production 
by SIVmac239AC8 and 1823AC8. This suggests that a fully intact nef gene is required 
for the efficient expression of virus. By contrast, all the Nef repair alleles, containing 
the various repair sequences, EKIL, EIYL, DMYL, 1820EKFLA10, 1823DIYL20 and 
1823 DIYL42 were expressed efficiently. This was confirmed by Western blot 
analysis of 293T cells and is in agreement with data obtained from Western blot
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analysis of SIV Nef-BD fusion protein expressed in yeast cells (section 4.2), whereby 
the level of expression of J5-Nef-BD and C8-Nef-BD revealed a marked difference 
between these two proteins. The consistency of these results between the two different 
groups using different expression systems suggests that the deletion of the four amino 
acid motif DMYL in C8 Nef affects the stability of the protein, possibly due to its 
position within the highly conserved core of the protein.
Another feature of the data presented by Carl et a l (1999) were the observations from 
the clone 1820EIYLA10 nef, which has a 30 bp deletion downstream removing amino 
acids 189-198 as well as the 12 bp mutation creating the EIYL motif. This clone was 
reported to be unable to downregulate CD4 expression. In that feature this result is 
similar to that generated for the repair sequence J5(EIYL+R>E) (section 4.2) which 
lost the ability to interact with the AP-47, AP-50, TCRÇi.n and TCRÇ2 .21 clones, 
unlike clone J5(EIYL) which did interact with these proteins. From these two parallel 
sets of data, it appears that the mutation of sequences downstream of the 12 bp 
deletion sequence in C8 could be of importance in enabling important functions of 
Nef to be carried out. These downstream mutations could involve amino acid 191. 
However the analyses of the R191E mutant, when presented in a J5 backbone alone 
(J5(R>E)), were inconclusive. Although this mutant Nef did not have the ability to 
bind KK70 attempts to analyse interactions with selected cellular proteins were 
uninterpretable due to the non-specific trans-activation of the GAL4-AD by this 
clone, thus the potential role of amino acid 191 to be able to influence interactions 
remains unanswered. Nevertheless, the presence of this mutation appeared to 
influence the binding of MAb KK70 depending upon whether it was expressed in 
combination with EIYL or DMYL motifs in Nef.
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It was disappointing that no valuable results were forthcoming from the analyses of 
Nef with members of the Src family of protein tyrosine kinases since it has been the 
subject of much investigation (Collette et al., 1997, Coates et al., 1997). The failure to 
gather any useful data appeared to be due to a technical difficulty, resulting from the 
biology of the system, as very few yeast cells were observed to survive the double 
transformation with Lck-SH3 and Nef. This is an intriguing observation and is 
suggestive that co-expression of these two proteins results in cellular toxicity not 
observed when either was expressed individually. This result makes it a very 
attractive topic to pursue within the system described within this thesis, with 
modifications as discussed in Chapter 4.3. However, others have investigated the 
interaction between these proteins. Arold et al. (1997) showed a high affinity binding 
of HIV-1 Nef with Hck-SH3 domain, which appeared to be dependant upon the 
isoleucine residue at position 96 in the RT loop of Hck. The SH3 domain of Lck, by 
contrast, has a serine at position 96 (Arold et al., 1997). Furthermore, it was shown 
that if the arginine at position 96 of Fyn-SH3 was mutated to an isoleucine, this 
restored the interaction of the SH3 domain with Nef, showing that this amino acid 
may be important in mediating this interaction, possibly by affecting the overall 
protein shape that is presented for an interaction with Nef, or possibly forming part of 
the region that the Nef protein binds to.
Contradictory results have been obtained from studies to investigate the interaction 
between HIV-1 Nef and Lck in vivo and in vitro. Some groups have documented 
interactions between HIV-1 Nef and Lck (Cheng et al., 1999, Collette et al., 1996, 
Dutartre et a l, 1998, Greenway et al., 1996) whilst others have not detected any 
interactions (Moarefi et al., 1997, Saksela et al., 1995). It is the PXXP motif at the N
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terminus of HIV-1 Nef, consisting of amino acids 72-75 which appears to mediate the 
interactions with the SH3 domain of the src family tyrosine kinases. This region is 
critical for the interaction between HIV-1 Nef and Hck-SH3 (Briggs et al, 1997, 
Cheng et a l, 1999, Collette et a l, 2000, Greenway et a l, 1999, Lee et a l, 1996). 
Some groups have found that the PXXP motif is required for an interaction with Lck 
(Collette et a l, 1996, Greenway et a l, 1996), whilst others have shown that it is 
dispensable (Baur et al, 1997, Cheng et al, 1999). The PXXP motif has also been 
demonstrated to be required for the interaction of SIV Nef with the Nef associated 
kinase (NAK) (Khan et a l, 1998, Manninen et a l, 1998). The NAK has since been 
identified as a p21 associated kinase (Renkema et a l, 1999), although opinions are 
divided as to whether it is PAKl (Fackler et a l, 2000) or PAK2 (Renkema et a l, 
1999, Arora et a l, 2000, Renkema et a l, 2001).
In vivo, experiments reported by Hanna and colleagues (2001) investigated the effects 
of mutating the HIV-1 Nef allele in the SH3 binding domain and expressing it in 
transgenic mice under the control of the CD4C gene. They also bred wild type 
transgenic mice on a Hck knockout background. It was found that these mice did not 
develop disease and the mutation in the Nef allele was the most likely cause of this. 
The absence of Hck had no effect on disease progression, therefore Hck was 
concluded to be dispensable for the development of AIDS-like disease in transgenic 
mice. However, the observation that disease progression was delayed in the hck 
knockout mice suggested that in the presence of Nef the level of Hck expressed may 
contribute to determining the rate of disease progression (normally Hck expression is 
restricted to cells of myeloid origin (Briggs et a l, 2002)). These results show that 
although within the system described in this thesis it was not possible to obtain any
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results for the interaction of Nef with Lck, others have successfully demonstrated 
interactions with members of the Src family of tyrosine kinases.
The proline rich motif in Nef has been concluded to be central to the ability of Nef to 
induce cellular activation and to be required for the support of viral replication in 
resting cells (Saksela et a l, 1995, Fackler et al., 1999). As discussed, the PXXP motif 
also contributes to the interaction between Nef and a NAK (Khan et al., 1998, 
Manninen et al., 1998), which is also required for the cellular activation of Nef, an 
increase in viral infectivity, production and disease progression (Sawai et al., 1996). 
Time permitting, it would have been valuable to investigate interactions between the 
various Nef mutants with Lck-SH3, Hck-SH3 and NAK, as well as testing a further 
Nef construct, mutated in the PXXP motif. The various assay modifications discussed 
in Chapter 4 would have been incorporated to ensure that viable results were obtained. 
A mammalian two-hybrid system has also been described for the screening of Nef 
with cellular partners, such as Hck (Murakami et al., 2002), which would be worth 
investigating as an alternative experimental system if the described yeast-2-hybrid 
system did not lead to viable results.
Use of the yeast-2-hybrid system could contribute towards understanding which of the 
interactions were dependant upon an intact PXXP motif, as well as identifying which 
of the novel mutants used in this study disrupt these interactions. Indeed, for the 
interaction of HIV-1 Nef with the NAK (Trono & Wang 1997, Sawai et al., 1996) two 
arginines at the N terminus of helix a4 of Nef (R105 and R106) have been 
demonstrated to be required in co-immunoprecipitation and pull down assays (Sawai 
et al., 1995, Fackler et al, 2000). This is particularly interesting given that the four 
amino acid deletion in C8 also sits within the equivalent a  helical region of SIV Nef
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(amino acids 143-146). Furthermore, considering the apparent importance of the 
PXXP motif in functional interactions between Nef and cellular proteins, it would 
also be useful to determine the effect of disrupting this motif on the ability of Nef to 
bind MAb KK70.
Of equal biological interest, but disappointing from the point of view of analysing Nef 
function, was the observation that two distinct Nef alleles GX2 and J5(R>E) exhibited 
binding activity with the parental activation domain plasmid. It is difficult to see how 
distinct changes in the amino and carboxy termini of the Nef protein result in binding 
to the GAL4 activation domain. This observation was confirmed on at least three 
independent occasions. Thus the results from these clones remain inconclusive. 
Hopefully it is possible that the application of alternative vectors to yeast-2-hybrid 
analyses may be more successful in reducing or removing this background binding 
activity (JF Allen, personal communication).
From the summary table (Table 5.1) the data accrued from the analyses of SIV Nef 
variants indicates that conservation of KK70 binding is necessary for the carboxy 
terminus of the protein to mediate its ability to support wild type virus replication 
kinetics in vivo (Table 5.1). In view of this observation it is surprising that mutation of 
amino acids 143-146 to an EIYL motif restored the interaction of Nef with AP47, 
AP50 and TCRÇ in a manner indistinguishable from wild type J5 Nef in the absence 
of restoration of the epitope recognised by KK70 (Table 5.1). More intriguing were 
the observations that these interactions were lost when the EIYL sequence was 
present in conjunction with the R191E mutation. These observations raise the 
question of whether 15(EIYL) would express a wild type phenotype in vivo, and as a
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result determine whether binding of TCRÇ, AP47 and AP50 are critical functions for 
wild-type Nef activity.
The J5(EIYL) nef allele has been reconstructed into the SIVmacJS clone background 
and a virus stock prepared for in vivo studies (N. Almond, personal communication). 
Preliminary results indicate that this virus exhibits an attenuated phenotype in vivo. 
This suggests that the interactions between Nef and TCRÇ, AP47 and AP50 whilst 
valuable to the virus are not critical in vivo and other properties may be more 
important. Nevertheless a more detailed examination of this preliminary data is 
necessary to determine whether J5(EIYL) is fully attenuated in vivo (N. Almond, 
personal communication).
The hypothesis that the interaction between SIV Nef and TCRÇ is important and 
critical for Nef to exert its function in vivo would appear attractive. The TCRÇ chains 
may prove important in elucidating the processes that could be subverted within an 
infected cell. Within this study, the cytoplasmic domain of the TCRÇ was found to be 
sufficient for the interaction with the various Nef proteins, whilst the membrane 
proximal ITAM (present in TCRÇi.n) was not required. It is well documented that the 
three ITAMs within the TCR are involved in specific signal transduction (Irving et 
al., 1991), TCR/CD3 biogenesis (Love et al., 1993, Shores et a l, 1994) and 
thymocyte selection (Shores et al, 1997). It has been demonstrated that the 
interaction of J5 Nef with the TCRÇ was not dependent upon a single ITAM motif, 
rather, J5 Nef was observed to interact with two separate domains of the TCRÇ. One 
domain was between amino acids 52 and 86 and the other between amino acids 111 
and 164, of which ITAMs 1 and 2 respectively are components (Schaefer et al., 
2000). Either of these interactions were found to be sufficient to lead to Nef-mediated
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downmodulation of the TCR. This would be consistent with the results presented 
within this study, whereby the interaction of J5 Nef with TCRÇ was unaffected by the 
absence of the most membrane proximal ITAM in the TCRÇ2 .21 clone, indicating that 
this interaction was dependent upon the presence of ITAMs 1 and 2. In the context of 
the results presented within this thesis and those of Schaefer {et al, 2000), it appears 
that overall, regions within both the TCRÇ and Nef are important in mediating the 
interaction. This would suggest that the phenotype of the attenuated viruses observed 
in vivo could, in part, be due to an inability to interact with the TCRÇ, hence 
preventing loss of immune function within the host. Although it is not clear how 
interaction with TCRÇ may be beneficial for the virus, it is likely that it is the result of 
facilitating the replication of infected cells through the TCR rather than by reducing 
the capacity of bystander cells to deliver anti-viral immune responses. Nevertheless, 
there may be an alternative mechanism of inducing disease through the interactions 
between Nef and the TCR. One possibility is by the induction of apoptosis in 
uninfected bystander cells. For example, both Nef and the TCR have been described 
to be required for HIV-mediated upregulation of FasL (Johnson 1997, Depraetere & 
Goldstein 1997). HIV infected patients exhibit upregulation of Fas and FasL, as well 
as an increased susceptibility of CD4+ and CD8+ cells to Fas-mediated killing 
(Katsikis et a l, 1995). Both Nef and TCRÇ are required for the upregulation of FasL 
by HIV. Furthermore, it has been demonstrated that, in Jurkat cells lacking TCR, 
binding of the Nef-associated serine kinase p62/NAK was disrupted (Xu et a l, 1999). 
As discussed previously, the PXXP motif within Nef, required for the interaction of 
Nef with members of the src family of tyrosine kinases, is also required for the 
interaction of Nef with p62/NAK. However, this study also demonstrates that
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reconstitution of Jurkat cells with TCRÇ ITAMs 2 and 3, restored binding of 
p62/NAK with Nef (Xu et a l, 1999). It would therefore be interesting to extend the 
studies described within this thesis and investigate whether Nef alleles interacted with 
the individual ITAMs of the TCRÇ as well with the p62/NAK. This would allow 
investigation of the importance of the attenuated clones of SIV Nef in a wider 
molecular context and determine the specificity of Nef mediating broad molecular 
interactions. It would also determine which parts of the TCRÇ was targeted by Nef.
The depletion of T cells observed during HIV infection is usually due to the effect of 
widespread apoptosis which is induced (Amiesen, 1992). Therefore, this is possibly a 
mechanism evolved by the virus in order to decrease the rate of apoptosis of infected 
cells. Several different apoptotic pathways have been described in HIV infection, such 
as Fas/FasL (Shearer 1998), TNF/TNFR (Herbein et a l, 1998) and TRAIL (TNF 
related apoptosis inducing ligand) and its receptors (Katsikis et al., 1995).
The sophisticated interaction of Nef with TCRÇ appears to bypass the requirement for 
TCR ligation by antigen, leading to upregulation of FasL. However, the upregulation 
of FasL by Nef is not the only mechanism by which the viral protein induces or 
accelerates apoptosis. It has been demonstrated that Nef directly interacts with p53 via 
amino acids 1-57 at the N terminus of Nef, which leads to the inhibition of p53 
mediated apoptotic events (Greenway et al., 2002). The ability of N ef to interfere with 
this apoptosis pathway, as well as that mediated by up-regulation of FasL, 
demonstrates clearly that certain interactions of Nef are dependant upon its 
subcellular localisation. Apoptosis is an important mechanism that can efficiently 
result in depletion of cells during HIV infection. Nef may contribute to two distinct
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mechanisms that results in apoptosis -  firstly, by up-regulation of FasL; secondly, by 
interacting with p53.
The interaction of Nef with the TCR(  ^ highlights an important property of Nef. 
Simmons and colleagues (2001) investigated Nef action in putative T cell activation 
and virulence induction by monitoring transcriptional changes observed on large scale 
gene expression profiling (Simmons et ah, 2001). Nef was found to exert a 
widespread transcriptional program in T cells that was 97% identical to that of anti 
CD3 T cell activation. A comparison of the Nef expression profile with that obtained 
after T cell activation through CD3 revealed a strong identity. Fifteen transcription 
factors upregulated by Nef, which were capable of transactivating the LTR were 
identified, seven of which were inducibly expressed on T cell activation. This could 
represent a mechanism through which virion production is facilitated by Nef. 
Interestingly, it was observed that proteins that interact with Tat were induced, which 
suggests that Nef may indirectly facilitate the function of other HIV accessory genes. 
Comparing both transcription profiles it was observed that there was an 
overrepresentation of genes which influence HIV replication. Whilst the exact 
mechanism by which Nef can generate an expression profile similar to that of anti- 
CD3 T cell activation remains unknown, this observation is important in identifying 
avenues to elucidate key Nef functions.
The ability of Nef to alter the activation state of an infected cell has been described 
(Stevenson 1996). It has been demonstrated that adenovirus-mediated expression of 
Nef in primary macrophages was sufficient for chemokine induction and induced the 
chemotaxis of resting T lymphocytes, resulting in productive HIV-1 infection of the T 
lymphocytes (Swingler et a l, 1999). An additional, unidentified factor(s) secreted by
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the Nef-expressing macrophages lead to the activation of the T lymphocytes, thereby 
creating an environment more permissive to the transmission of infection. This 
demonstrates how the vims has adapted the infection of macrophages as an indirect 
mechanism for increasing the transmission of infection.
A culture system which allows a direct comparison of the replication kinetics of an 
attenuated vims to a wild type vims would be valuable. To this end, Messmer et al.
(2000) demonstrated that immature dendritic cells, when exposed to a Isnef vims 
(with the nef gene deleted) and co-cultured with T cells, exhibited vims replication 
which was significantly lower than that observed for wild type vims. It was suggested 
that the immature dendritic cells are unable to support the replication of hnef in vitro 
which may contribute to the decreased pathogenicity of Isnef in vivo. Indeed, it would 
be interesting to investigate if SIVmacCS would exhibit an attenuated phenotype 
within this system described, especially as the deletion within it consists of only four 
amino acids. This could contribute to our understanding of the mechanisms 
underlying the attenuated phenotype observed in vivo for SIVmacCS.
Data from these studies did not determine how deletions in two genetically distinct 
regions of Nef could attenuate the in vivo viral replication to a similar degree. Both 
C8 and GX2 replicate in a similar manner in vivo (Chapter 3, Table 3.1.1) yet the 
studies presented have demonstrated that the two genetic mutations occur in 
antigenically distinct regions of the protein that dismpt distinct sets of protein 
interactions. One model to account for these observations is that Nef may exist in 
either a dimeric or a multimeric form in order to be functional and one of these 
genetic mutations may affect multimerisation (GX2, as evident by the ability to
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transactivate native GAL4) and the other affects regions which interact with cellular 
components (C8). It is conceivable that one of the genetic mutations may affect 
multimerisation. Indeed it has been reported that HIV-1 Nef can form stable homo­
dimers and trimers in solution (Arold et al., 2000, section 4.4). Another potential 
model is that Nef acts as an adaptor protein that brings together specific cellular 
pathways or components resulting in enhanced viral replication. However, to prove 
this, further investigation into the interactions of Nef are required.
One property of Nef that was not investigated in the studies presented here was the 
downmodulation of cell surface MHC-1 molecules (Schwartz et al., 1996, Le Gall et 
a l, 1998, Collins et al., 1998). It had been demonstrated previously that there was 
little differential activity between J5 Nef and C8 Nef with regards to CD4 
downmodulation (Bell et al., 1998). However, selected Nef alleles have been 
observed to down-regulate MHC Class 1 and it has been ascertained that SIV and 
HIV Nef use different mechanisms in order to achieve this (Swigut et al., 2000, 
section 1.2d). The downregulation of MHC-1 molecules may confer partial protection 
to cells from lysis by CTLs, which play an important role in viral load decline during 
primary infection and in determining the subsequent viral load set point. Furthermore, 
the downmodulation of MHC-1 by Nef may depend upon the rate or stage of disease 
progression. For example, it has been demonstrated that nef alleles derived from 
asymptomatic individuals efficiently downregulated the cell surface expression of 
MHC-1, whilst nef alleles obtained after progression to AIDS were unable to 
downregulate MHC-1 (Carl et al., 2001). The ability of Nef to regulate interactions at 
specific points during disease progression, as well as that of being able to utilise more
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than one mechanism of inducing apoptosis shows how sophisticated the level of 
interactions elicited by this protein are. The mechanism of downmodulation of MHC- 
1 by Nef suggests that in an immunocompetent host those properties of Nef which 
allow the virus to escape a CTL response are selected, such as MHC-1 
downmodulation. Furthermore, Betts et a l (2001) used cytokine flow cytometry and 
overlapping peptide pools encompassing all of the HIV-1 genome to investigate the 
total T cell response to all potential epitopes in a group of 23 untreated HIV positive 
patients. High levels of HIV specific CD8+ and CD4+ T cell responses were 
detectable in nearly all 23 patients observed, demonstrating the importance of MHC-1 
molecules and CTL responses in controlling infection. Therefore, if  the virus is able 
to downmodulate MHC-1 molecules and consequently escape an immune response, it 
will be able to persist in the host and spread. It would be interesting, therefore, to 
investigate the levels of expression of TCRÇ clones, MHC class 1 molecules and CD4 
(given previous data on interactions with the APs) on cells which have been 
transfected with these proteins and the various Nef clones.
It was recently described that uncloned SIVmac239 variants expressing a truncated 
Nef (tnef) protein of approximately 25 kDa were pathogenic in infected rhesus 
macaques (Sawai et al., 2000). These variants were observed in animals infected with 
recombinant SIVmac239 viruses containing a missense mutation of the Nef initiator 
methionine, combined with either a 152 bp deletion in the «^unique region or an 
insertion of the interleukin-2 (IL-2) cDNA in place of the 152 bp deletion. Both of 
these resulted in a ffameshift into the nef open reading frame (ORF). In reverted tnef 
alleles, the nef ATG initiation codon was restored and ffameshift mutations were
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repaired to restore contiguous, although truncated nef ORFs. The tNef proteins lacked 
approximately 50 amino acid long region overlapping the highly conserved core of 
the Nef protein. This deletion was reported to fall between elements which mediate 
the interactions of Nef with the adaptor proteins required for downregulation of CD4 
and elements required for an interaction with PAK2 (Carl et al., 2001, Lang et al., 
1997, Manninen et al., 1998). Interestingly, the deletion in clone GX2, between amino 
acids 66-88, would also fall within the equivalent region in a SIVmac32H backbone. 
However, the DMYL sequence deleted in C8 falls outside of this region. Within this 
context it appeared surprising that a pathogenic phenotype was observed in vivo, as it 
has been observed that the deletion of 20 amino acids in GX2 is sufficient to confer an 
attenuated phenotype in vivo (Chapter 3, Figure 3.1.1). Also, it is surprising that a 
wild type phenotype was observed in the absence of a wide range of functions and 
interactions of the Nef protein. However, this is an example of the ability of the Nef 
protein to utilise a multitude of mechanisms and pathways, whereby, in the absence of 
specific interactions, the protein is still able to utilise alternative regions in order to 
subvert alternative pathways and ultimately to enhance pathogenesis.
Munch and colleagues (2002) took these studies further by reconstructing viruses 
containing the restored sequences. It was observed, by comparison to wild type Nef, 
the mutated Nef proteins did not have any effect on cell surface levels of CD4, CD28 
and MHC-1 molecules. However, the mutated Nef was able to downregulate the cell 
surface expression of the T cell receptor in a manner indistinguishable from that of 
wild type Nef. No differences in growth kinetics between wild type and mutated nef 
alleles were observed in vitro in CEMxl74 cells, however there was a marked 
difference between viral replication in rhesus PBMCs and herpes virus saimiri
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transformed macaque T cell line 221, whereby the mutated nef alleles could not 
stimulate SIVmac239 replication. Six juvenile rhesus macaques infected with one of 
the mutated viruses were found to exhibit an attenuated phenotype. These results are 
partly consistent with the observations described within this thesis, whereby clone 
VLA*del and C8 (Chapter 3, Figure 3.1.1) did not interact with AP47 or AP50 and 
exhibited an attenuated phenotype in vivo, by comparison to wild type SIVmacJS 
infection. However, VLA*del and C8 also failed to interact with the TCRÇ clones, 
whereas Munch and colleagues observed downregulation of the T cell receptor by the 
attenuated clones.
It is possible that the down modulation of the TCR:CD3 complex is not governed by 
the regions mutated in the Nef protein within the studies performed by Munch and 
colleagues, and that the attenuations of VLA*del and C8 are sufficient to prevent an 
interaction with the TCRÇ clones within the yeast-2-hybrid system.. This also 
demonstrates, once again, that in the absence of specific fimctional interactions, the 
virus is able to utilise alternative pathways or interactions to exert a pathogenic 
phenotype in vivo.
The studies presented in this thesis, taken in the context of other concurrent research 
have paved the way for highlighting important areas of experimentation that could 
elucidate further information regarding the various molecular interactions of SIV Nef. 
Furthermore, they have demonstrated that the selective removal or disruption of 
selected regions of Nef can be sufficient to attenuate virus replication. If the critical 
fiinctions mediated through specific regions of Nef can be interrupted, then it could 
identify novel targets for a therapeutic strategy against HIV. However, until key
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fonctions of Nef can be identified this will prove difficult. Clearly, Nef augments 
virus replication through its interaction with cellular proteins to modify the 
environment within which it is located. The results from this study have provided 
valuable information as to the properties of SIV Nef that facilitate virus replication or 
enhance evasion of the immune system. Definition of any interactions that enhance 
the pathogenesis of HIV may allow a better focus of future resources to apply our 
knowledge to control virus infection and combat the global pandemic of AIDS by the 
development of more effective drugs and vaccines.
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7. Appendix 1; Sequences of SIV nef  clones
Figure 7.1. Sequence alignment of SIV Nef clones used in the studies described. 
Highlighted are the attenuations or mutations within these clones. To summarise, C8, 
carries a four base pair deletion between amino acids 143-146 and two additional 
nucleotide changes relative to 15, C8del carries a four amino acid deletion between 
amino acids 143-146, J5(R>E) has a R>E mutation at amino acid 191, Nef 32H is the 
parental SIVmac32H from which J5 is derived, J5(EIYL) has the repair sequence 
EIYL between amino acids 143-146, EIYL+R>E has the repair sequence EIYL 
between amino acids 143-146 as well as the nucleotide change at amino acid 191 of 
R>E, GX2 carries a 66 nucleotide deletion at the N terminus, VLA*del is truncated 
prematurely by a stop codon at position 213, and the consensus wild type sequence 15.
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8. Appendix 2; Plasmid maps
MCS
(5082-4981)
Bglll 
HA epitope 
Ndel 
Sfil 
Ncol 
Smal 
Xmal 
BamHI 
EcorRI 
Sad 
Xhol 
Bglll
Ndel
(""") Xba I
(598)
Col El 
or!
"ADH1 pACT2 
A8.1 kb
GAL4 AD 
HA
^ADH1 loxP 
¥
L
Hind III
(4739)
Ola I
(2626)
Not I (4163) 
Not I (4345)
Figure 8.2. The map of plasmid pACTII (8.1 kb, Molecular Immunolonogy Unit, GSK). The 
multiple cloning sites are shown. The plasmid was made available with the genes for AP47, 
AP50, SH3-Lck, TCRÇm and TCRÇ2.21 already cloned, for use within the yeast-2-hybrid 
assay.
Leu2; the selection maker for the plasmid. Only yeast expressing the Leu2 gene can grow in 
media lacking leucine.
ADH1 ; alcohol dehydrogenase 1, the ADH promoter region, a constitutive gene promoter.
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Thrombin_______
Val Pro ArgjrGly Ser Pro Asn Ser Arg Val Asp Ser Ser Gly Arg lie Val Thr Asp 
GTT CCG CGT GGA TOO CCG AAT TOO CGG GTC GAG TOG AGO GGC CGC ATC GTG ACT GAC TGA
Stop Codons
Ecor I Sma I Sal I Xho I NotBamH
Tth111 
/  Aat
Bal
Ptac
BspM pSj10 Bam7Stop7
Pst1
pGEX
-4900 bp
Nar
AlwN I
p4.5'EcoR V
BssH
Ape pBR322
oriBstE II
Mlu I
Figure 8.1. The map of plasmid pGEX-4T3 (4.9 kb, Pharmacia, UK), a GST fusion protein 
expression vector. The mutiple cloning sites are shown. For cloning of SIV nef mutants, restriction 
endonuclease sites BamYH andÆ'coRI were used.
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Ndel \  \
EcoRI(5715) \
Xbal*(4600)
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N d e l l  S f i l  N c o l  B s s H I I  BamHI
C A T - A T G - G C C - A T G - G A G - G C C - C C G - G C G - C G C - T C T - G G A - T C C - G T C -  
H M  A M E A P A R S G S V
- G A C - C T G - C A G - C C A - A G C - T A A -  
D L Q P S s t o p
Figure 8.3: The map of plasmid pAS-CYHII. A modified was introduced into
the multiple cloning site to generate pASI-CYHII/5^^HII.I (M. Morse, Molecular 
Immunology Unit, GSK).
ADH; alcohol dehydrogenase, the ADH promoter region, a constitutive gene promoter. 
CYH2; a cyclohexamide sesitivity gene. Allows for the selective loss of the pASI- 
CYHII plasmid if yeast are grown in cyclohaxamide. This is utilised if performing a 
yeast-2-hybrid library screen with episomal plasmids and the pACTII (activation 
domain) plasmid is extracted from the yeast -  this allows selection for the loss of the 
binding domain of the pASI-CYHII plasmid.
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9. Appendix 3: Recipes for Buffers and Media
9.1. Antigenic studies
Unless stated, water was purified using the Milli-Q plus Ultra-pure water system 
(Millipore). This is equivalent to using double distilled water.
Filtered water milli Q water, filtered through a 0.75 pm filter 
unit
Phosphate buffered saline 10 g sodium chloride
0.25 g potassium chloride
1.44 g di-sodium hydrogen orthophosphate
0.25 g potassium dihydrogen orthophosphate
water to 1 litre
Denaturing Solution 584 g sodium chloride
500 ml 10 M sodium hydroxide
water to 10 litres
Neutralising Solution 605 g Trizma base
816 g sodium chloride
400 ml concentrated hydrochloric acid
water to 10 litres
adjust pH to 7.4
Standard Saline Citrate (SSC) (20x) 1753 g sodium chloride
882 g sodium citrate 
water to 10 litres
20% Hvbridisation Buffer 10 ml formamide
12.5 ml 20 X SSC 
2 ml 500 mM sodium phosphate
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1 ml 50 X Denhardt’s
0.5 ml 10% (w/v) SDS
0.5 ml 100 mg/ml salmon sperm DNA
water to 50 ml
Hvbridisation buffer 
(low strigency incubations)
10 ml 5 X SSC
12.5 ml 20 X SSC
2 ml 500 mM sodium phosphate
1 ml 50 X Denhardt’s
0.5 ml 10% (w/v) SDS
0.5 ml X 100 mg/ml salmon sperm
water to 50 ml
10% SDS 10 g SDS 
water to 100 ml
50 X Denhardts 2 g Ficoll
2 g bovine serum albumin
2gPVP-40
water to 200 ml
Luria-Bertram tLBl broth 25 g LB powder (Anachem, UK) per litre of 
water
Luria-Betram (LB) agar for plates 40 g LB agar powder (Anachem, UK) per litre
of water
TAB Buffer for gel electrophoresis 
(50 x)
242 g Trizma base
57.1 ml glacial acetic acid
100 ml 0.5 M (EDTA) (pH 8.0) per litre of
water
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5 X sample buffer 1.25 g Ficoll
0.25 g SDS
0.5 ml 0.5 M EDTA
0.5 ml 5% bromophenol blue
water to 5 ml
ELISA substrate 10 ml 0.1 M sodium acetate
1.4 ml 0.1 M citric acid 
90 ml water
1 ml (10 mg/ml) 3,3% 5 ,5 ’ TMB in DMSO
Equilibrated Phenol Equilibrated with IM Tris-HCl pH 7.6
10 mg/ml 3. 3’. 5. 5’ TMB in DMSO 10 mg 3, 3% 5, 5’ TMB
1 ml DMSO
0.1 M sodium acetate 41.01 g sodium acetate 
water to 500 ml
0.1 M citric acid 2.1 g citric acid 
water to 100 ml
30% hydrogen peroxide 30 ml hydrogen peroxide 
water to 100 ml
100 mg/ml Amnicillin 5 g ampicillin 
water to 50 ml
IM  Tris-HCl nH 8.8 60.55 g Trizma base 
water to 500 ml 
adjust pH to 8.8
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IM  Tris-HCl pH 6.8 60.55 g Trizma base 
water to 500 ml 
adjust pH to 6.8
10% ammonium persulphate 1 g ammonium persulphate 
water to 10 ml
100 mM calcium chloride 7.35 g calcium chloride 
water to 500 ml
50% glycerol in LB broth 50 ml glycerol
50 ml luria-bertram broth
lOOmMIPTG Ig lP T G
41.96 ml sterile filtered water
5% (w/y) milk /1% (v/v) Tween-20 5 g milk powder (Marvel) 
1 ml Tween-20 
100 ml PBS
10 mg/ml ethidium bromide 10 mg tablet ethidium bromide 
1 ml water
5 M sodium perchlorate 61.2 g sodium perchlorate 
water to 100 ml
5% TCA 5gTCA 
water to 100 ml
Running buffer 150 ml 10 X  Tris Glycine
15 ml 10% (w/y) SDS
1335 ml filtered sterile water
Reserye 350 ml of aboye
Dilute the remainder with 800 ml water
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Blotting buffer
(for semi dry electrophorationl
250 ml 10 X Tris glycine 
500 ml methanol 
water to 1 litre
Tris glycine 144 g glycine 
30.27 g Trizma base 
water to 1 litre
SDS-PAGE sample buffer 48.4 g Trizma base
16.4 g sodium acetate
7.4 g EDTA 
water to 1 litre 
Adjust pH to 7.8
10 M sodium hydroxide 400 g sodium hydroxide 
water to 1 litre
500 mM sodium phosphate 69 g sodium phosphate (monobasic,
monhydrate)
water to 1 litre
IM  Tris-HCl pH 7.6 121 g Trizma base
water to 1 litre
pH to 7.6 using 11.6 M HCl
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9.2. Yeast-2-Hvbrid studies
Unless stated, water was purified using the Milli-Q plus Ultra-pure water system 
(Millipore). This is equivalent to using double distilled water.
All media, unless stated otherwise, was obtained from Sigma, UK.
Phosphate buffered saline 8 g sodium chloride 
0.2 g potassium chloride 
0.2 g potassium dihydrogen 
orthophosphate
1.15 g di-sodium hydrogen orthophosphate 
water to 1 litre 
adjust to pH 7.2
IXTBE 108 g tris 
55 g boric acid
7.4 g EDTA 
water to 1 litre 
adjust to pH 8.0
Transfer buffer (for SDS-PAGE gels) 20% methanol
10% running buffer (Novex, UK)
YEPD agar 10 g yeast extract 
20 g peptone 
20 g glucose 
20 g agar 
water to 1 litre
YEPD agar plates 270 ml YEPD agar
7.5 ml adenine
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YEPD media 10 g yeast extract 
20 g peptone 
20 g glucose 
water to 1 litre
YEPD media (for overnight cultures) 170 ml YEPD media 
10 ml 40% glucose 
5 ml adenine
lOX Yeast Nitrogen Base (YNB) 
without amino acids (GibcoBRLl
67gYNB 
water to 1 litre
40% Glucose 400 g glucose 
water to 1 litre
-WHAUL dropout broth 1.1 g -WHAUL dropout powder 
water to 1 litre 
Adjust to pH 5.4
Histidine solution 2.4 g L-histidine 
water to 1 litre
Adenine solution 5 g L-adenine 
water to 1 litre
Uracil solution 2.4 g L-uracil 
water to 1 litre
Leucine solution 7.2 g L-leucine 
water to 1 litre
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-WHAUL dropout agar 1.1 g -WHAUL dropout powder
23.53 g bacto agar
Adjust to pH 5.4
water to approximately 220 ml
-WHAUL droput powder 1.2 g L-arginine
6 g L-aspartic acid 
6 g L-glutamic acid
1.8 g L-lysine-HCl
1.2 g L-methionine 
3 g L-phenylalanine
22.5 g L-serine
12 g L-threonine
1.8 g L-tyrosine 
9 g L-valine
WHAUL selection plates 240 ml WHAUL agar
3 0 m l l0 x Y N B
15 ml 40% (w/v) glucose
3 ml tryptophan
3 ml histidine
7.5 ml adenine
3 ml uracil
3 ml leucine
3 ml methionine
1 M Lithium acetate 102 g lithium acetate 
water to 1 litre
lOX Tris EDTA (TE) 10 ml lOOX TE (Sigma, UK) 
water to 100 ml
50% Polvthvlene Glvcol (PEG) 
MW 3.350
50 g PEG 
water to 1 litre
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LiAc/TE solution 10 ml lithium acetate 
10 ml lOXTE 
80 ml water
40% PEG/LiAc/TE 5 ml IM lithium acetate 
5 ml lOX TE 
40 ml 50% PEG
Z buffer 16.1 g sodium phosphate (dibasic, 
heptahydrate)
5.5 g sodium phosphate (monobasic, 
monohydrate)
0.75 g potassium chloride
0.25 g magnesium sulphate (heptahydrate)
water to 1 litre
adjust to pH 7.0
100 mg/ml X-gal in DMF 100 mg X-gal 
1 ml DMF
X-Gal/DMF/B-ME 100 mg/ml X-gal in DMF
100 ml Z-buffer
270 pi p-mercaptoethanol
Lvsis buffer 0.1 M Tris-Cl pH 7.4 +/-0.05 (Sigma, UK) 
0.05% Triton X-100 (final volume) 
water to 100 ml
Zbuffer/ONPG/B-ME 50 ml Z-buffer
10 ml 4 mg/ml ONPG in O.IM sodium
phosphate pH 7.4
164.4 pi p-mercaptoethanol
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4 mg/ml ONPG in 0.1 M sodium 
phosphate nH7.4
4 mg ONPG
1 ml O.IM sodium phosphate pH7.4
1 M sodium carbonate 105.99 g sodium carbonate 
water to 1 litre
10% TCA 10 g TCA 
water to 100 ml
5 M sodium hydroxide 200 g sodium hydroxide 
water to 1 litre
0.1 M sodium phosphate pH 7.4 13.8 g sodium phosphate 
water to 1 litre 
adjust pH to 7.4
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10. Appendix 4; Sources of Reagents
10. Appendix 4: Sources of Reagents
Reagent Source
Ampli-Taq Gold™ polymerase Perkin-Elmer (Roche)
dNTPs Boehringer Mannheim
MgCl2 Perkin-Elmer (Roche)
10 X PCR buffer Perkin-Elmer (Roche)
0X174 DNA ladder Gibco BRL
m indlllD N A  ladder Gibco BRL
1 Kb DNA ladder Gibco BRL
DNA gel loading buffer lOx Eppendorf
ATP ICN,UK
lOx One-Phor-All buffer Pharmacia, UK
T4 polynucleotide kinase Gibco BRL
Glass microfibre filters Whatman
X-ray film Konica
T4 DNA ligase Gibco BRL
5x ligation buffer Gibco BRL
protein ladder (NCBSC) Gibco BRL
protein ladder (GSK) Gibco BRL
ELISA plates Nunc
Alkaline phosphatase-calf intestinal NE Biolabs
pUC19 Gibco BRL
Anti HA monoclonal antibody Boehringer Mannheim
50 mM non fat milk powder (pH7.4) Sigma
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Salmon sperm DNA Amersham USB
Ethidium bromide tablets Amersham USB
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11. Appendix 5: List of Primers
11. Appendix 5: List of primers
For PCR purposes:
SN9075N
5’ GTT CCG CGT GGATCC ATG GGT GGA GCT AT IC C  3’ 
SN9866C
5’AAA GTC CGT GAATTC TCA GCG AGT TTC CTT CTT 3’ 
Designed to incorporate BamHl and EcoBl restriction sites, respectively.
For hybridisation purposes:
SN9763C
Synthesised by Gibco Life Technologies Ltd, UK.
%
For sequencing purposes:
NefFl:
5’ CCA GTG ATG CCA CGA GTT 3’
NefRl:
5 ’ AAC TCG TGG CAT CAC TGG 3 ’
Gal4BD Forward:
5’ GAC AGC ATA GAA TAA GTG GCG 3’
Gal4BD Reverse:
5’ CGT TTT AAA ACC TAA GAG TCA C 3’
Synthesised by Sigma-Genosys Ltd, UK.
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